


COMPLAINT COUNSEL'S EXHIBIT INDEX



ORIGINAL

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX0001	Intentionally Not Used					N/A			
CX0002	Email from Todd Engle to John Anthony, Chris Mengler, Joe Camargo, et al. re: Oxymorphone w/Attach: 1936_001.pdf; Oxymorphone Forecast Detail 01 11 10 R2.xls	1/11/2010	IMPAX-OPANA-CID00012237	IMPAX-OPANA-CID00012251	GX0002	JX-002			
CX0003	Email from Todd Engle to Chris Mengler, Larry Hsu, Chuck Hildenbrand, et al. re: Quarterly Launch Planning Meeting Background Documentation w/Attach: launch planning 02 02 10 R2.doc	2/2/2010	IMPAX-OPANA-CID00002168	IMPAX-OPANA-CID00002170	GX0003	JX-002			
CX0004	Email from Kevin Sica to Chris Mengler, Todd Engle, Ted Smolenski re: Updated 5 year Plan	2/19/2010	IMPAX-OPANA-CID00007058	IMPAX-OPANA-CID00007060	GX0004	JX-002			
CX0005	Email from Todd Engle to Mike Grigsby, Ted Smolenski, Gary Skalski, et al. re: Tentative Oxy ER approval	5/17/2010	IMPAX-OPANA-CID00006039	IMPAX-OPANA-CID00006039	GX0005	JX-002			
CX0006	Email from Todd Engle to Chuck Hildenbrand, Meg Snowden re: Oxymorphone Question w/Attach: Book2.xls	5/28/2010	IMPAX-OPANA-CID00021740	IMPAX-OPANA-CID00021741	GX0006	JX-002			Tr. 1721:09; 1721:15; 1722:09; 1722:13; 1726:08; 1728:08; 1730:08; 1767:11
CX0007	Email from Todd Engle to Chris Mengler, Larry Hsu, Chuck Hildenbrand, et al. re: Quarterly Launch Planning Meeting May 20, 2010 Agenda Materials w/Attach: QLPM 052010.doc	5/20/2010	IMPAX-OPANA-CID00002150	IMPAX-OPANA-CID00002155	GX0007; GX0107	JX-002			
CX0008	Email from Chris Mengler to Todd Engle, Larry Hsu, Meg Snowden re: Mengler Board Slides	5/14/2010	IMPAX-OPANA-CID00006693	IMPAX-OPANA-CID00006694	GX0008; GX0105; RX-329	JX-002			Tr. 546:03
CX0009	Intentionally Not Used					N/A			
CX0010	Email from Todd Engle to Carole Ben-Maimon, Bryan Reasons, Larry Hsu, et al. re: Maximizing the Oxymorphone ER Opportunity	5/16/2013	IMPAX-OPANA-CID00019374	IMPAX-OPANA-CID00019374	GX0010	JX-002			
CX0011- CX0012	Intentionally Not Used					N/A			
CX0013	Email from Todd Engle to William Ball, rjh@rjhgroupinc.com, Joe Farkas re: Kaiser 60% off 65% off	2/1/2013	IMPAX-OPANA-CID00004335	IMPAX-OPANA-CID00004336	GX0013	JX-002		Ordered 10/23/2017	
CX0014	Email from Todd Engle to Shawn Fatholahi, Tom Ciampa, Carole Ben-Maimon re: Oxymorphone ER data for your review w/Attach: Graphs 07_17_13.xlsx; Oxymorphone ER weekly data 071213.xlsx	7/22/2013	IMPAX-OPANA-CID00005472	IMPAX-OPANA-CID00005477	GX0014	JX-002			
CX0015- CX0016	Intentionally Not Used					N/A			
CX0017	Email from Rowan D'Annibale to Todd Engle, Joyce de los Reyes re: Opana ER Peak Calculation Steering Committee Meeting w/Attach: IMPAX Prescription Sales and Quarterly Peak Calculations July 2010 - June 2012.xlsx	8/23/2012	IMPAX-OPANA-CID00005543	IMPAX-OPANA-CID00005546	GX0017	JX-002			
CX0018- CX0113	Intentionally Not Used					N/A			
CX0114	Email from Chris Mengler to Michael Nestor re: <no subject>	6/3/2010	IMPAX-OPANA-CID00011817	IMPAX-OPANA-CID00011818		JX-002		Ordered 10/23/2017	
CX0115- CX0116	Intentionally Not Used					N/A			
CX0117	Email from Chris Mengler to Meg Snowden re: ENDP: Endo Pharmaceuticals Agrees to Acquire Penwest Pharmaceuticals and Submits NDA for New Formulation of Long-Acting Oxymorphone Designed to be Crush-Resistant	8/10/2010	IMPAX-OPANA-CID00012004	IMPAX-OPANA-CID00012006	GX0117; RX-360	JX-002			
CX0118- CX0200	Intentionally Not Used					N/A			
CX0201	Email from Ted Smolenski to Joe Camargo, Kevin Sica, Todd Engle, et al. re: Opana ER forecast 1 of 1 w/Attach: Opana ER 1 of 1 forecast--2009-07-22.xls	7/23/2009	IMPAX-OPANA-CID00011906	IMPAX-OPANA-CID00011907	GX0201; RX-567	JX-002			
CX0202	Email from Ted Smolenski to Joe Camargo re: Opana ER forecast 1 of 1	7/30/2009	IMPAX-OPANA-CID00019479	IMPAX-OPANA-CID00019480	GX0202; RX-392	JX-002			
CX0203	Email from Chris Mengler to Ted Smolenski re: opana ER	11/13/2009	IMPAX-OPANA-CID00006922	IMPAX-OPANA-CID00006922	GX0203; GX0101	JX-002			
CX0204	Email from Todd Engle to Chris Mengler, Larry Hsu, Chuck Hildenbrand, et al. re: Meeting Minutes from the Feb 2, 2010 Quarterly Launch Planning Meeting w/Attach: launch planning 02 02 10 R2Meeting Minutes.doc	2/6/2010	IMPAX-OPANA-CID00002191	IMPAX-OPANA-CID00002193	GX0204; GX0512; GX0102	JX-002			

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX0205	Email from Ted Smolenski to Joyce De Los Reyes, Kevin Sica, Todd Engle, et al. re: Endo: One Deal Away from Being Interesting w/Attach: ENDP--UBS--2010-02-22.pdf	2/23/2010	IMPAX-OPANA-CID00020815	IMPAX-OPANA-CID00020832	GX0205; RX-396	JX-002			
CX0206	Email from Ted Smolenski to June Hughes re: Oxygne GM %	5/6/2010	IMPAX-OPANA-CID00018218	IMPAX-OPANA-CID00018218	GX0206	JX-002			
CX0207- CX0210	Intentionally Not Used					N/A			
CX0211	Email from Ted Smolenski to Meg Snowden, Chris Mengler, Huong Nguyen, et al. re: Impax - Endo w/Attach: Opana ER CAGR 2010-06-07.xlsx	6/7/2010	IMPAX-OPANA-CID00021881	IMPAX-OPANA-CID00021884	GX0211	JX-002			
CX0212- CX0213	Intentionally Not Used					N/A			
CX0214	Email from Ted Smolenski to Larry Hsu, Chris Mengler re: Research Notes - ENDO First Settlement for Generic Opana ER	2/23/2009	IMPAX-OPANA-CID00020833	IMPAX-OPANA-CID00020833	GX0214; RX-397	JX-002			
CX0215	Intentionally Not Used					N/A			
CX0216	Email from Ted Smolenski to Chris Mengler, David Berman re: opana ER	5/27/2010	IMPAX-OPANA-CID00006048	IMPAX-OPANA-CID00006048	GX0216; GX0110	JX-002			
CX0217	Email from Chris Mengler to Ted Smolenski re: Oxymporphone	6/2/2010	IMPAX-OPANA-CID00019449	IMPAX-OPANA-CID00019450	GX0217; GX0113; RX-389	JX-002			
CX0218	Email from Ted Smolenski to Chris Mengler re: No Subject	6/7/2010	IMPAX-OPANA-CID00019477	IMPAX-OPANA-CID00019477	GX0218; RX-391	JX-002			
CX0219	Email from Ted Smolenski to Larry Hsu, Art Koch re: opana ER	1/8/2011	IMPAX-OPANA-CID00003537	IMPAX-OPANA-CID00003538	GX0219	JX-002			
CX0220- CX0221	Intentionally Not Used					N/A			
CX0222	Email from Ted Smolenski to Kevin Sica, June Hughes, and Larry Kloss re: 5-year forecast 2010-May Update 2010--05- 14v5.xls w/Attach: 5-year forecast 2010-May Update 2010--05- 14v5.xls	5/15/2010	IMPAX-OPANA-CID00007067	IMPAX-OPANA-CID00007068	GX0222	JX-002			
CX0223- CX0300	Intentionally Not Used					N/A			
CX0301	FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, Application No N21610	9/24/2014	CX0301-001	CX0301-001	GX0301; GX0401	JX-002			Tr. 350:02; 350:05
CX0302	Email from Huong Nguyen to Art Koch, Meg Snowden, echoy@wsgr.com re: Draft Impax/Endo/Penwest Settlement and License Agreement w/Attach: Impax - Endo Settlement Agreement (Opana) [Execution Version].DOC	6/7/2010	IMPAX-OPANA-CID00007031	IMPAX-OPANA-CID00007057	GX0302; RX-338	JX-002			
CX0303	Case 2:09-cv-00831-KSH-PS: Complaint	11/15/2007	CX0303-001	CX0303-071	GX0303	JX-002			
CX0304	Case 2:09-cv-00832-KSH-PS: Complaint	1/25/2008	CX0304-001	CX0304-042	GX0304	JX-002			
CX0305	Case 2:09-cv-00833-KSH-PS: Complaint	7/25/2008	CX0305-001	CX0305-044	GX0305	JX-002			
CX0306	Intentionally Not Used					N/A			
CX0307	Case 2:09-cv-00832-KSH-PS: Answer, Affirmative Defenses and Counterclaims of Defendant Impax Laboratories, Inc.	2/19/2008	CX0307-001	CX0307-008	GX0307	JX-002			
CX0308	Case 2:09-cv-00833-KSH-PS: Answer, Affirmative Defenses and Counterclaims of Defendant Impax Laboratories, Inc.	8/19/2008	CX0308-001	CX0308-012	GX0308	JX-002			
CX0309	Email from Meg Snowden to Huong Nguyen re: Research Notes - ENDO First Settlement for Generic Opana ER w/Attach: ENDO - First Settlement for Generic Opana ER.pdf	2/23/2009	IMPAX-OPANA-CID00022178	IMPAX-OPANA-CID00022185	GX0309; RX-409	JX-002			
CX0310	Letter from Benedict Y. Hur to Jamie Towey and Maren Schmidt re: Opana Investigation and CID to Impax Laboratories, FTC File No. 1410004	9/5/2014	CX0310-001	CX0310-029	GX0310; GX0408	JX-002			
CX0311- CX0313	Intentionally Not Used					N/A			
CX0314	Email from Meg Snowden to Stephanie Hsieh, Huong Thien Nguyen, Don Anthony re: Generic new product launch projection 091808.xls w/Attach: Generic new product launch projection 091808.xls	9/19/2008	IMPAX-OPANA-CID00018229	IMPAX-OPANA-CID00018230	GX0314; GX0001	JX-002			
CX0315	Email from Meg Snowden to Todd Engle re: QLPM 050310 Draftmms w/Attach: QLPM 050310 Draftmms.doc	5/7/2010	IMPAX-OPANA-CID00001879	IMPAX-OPANA-CID00001883	GX0315	JX-002			
CX0316	Intentionally Not Used					N/A			
CX0317	Email from Meg Snowden to Chris Mengler re: t/c with Endo	5/18/2010	IMPAX-OPANA-CID00019431	IMPAX-OPANA-CID00019431	GX0317	JX-002			
CX0318- CX0319	Intentionally Not Used					N/A			

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX0320	Email from Guy Donatiello to Chris Mengler, Meg Snowden, Alan Levin, et al. re: Highly Confidential - Rule 408 Settlement Communication w/Attach: Endo - Impax - Development Term Sheet (5-26-2010).DOC; Endo - Impax - Settlement Term Sheet(5-26-2010).docx	5/26/2010	IMPAX-OPANA-CID00001716	IMPAX-OPANA-CID00001726	GX0320; GX0403; GX0109; RX-276	JX-002			Tr. 427:04; 427:10; 488:23; 489:06
CX0321	Email from Alan Levin to Chris Mengler, Meg Snowden, Guy Donatiello re: Highly Confidential - Rule 408 Settlement Communication	5/30/2010	IMPAX-OPANA-CID00005952	IMPAX-OPANA-CID00005954	GX0321; GX0111	JX-002			Tr. 538:18; 538:20; 539:01
CX0322	Intentionally Not Used					N/A			
CX0323	Email from Guy Donatiello to Meg Snowden, Chris Mengler, Alan Levin, et al. re: <no subject> w/Attach: Draft Impax - Endo Settlement and License Agreement.DOC	6/4/2010	IMPAX-OPANA-CID00001693	IMPAX-OPANA-CID00001715	GX0323; GX0409; GX1210; RX-275	JX-002			
CX0324	Email from Eliot Choy to Alan Levin, Guy Donatiello, Martin Black, et al. re: Impax - Endo w/Attach: 639178_Result.rtf; Impax - Endo - Rider to Settlement Agreement_(PALIB1_3993057_1).DOC; Impax - Endo - Settlement Agreement_(PALIB1_3992129_3).DOC	6/5/2010	IMPAX-OPANA-CID00001738	IMPAX-OPANA-CID00001783	GX0324; GX0413; GX1812; RX-279	JX-002			Tr. 147:15
CX0325	Intentionally Not Used					N/A			
CX0326	Email from Alison Freeman-Gleason to Justin Watkins, Meg Snowden, Alan Levin, et al. re: Co-Promote Revisions w/Attach: Impax-Endo_Development_and_Co-Promotion_Agreement_final.pdf; et al.	6/7/2010	IMPAX-OPANA-CID00011838	IMPAX-OPANA-CID00011904	GX0326; GX0417; RX-357	JX-002			
CX0327	Email from Robert Cooper to Steve Mollichella, Guy Donatiello, Meg Snowden, et al. re: Upfront payment	6/24/2010	IMPAX-OPANA-CID00003054	IMPAX-OPANA-CID00003055	GX0327	JX-002			
CX0328	Email from Meg Snowden to Guy Donatiello re: Endo/Opana	10/7/2010	IMPAX-OPANA-CID00005749	IMPAX-OPANA-CID00005749	GX0328; RX-314	JX-002			
CX0329	Email from Meg Snowden to Guy Donatiello re: steering committee	12/16/2010	IMPAX-OPANA-CID00002274	IMPAX-OPANA-CID00002275	GX0329; RX-286	JX-002			
CX0330	Email from Guy Donatiello to Chris Mengler, Meg Snowden, Caroline Manogue re: Letter from Endo to Impax Labs w/Attach: img-Z27121156-0001.pdf	12/27/2012	IMPAX-OPANA-CID00012058	IMPAX-OPANA-CID00012060	GX0330; GX1214; GX1822; RX-361	JX-002			
CX0331	Letter from Margaret Snowden to Caroline Manogue re: Settlement and License Agreement of June 8, 2010 Made By and Among Endo Pharmaceuticals Inc., Penwest Pharmaceuticals Co., and Impax Laboratories, Inc.	1/3/2013	IMPAX-OPANA-CID00000322	IMPAX-OPANA-CID00000322	GX0331	JX-002			
CX0332	Email from Huong Nguyen to Guy Donatiello, Meg Snowden re: Settlement and License Agreement by Endo, Penwest, and Impax ("License Agreement") w/Attach: Copy of Endo Credit Calculation (2).xlsx; DOC.PDF	1/22/2013	IMPAX-OPANA-CID00005750	IMPAX-OPANA-CID00005765	GX0332; RX-315	JX-002			Tr. 387:12; 436:16; 490:19
CX0333	Email from Brad Lucas to Dacia Kutnyak, Accounts Receivable, Robin Rieben, et al. re: Endo Deposit - 04/18/2013 - \$102,049,199.64	4/18/2013	IMPAX-OPANA-CID00000275	IMPAX-OPANA-CID00000277	GX0333	JX-002			
CX0334- CX0405	Intentionally Not Used					N/A			
CX0406	Email from Chris Mengler to Larry Hsu, Art Koch, Michael Nestor, et al. re: <no subject>	6/2/2010	IMPAX-OPANA-CID00019448	IMPAX-OPANA-CID00019448	GX0406	JX-002			
CX0407	Email from Art Koch to Chris Mengler, Larry Hsu, Chuck Hildenbrand, et al. re: Status	6/3/2010	IMPAX-OPANA-CID00011819	IMPAX-OPANA-CID00011820	GX0407; RX-356	JX-002			Tr. 543:15; 543:22
CX0408- CX0409	Intentionally Not Used					N/A			
CX0410	Email from Alan Levin to Art Koch, Guy Donatiello, Meg Snowden, et al. re: <no subject>	6/4/2010	IMPAX-OPANA-CID00001592	IMPAX-OPANA-CID00001596		JX-002			
CX0411	Email from Guy Donatiello to Meg Snowden, Art Koch, Alan Levin re: Revised Draft #2 w/Attach: #710157v3_BE01_ - Impax- Co-Promotion Agreement.DOC	6/4/2010	IMPAX-OPANA-CID00006365	IMPAX-OPANA-CID00006394	GX0408; RX-280	JX-002			
CX0412- CX0414	Intentionally Not Used					N/A			
CX0415	Email from Alan Levin to Art Koch, Meg Snowden, Larry Hsu, et al. re: Endo/Impax: R&D Collaboration	6/6/2010	IMPAX-OPANA-CID00001727	IMPAX-OPANA-CID00001728	GX0415; RX-277	JX-002			
CX0416	Email from Art Koch to Alan Levin, Meg Snowden, Guy Donatiello, et al. re: Gross Margin	6/6/2010	IMPAX-OPANA-CID00001815	IMPAX-OPANA-CID00001815	GX0416; GX0510; RX-281	JX-002			
CX0417	Intentionally Not Used					N/A			

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX0418	Email from Thomas Rayski to Huong Nguyen, Guy Donatiello, Jennifer Saionz, et al. re: Draft Impax/Endo/Penwest Settlement and License Agreement w/Attach: Impax - Endo Settlement Agreement (Opana) [Execution Version].DOC: Redline.pdf	6/7/2010	IMPAX-OPANA-CID00001910	IMPAX-OPANA-CID00001960	GX0418	JX-002			
CX0419- CX0420	Intentionally Not Used					N/A			
CX0421	Email from Chuck Hildenbrand to Art Koch re: Impax: Inventory Carrying Value - June 30, 2010 - OXM w/Attach: Oxymorphone Expiration Dates	6/21/2010	IMPAX-OPANA-CID00008018	IMPAX-OPANA-CID00008025	GX0421; RX-345	JX-002			
CX0422	Email from Jennifer Hsu to Leslie Benet, Allen Chao, Art Koch, et al. re: BOD Monthly Update -- June 2010 - CONFIDENTIAL w/Attach: BOD Monthly Update June 2010 072310.doc	7/23/2010	IMPAX-OPANA-CID00018515	IMPAX-OPANA-CID00018542	GX0422	JX-002		Ordered 10/23/2017	
CX0423 CX0424	Email from Mark Donohue to Chris Mengler, Larry Hsu, Art Koch, et al. re: Courtesy of Business Wire: - Endo, Penwest settle patent lawsuits over painkiller Intentionally Not Used	6/8/2010	IMPAX-OPANA-CID00021058	IMPAX-OPANA-CID00021059	GX0423	JX-002			
CX0425 CX0426- CX0501	Impax Annual Report 2013: Focusing on Quality and Growth (December 31, 2013 SEC Form 10-K) Intentionally Not Used	2/24/2014	CX0425-001	CX0425-157	GX0425	JX-002			Tr. 1206:09, 10, 14, 24; 1207:12
CX0502 CX0503- CX0504	Email from Michael Nestor to Chris Mengler, Larry Hsu, Meg Snowden re: <no subject> Intentionally Not Used	5/26/2010	IMPAX-OPANA-CID00019432	IMPAX-OPANA-CID00019432	GX0502; GX0108; GX0318	JX-002			
CX0505	Email from Chris Mengler to Larry Hsu re: Mengler Board Slides	5/14/2010	IMPAX-OPANA-CID00007101	IMPAX-OPANA-CID00007102	GX0505; GX0104	JX-002			
CX0506 CX0507 CX0508- CX0512	Email from Chris Mengler to Michael Nestor, Larry Hsu, Meg Snowden, et al. re: Today's Meeting Email from Larry Hsu to Chris Mengler re: Status Intentionally Not Used	6/2/2010 6/4/2010	IMPAX-OPANA-CID00019444 IMPAX-OPANA-CID00018248	IMPAX-OPANA-CID00019445 IMPAX-OPANA-CID00018250	GX0405 GX0507; GX0115	JX-002 JX-002			Tr. 540:24; 541:24; 3031:09
CX0513	Email from Meg Snowden to Larry Hsu, Chris Mengler, Chuck Hildenbrand, et al. re: Oxymorphone ER Tablets Tentatively Approved Today!!	5/13/2010	IMPAX-OPANA-CID00018243	IMPAX-OPANA-CID00018243	GX0513; GX0419; GX0103; GX0313	JX-002			
CX0514	Email from Chris Mengler to Larry Hsu, Art Koch, Michael Nestor, et al. re: 5-year forecast 2010-May Update with Impax.xls w/Attach: 5-year forecast 2010-May Update with Impax.xls	5/16/2010	IMPAX-OPANA-CID00006712	IMPAX-OPANA-CID00006713	GX0514; GX0420; RX-330	JX-002			Tr. 49:24
CX0515 CX0516	Email from Larry Hsu to Laura Bisbing, Jennifer Hsu re: Mengler Board Slides w/Attach: Mengler Board Presentation Aug10 080510b.ppt Intentionally Not Used	8/8/2010	IMPAX-OPANA-CID00012917	IMPAX-OPANA-CID00012959	GX0515	JX-002		Ordered 10/23/2017	
CX0517 CX0518	Email from Meg Snowden to Larry Hsu, Carole Ben-Maimon, Mark Donohue, et al. re: Letter from Endo to Impax Labs Intentionally Not Used	12/29/2012	IMPAX-OPANA-CID00021673	IMPAX-OPANA-CID00021676	GX0517; RX-404	JX-002			
CX0519 CX0520	Email from Carole Ben-Maimon to Larry Hsu re: Oxymorphone Intentionally Not Used	1/5/2013	IMPAX-OPANA-CID00019290	IMPAX-OPANA-CID00019293	GX0519	JX-002			
CX0521 CX0522- CX1000	Impax Presentation: IMPAX Pharmaceuticals R&D Update Intentionally Not Used	2/26/2014	IMPAX-OPANA-CID00019495	IMPAX-OPANA-CID00019542	GX0521	JX-002		Ordered 10/23/2017	
CX1001 CX1002 CX1003- CX1004	Endo Presentation: Corporate Development Update: Endo Board of Directors Meeting Endo Presentation: Corporate Development & Strategy Departmental Offsite Intentionally Not Used	2/24/2010 3/7/2010	EPI000821205 EPI001305772	EPI000821205 EPI001305772	GX1001; RX-041 GX1002	JX-002 JX-002			Tr. 2580:17; 2580:19; 2580:22; 2581:15; 2581:21; 2582:05 Tr. 2582:16; 2582:19; 2582:22; 2583:08
CX1005	Email from Vik Seoni to Nancy Wysenski, Robert Cobuzzi, Carolyn Kong, et al. re: Latest draft pick w/Attach: FP_Endo Strategic Opportunities_vFinal.PPT	5/30/2008	EPI001114983	EPI001114984	GX1005	JX-002			Tr. 2576:06; 2576:12; 2578:20; 2580:05
CX1006	Email from Robert Cobuzzi to Kevin Pong, Alan Butcher re: IPX66 w/Attach: IPX066_IMPAX_Partner_Confidential_032010_FINAL.PDF; ATT621896.htm: 066 Apr2010AAN poster final poster.ppt; ATT621898.htm	5/20/2010	EPI001433402	EPI001433505	GX1006; RX-068	JX-002			

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX1007	Email from Robert Cobuzzi to Ernest Kopecky, Paula Clark, Frank Diana, et al. re: IPX066 w/Attach: 066 Apr2010AAN poster final poster.ppt; IPX066_IMPAX_Partner_Confidential_032010_FINAL.PDF	5/25/2010	EPI001445208	EPI001445307	GX1007; GX1703; RX-074	JX-002		Ordered 10/23/2017	Tr. 2547:06; 2590:11; 2590:13
CX1008	Email from Mark Bradley to Robert Cobuzzi re: Project Imperial	5/27/2010	EPI001433631	EPI001433638	GX1008; RX-071	JX-002			Tr. 2585:08; 2585:12; 2585:15; 2585:23; 2588:03; 2588:04; 2589:02; 2591:09; 2591:10
CX1009	Email from Allan Miller to Robert Cobuzzi, Ellen Bernstein, David Godolphin re: Data request w/Attach: Strategic Insights.ppt	5/26/2010	EPI001433613	EPI001433618	GX1009; RX-069	JX-002			
CX1010	Intentionally Not Used					N/A			
CX1011	Email from Alan Levin to Chris Mengler, Guy Donatiello, Robert Cobuzzi re: R&D Collaboration	6/2/2010	EPI000821991	EPI000821991	GX1011; RX-043	JX-002			
CX1012	Email from Robert Cobuzzi to Michael Nestor, Chris Mengler, Alan Levin re: R&D Contract?	6/4/2010	EPI000874111	EPI000874112	GX1012	JX-002			
CX1013	Endo Document: Imperial Opportunity Evaluation Worksheet (OEWS) v6	6/7/2010	EPI001306066	EPI001306082	GX1013	JX-002			
CX1014	Endo Document: Imperial Opportunity Evaluation Worksheet (OEWS) v10	6/8/2010	EPI001306083	EPI001306099	GX1014	JX-002			
CX1015	Email from Kevin Pong to Mark Bradley, Robert Cobuzzi re: GlaxoSmithKline gains rights to Impax's experimental Parkinson's disease therapy	12/17/2010	EPI001122284	EPI001122284	GX1015; GX1708; RX-058	JX-002			
CX1016	Endo Document: Development and Co-Promotion Agreement by and between Endo Pharmaceuticals Inc. and Impax Laboratories, Inc.	6/7/2010	EPI000821661	EPI000821693	GX1016	JX-002			
CX1017- CX1100	Intentionally Not Used					N/A			
CX1101	Email from Bob Barto to Tara Chapman re: documentation requested w/Attach: 20120103-Endo-NCH-DrugShortage (2).pdf	1/8/2013	EPI000033569	EPI000033578	GX1101	JX-002			Tr. 2601:05; 2601:07
CX1102 CX1103- CX1105	Email from Larry Romaine to Kathleen Cronshaw re: All field documents w/Attach: Endo Field Communication Letter_FAQ_FINAL.pdf, Dear HCP Letter Endo_FINAL.pdf, DearPharmacy Letter Endo Products_FINAL.pdf, Dear Patient Letter Endo_FINAL.pdf...	1/9/2012	EPI001065976	EPI001065991	GX1102	JX-002			
	Intentionally Not Used					N/A			
CX1106	Email from Demir Bingol to Brian Lortie re: OPANA ER Strat. Plan w/Attach: 2010 OPANA Brand Strategic Plan-07-22-09.v7(Presentation).pptx	7/22/2009	EPI001167270	EPI001167271	GX1106; RX-061	JX-002			Tr. 2292:03; 2292:09; 2482:05; 2482:09; 2482:21; 2483:03; 2483:25
CX1107	Document: Declaration of Brian Lortie in Support of Plaintiff's Motion for Preliminary Injunction, Endo v. Actavis, Endo v. Roxane	8/5/2013	EPI001487796	EPI001488267	GX1107	JX-002		Ordered 10/20/2017	
CX1108	Email from Demir Bingol to Robert Prachar and Brian Lortie re: Revopan BoD slides w/Attach: Revopan BoD Slides-11-16-10.pptx	11/16/2010	EPI000189454	EPI000189455	GX1108	JX-002			Tr. 2451:01; 2451:02; 2451:07; 2451:22; 2453:07
CX1109	Intentionally Not Used					N/A			
CX1110	Memo from Brian Lortie to Endo Health Solutions Board of Directors re: Endo Pharmaceuticals Business Unit Performance Update	6/26/2013	EPI000003693	EPI000003696	GX1110	JX-002		Ordered 10/20/2017	
CX1111 CX1112- CX1200	Email from Kevin OBrien to Brian Lortie and Kevin OBrien re: Actavis Generic OER w/Attach: OXYMORPHONE ACTAVIS ANALYSOURCE.xlsx	9/24/2013	EPI000427933	EPI000427935	GX1111	JX-002			
	Intentionally Not Used					N/A			
CX1201	FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations: Application No N020612	9/24/2014	CX1201-001	CX1201-001	GX1201; GX1229	JX-002			
CX1202	Intentionally Not Used					N/A			
CX1203 CX1204	Email from Martin Black to Stephen Hash, Guy Donatiello re: Opana w/Attach: Document.pdf	2/20/2009	EPI000872253	EPI000872274	GX1203; RX-049	JX-002		Ordered 10/20/2017	
	Intentionally Not Used					N/A			
CX1205	FDA: Oxymorphone Hydrochloride, ANDA no. 079087 Approval History	9/24/2014	CX1205-001	CX1205-003	GX1205; GX1803	JX-002			
CX1206 CX1207	Email from Robert Cobuzzi to Guy Donatiello, Alan Levin, Roberto Cuca, et al. re: IPX066 w/Attach: DATA LIST.docx; ATT808802.htm	5/22/2010	EPI001588123	EPI001588132	GX1206	JX-002			
	Intentionally Not Used					N/A			

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX1208	Email from Robert Cobuzzi to Dave Holveck, Alan Levin, Caroline Manogue, et al. re: Imperial OEW w/Attach: 052810 Imperial OEW v5.docx	6/1/2010	EPI001448405	EPI001448421	GX1208; GX1010; GX1416	JX-002			Tr. 2593:06; 2593:08; 2594:06; 2594:15; 2595:12
CX1209	Email from Robert Cobuzzi to rkimmel@ny.rothinc.com, JohnJDelucca@aol.com, Dave Holveck, et al. re: License with Impax Completed w/Attach: Imperial OEW final.docx	6/8/2010	EPI001448440	EPI001448457	GX1209; RX-077	JX-002		Ordered 10/23/2017	Tr. 1088:12, 13, 19, 23; 1089:06; 1122:05; 1161:06; 2549:10; 2609:12; 2609:19; 2610:01; 2611:20; 2613:13; 2616:14; 2617:21; 2618:10; 2618:22; 2622:07
CX1210- CX1212	Intentionally Not Used					N/A			
CX1213	Case 2:09-cv-00831-KSH-PS: Answer, Affirmative Defenses, Counterclaim and Prayer for Relief of Defendant Impax Laboratories, Inc.	12/20/2007	CX1213-001	CX1213-008	GX1213; GX0306	JX-002			
CX1214	Intentionally Not Used					N/A			
CX1215	Email from Linda Marchione to Guy Donatiello re: Impax Letter dated 1-3-2013 from Margaret Snowden in response to Caroline Manogue's 12-27-2012 Letter w/Attach: Impax Letter dated 1-3-2013 from Margaret Snowden in response to Caroline Manogue's 12-27-2012	1/4/2013	EPI000184308	EPI000184309	GX1215	JX-002			
CX1216	Email from Paula Schiavo to Alan Levin re: Approvals Needing your request w/Attach: To Do: Approval for END-110793-IMPAX LABORATORIES INC Invoice; IMPAX.pdf; To Do: Approval for END-101855-NOVARTIS CONSUMER HEALTH INC. Invoice; ROYALTIES.pdf	4/15/2013	EPI001912283	EPI001912305	GX1216	JX-002			
CX1217	Email from Nancy Olson to Alan Levin, Caroline Manogue, Julie McHugh, et al. re: Executive Pricing Committee Meeting w/Attach: Mycophenolate Mofetil Price A Pricing 6.3.10.pdf; Oxymorphone ER Price Proposal Summary 06-02-10.pdf	5/14/2010	EPI000193074	EPI000193078	GX1217; GX1315	JX-002			
CX1218	Endo Document: Highlights of Opana ER Prescribing Information	5/00/2013	EPI000000451	EPI000000539	GX1218; GX2507; RX-006	JX-002			
CX1219	FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, Application No N201655	9/24/2014	CX1219-001	CX1219-001	GX1219	JX-002			
CX1220	Email from Tara Chapman to maryann.holovac@fda.hhs.gov, lisa.basham@fda.hhs.gov re: Request to move Opana ER NDA 21-610 to the Orange Book Discontinued List	5/31/2012	EPI000027305	EPI000027305	GX1220; GX2506; RX-008	JX-002			
CX1221- CX1222	Intentionally Not Used					N/A			
CX1223	Email from Bob Barto to Alan Minsk re: Complaint Filed w/Attach: Endo -- Complaint with ECF Header.PDF.PDF; Memorandum in Support of Motion for Pl.pdf.pdf	12/3/2012	EPI000754087	EPI000754146	GX1223; GX2508	JX-002			
CX1224	Facsimile from FDA/Office of Regulatory Policy (ORP) to Robert Barto re: Citizen Petition Response (FDA-2012-P-0895)	5/10/2013	EPI000337189	EPI000337198	GX1224	JX-002			
CX1225- CX1300	Intentionally Not Used					N/A			
CX1301	Response of Endo Pharmaceuticals Inc. to Civil Investigative Demands Issued on February 20, 2014 and March 25, 2014	8/11/2014	CX1301-001	CX1301-131	GX1204; GX1301; GX1302; GX1802	JX-002			
CX1302- CX1304	Intentionally Not Used					N/A			
CX1305	Email from Chris Mengler to Alan Levin re: Highly Confidential - Rule 408 Settlement Communication	5/27/2010	EPI000874042	EPI000874043	GX1305; RX-050	JX-002			
CX1306	Email from Roberto Cuca to Alan Levin re: Highly Confidential - Rule 408 Settlement Communication	5/31/2010	EPI001379213	EPI001379216	GX1306	JX-002			
CX1307	Email from Blaine Davis to Dave Holveck, Alan Levin, Jonathan Neely re: Impax Laboratories Receives Tentative FDA Approval for Generic Opana(R) ER 5, 7.5, 10, 15, 20, 30, and 40 mg Tablets	5/14/2010	EPI001688556	EPI001688557	GX1307	JX-002			
CX1308	Email from Alan Levin to Chris Mengler re: <no subject>	6/3/2010	EPI000874166	EPI000874166	GX1308; RX-053	JX-002			
CX1309- CX1310	Intentionally Not Used					N/A			
CX1311	Email from Alan Levin to Dave Holveck re: It's not over till the fat lady sings.....	6/4/2010	EPI002155322	EPI002155322	GX1311; GX1404; RX-124	JX-002			

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX1312- CX1313	Intentionally Not Used					N/A			
CX1314	Email from Roberto Cuca to Alan Levin re: <no subject>	6/1/2010	EPI000873999	EPI000873999	GX1314	JX-002			Tr. 659:11
CX1315	Intentionally Not Used					N/A			
CX1316	Email from Julie McHugh to Alan Levin, Denise Craig, Nancy Olson re: Two Documents for EPC Today at 4:30 w/Attach: FW: Approval Requested - Oxymorphone ER Pricing; FW: Approval Requested - Oxymorphone ER Pricing	6/7/2010	EPI001688928	EPI001688930	GX1316	JX-002			
CX1317	Intentionally Not Used					N/A			
CX1318	Email from Cindy Cary to Dave Holveck re: Three Year Forecast for Compensation Discussion at 3 pm w/Attach: Three Year Company Total--OPANA-TRF scenarios (2).xlsx; Three Year Plan 2010 (3).xlsx	2/9/2010	EPI001683075	EPI001683077	GX1318; GX1413	JX-002			
CX1319	Intentionally Not Used					N/A			
CX1320	Email from Nancy Santilli to Alan Levin, Dave Holveck, Robert Cobuzzi, et al. re: Updated Three Year Forecast 2010-2012 w/Attach: Three Year Plan 2010 Final.xlsx	2/11/2010	EPI001685460	EPI001685461	GX1320	JX-002			
CX1321	Email from Alan Levin to Nancy Santilli re: Updated Three Year Forecast 2010-2012	2/11/2010	EPI001685465	EPI001685465	GX1321	JX-002			
CX1322- CX1402	Intentionally Not Used					N/A			
CX1403	Email from Dave Holveck to Alan Levin re: Impax-- Status Update	6/1/2010	EPI001688723	EPI001688723	GX1403; RX-097	JX-002			
CX1404	Intentionally Not Used					N/A			
CX1405	Email from Alan Levin to Dave Holveck re: Impax-- Status Update (Monday morning)	6/7/2010	EPI000874099	EPI000874099	GX1405	JX-002			
CX1406- CX1413	Intentionally Not Used					N/A			
CX1414	Email from Dave Holveck to Alan Levin re: No Subject	5/17/2010	EPI000873965	EPI000873965	GX1414	JX-002			
CX1415- CX1700	Intentionally Not Used					N/A			
CX1701	Email from Robert Cobuzzi to Brian Lortie, Richard Dudek, Daniel Carbery, et al. re: Corp Dev Update 29Jul2010.ppt w/Attach: Corp Dev Update 29Jul2010.ppt	7/30/2010	EPI000189176	EPI000189177	GX1701	JX-002			Tr. 2568:16; 2568:25; 2569:25; 2570:16
CX1702- CX1703	Intentionally Not Used					N/A			
CX1704	Email from Kevin Pong to Robert Cobuzzi, Alan Butcher re: Imperial OEW w/Attach: 052110 Imperial OEW v1.docx	5/24/2010	EPI001433673	EPI001433681	GX1704	JX-002			
CX1705	Email from Kevin Pong to Mark Bradley, Robert Cobuzzi re: Imperial OEW w/Attach: 052810 Imperial OEW v2.docx	5/28/2010	EPI001433659	EPI001433668	GX1705	JX-002			
CX1706	Endo Document: Imperial Opportunity Evaluation Worksheet (OEW) _v4	5/28/2010	EPI001643881	EPI001643897	GX1706	JX-002			
CX1707	Endo Document: Imperial Opportunity Evaluation Worksheet (OEW) final	6/8/2010	EPI001644520	EPI001644537	GX1707	JX-002		Ordered 10/23/2017	
CX1708	Intentionally Not Used					N/A			
CX1709	Endo Document: Paris OEW 073010 v4	7/30/2010	EPI001941235	EPI001941243	GX1709	JX-002			
CX1710- CX1812	Intentionally Not Used					N/A			
CX1813	Email from Guy Donatiello to Jennifer Saionz, Thomas Rayski, Meg Snowden, et al. re: Impax - Endo w/Attach: Impax - Endo - Settlement Agreement (060710 740pm).DOC	6/7/2010	IMPAX-OPANA-CID00001439	IMPAX-OPANA-CID00001465	GX1813; EPI000593974	JX-002			
CX1814	Intentionally Not Used					N/A			
CX1815	Email from Eliot Choy to Huong Nguyen, Meg Snowden, Jennifer Saionz re: Endo Signature Pages w/Attach: ATT00001.htm; ATT00002.htm; Co-Promote Agmt - Endo Sig Page.pdf; Settlement Agmt - Endo Sig Page.pdf	6/8/2010	IMPAX-OPANA-CID00022190	IMPAX-OPANA-CID00022193	GX1815; EPI000183779	JX-002			
CX1816	Email from Guy Donatiello to Meg Snowden, Christopher Mengler, Robert Cobuzzi re: email address w/Attach: Endo Pharmaceuticals Inc. 10-13-2009.pdf	5/19/2010	EPI000828076	EPI000828079	GX1816; RX-317	JX-002			Tr. 455:15
CX1817	Intentionally Not Used					N/A			

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX1818	Email from Guy Donatiello to Edward Sweeney re: <no subject> w/Attach: Impax Laboratories, Inc.-Development&Co-PromotionAgmtJun10.pdf; Emailing: Impax Laboratories, Inc.-Development&Co-PromotionAgmtJun10.pdf	6/24/2010	EPI000874308	EPI000874343	GX1818	JX-002			
CX1819	Email from Steve Mollichella to Robert Cooper, Guy Donatiello, Meg Snowden, et al. re: Upfront payment	6/24/2010	EPI000874347	EPI000874348	GX1819	JX-002			
CX1820	Intentionally Not Used					N/A			
CX1821	Email from Guy Donatiello to Meg Snowden re: steering committee	12/16/2010	EPI001380387	EPI001380388	GX1821	JX-002			
CX1822- CX2503	Intentionally Not Used					N/A			
CX2504	Email from Bob Barto to Lizhuo Nouaime re: Action letter for NDA 201655 w/Attach: Complete Reponse Letter FINAL.pdf	1/10/2011	EPI000078096	EPI000078101	GX2504; RX-009	JX-002			
CX2505	Email from Tara Chapman to Ivan Gergel, Bob Barto, and Paula Clark re: OPANA ER - APPROVAL LETTER w/Attach: NDA 201655 APPROVAL letter with attachments.pdf	12/9/2011	EPI000080293	EPI000080385	GX2505; RX-010	JX-002			
CX2506- CX2518	Intentionally Not Used					N/A			
CX2519	Presentation: Opana ER Financial Scenario Overview	4/22/2013	EPI000003937	EPI000003943		JX-002			
CX2520	Document: Endo Pharmaceuticals EOC Meeting, Brian Lortie	1/14/2011	EPI000004460	EPI000004631		JX-002			
CX2521- CX2522	Intentionally Not Used					N/A			
CX2523	Email from John Kranyak to Alicia Logan re: RE: Christine Crooks Contact Info w/Attach: OPANA ER Growth Project MR Plan summary deck.pptx, Microsoft_Excel_Worksheet1 .xlsx, Microsoft_Excel_Worksheet2.xlsx	7/12/2011	EPI000187180	EPI000187184		JX-002			
CX2524	Email from Brian Lortie to Mark Bradley, Julie McHugh, and Roberto Cuca re: Data request	6/7/2010	EPI000192445	EPI000192457	RX-018	JX-002			
CX2525	Intentionally Not Used					N/A			
CX2526	Email from Chris Mengler to Alan Levin re: Highly Confidential - Rule 408 Settlement Communication	5/27/2010	EPI000874038	EPI000874039		JX-002			
CX2527	Email from Alan Levin to Mark Bradley and Karen Adler re: Impax Update	6/4/2010	EPI000874049	EPI000874049	RX-051	JX-002			
CX2528	Presentation: Revopan Launch Readiness Review	12/16/2010	EPI001538172	EPI001538172		JX-002		Ordered 10/20/2017	
CX2529	Endo Presentation: Opana ER Strategic Platform: Chronic Pain	9/00/2012	EPI000000240	EPI000000303		JX-002			
CX2530	Email from Tara Chapman to Demir Bingol, Bob Barto, Diana Frank, et al. re: EN3288 Review-05-5-10 TC.pptx w/Attach: EN3288 Review-05-5-10 TC.pptx	5/5/2010	EPI000069099	EPI000069100		JX-002			
CX2531	Email from Mark Bradley to Alan Levin, Karen Adler re: Imperial: Counter Offer Considerations	6/5/2010	EPI001688790	EPI001688795		JX-002			
CX2532	Email from Mark Bradley to Alan Levin, Karen Adler, Robert Cobuzzi re: Endo/Impax: R&D Collaboration	6/6/2010	EPI002156059	EPI002156061	RX-125	JX-002			
CX2533	Email from Julie McHugh to Robert Cobuzzi, Alan Levin, Karen Adler, et al. re: Information requested	6/5/2010	EPI002156071	EPI002156074	RX-126	JX-002			
CX2534	Email from Alan Levin to Robert Cobuzzi re: <no subject>	6/6/2010	EPI002156093	EPI002156095		JX-002			
CX2535	Email from Todd Engle to Kevin Sica re: BOD Slides Aug 2012 - Rev 4 Todd.pptx w/Attach: BOD Slides Aug 2012 - Rev 4 Todd.pptx	11/5/2012	IMPAX-OPANA-CID00013814	IMPAX-OPANA-CID00013849		JX-002			
CX2536	Email from Todd Engle to Susan Ostrander re: BOD Slides Feb 2013.pptx w/Attach: BOD Slides Feb 2013.pptx	2/5/2013	IMPAX-OPANA-CID00014814	IMPAX-OPANA-CID00014842		JX-002			
CX2537	Email from Todd Engle to Susan Ostrander re: Todd's Board Slides February 2014 V4.pptx w/Attach: Todd's Board Slides February 2014 V4.pptx	2/7/2014	IMPAX-OPANA-CID00015721	IMPAX-OPANA-CID00015759		JX-002			
CX2538	Email from Susan Ostrander to Todd Engle, Carole Ben-Maimon re: Updated Slides for 7/9/13 Board Presentation w/Attach: July 2013 Board Presentation (2).ppt	7/8/2013	IMPAX-OPANA-CID00016426	IMPAX-OPANA-CID00016454		JX-002			
CX2539	Email from Laura Zhu to Michael Nestor, David Paterson re: Fropa, Endo w/Attach: Opana_Sales.xls	1/18/2009	IMPAX-OPANA-CID00022154	IMPAX-OPANA-CID00022156	RX-407	JX-002			



COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX2540	Email from Ted Smolenski to Joyce De Los Reyes, David Berman, Meg Snowden, et al. re: ENDP US: Endo Pharmaceuticals Holdings Inc: Tidbits from management meet... w/Attach: mbull.gif; spacer.gif	12/4/2009	IMPAX-OPANA-CID00022170	IMPAX-OPANA-CID00022171	RX-408	JX-002			Tr. 570:16
CX2541	Intentionally Not Used					N/A			
CX2542	Email from Mark Shaw to John Anthony, Chuck Hildenbrand, Joe Camargo re: Impax requested a revised 2010 Oxymorphone Quota	6/10/2010	IMPAX-OPANA-CID00022358	IMPAX-OPANA-CID00022358		JX-002			
CX2543	Case 1:12-cv-01936-RBW: Declaration of Julie H. McHugh in Support of Plaintiff's Motion for Preliminary Injunction and Opposition to Defendants' Motions to Dismiss	12/14/2012	IMPAX-OPANA-CID00022780	IMPAX-OPANA-CID00022784		JX-002			
CX2544	Intentionally Not Used					N/A			
CX2545	Email from Larry Hsu to Richard Ting, Mark Donohue, Carole Ben-Maimon, et al. re: Endo Pharma. (ENDP, BUY): Another Hurdle for Generic Opana - No RLD	6/27/2012	IMPAX-OPANA-CID00023482	IMPAX-OPANA-CID00023485		JX-002			
CX2546- CX2547	Intentionally Not Used					N/A			
CX2548	Impax Spreadsheet: Lot Assignments Final 111711 12/1/2014	12/1/2014	IMPAX-OPANA-CID00024582	IMPAX-OPANA-CID00024582		JX-002			
CX2549	Email from Kent Summers to Mark Rubino, Steve Camper re: Roles, AEs - HFSs w/Attach: OM - HOPE launch plans v11AEs.pptx	10/27/2010	EPI000327296	EPI000327297		JX-002			
CX2550	Email from Debbie Travers to Demir Bingol, Art Vrecenak, Tara Chapman, et al. re: EN3288 Prep for May 10th ELC meeting w/Attach: EN3288 Review-04-28-10 DT comments.pptx	4/29/2010	EPI000130110	EPI000130112		JX-002			
CX2551	Endo Presentation: Opana ER: Host Meeting, 03/14/11	3/14/2011	EPI000289754	EPI000289754		JX-002		Ordered 10/20/2017	
CX2552	Email from Demir Bingol to Cassie Mapp, Chad Simon, Linda Wyse re: Oxymorphone Situation Analysis w/Attach: EN3288-05-17-10.pptx; Microsoft_Office_Excel_97-2003_Worksheet2.xls; Microsoft_Office_Excel_97-2003_Worksheet1.xls	5/19/2010	EPI000314303	EPI000314306		JX-002			
CX2553	Endo Presentation: Oxymorphone Franchise Business Plan 2011 thru 2021	6/8/2010	EPI000292190	EPI000292190		JX-002		Ordered 10/20/2017	
CX2554	Email from Alyssa Dicker to TJ Fuller, Matthew Wieman, Rob Gatley, Rose Wessells, et al. re: RESPONSE REQUESTED - Opana Monograph for MARC w/Attach: Opana_Mono_022112 for MARC.pdf	2/21/2012	EPI000060051	EPI000060137		JX-002			
CX2555	Endo Presentation: Opana ER: Protect and Grow Strategy	12/28/2012	EPI000003964	EPI000003975		JX-002			
CX2556	Email from Darnell Turner to Alicia Logan re: Grunenthal floor prices w/Attach: GRT Floor Price Analysis.xlsx	8/26/2010	EPI000186709	EPI000186713		JX-002			
CX2557	Email from Mark Bradley to James Bradley re: EN3288/OPANA ER scenario follow up w/Attach: Topline EN3288 Forecast-06-28-10 scenarios v2.xlsx	6/30/2010	EPI000315082	EPI000315086	RX-031	JX-002			
CX2558	Endo Presentation: Opana® ER (oxymorphone HCl) Extended-Release tablets, CIIWith INTAC® Technology	10/00/2012	EPI000419710	EPI000419710		JX-002			
CX2559- CX2560	Intentionally Not Used					N/A			
CX2561	Email from Ted Smolenski to Michelle Wong, Richard Ting, Meg Snowden, et al. re: Generic new product launch projection.031808.xls w/Attach: Generic new product launch projection.031808.xls	3/18/2008	IMPAX-OPANA-CID00014243	IMPAX-OPANA-CID00014244		JX-002			
CX2562	Email from Larry Hsu to Michael Nestor, Suneel Gupta, Shawn Fatholahi, et al. re: 2010 Company Key Goals - Confidential Information - Please do not distribute w/Attach: 2010 company key goals.doc	2/28/2010	IMPAX-OPANA-CID00020838	IMPAX-OPANA-CID00020841		JX-002			Tr. 250:08; 251:20
CX2563	Email from Kangwen Lin to Andrew Fox, Art Koch, Chris Mengler, et al. re: Generic meeting update - operation activities for 6/15 meeting w/Attach: OA for Generic meeting June 15.doc	6/15/2010	IMPAX-OPANA-CID00023206	IMPAX-OPANA-CID00023208		JX-002			
CX2564	Email from Mark Bradley to Roberto Cuca, David Macera, and Karen Adler re: 10 Year Outlook - New v4.xls w/Attach: 10 Year Outlook - New v4.xls	3/23/2010	EPI000180093	EPI000180094	RX-012	JX-002			
CX2565	Intentionally Not Used					N/A			

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX2566	Email from Andy Gesek to Alan Levin, Roberto Cuca, Jack Boyle re: 2013 Apr LBE AG Version.pptx w/Attach: 2013 Apr LBE AG Version.pptx	4/17/2013	EPI000342149	EPI000342150		JX-002			
CX2567 CX2568- CX2569	Email from Alan Levin to Roberto Cuca re: Impax - Endo w/Attach: Redline - Impax-Endo Settlement and License Agreement.pdf; Draft Impax - Endo SettlementAgreement (Opana) [Endo Markup] (3).DOC Intentionally Not Used	6/7/2010	EPI001588988	EPI001588937		JX-002			
CX2570	Document: Impax Strategy for Opana ER	6/27/2012	EPI000003426	EPI000003430		N/A			
CX2571	Email from Debbie Travers to Kristin Livingston, Beth Aranilla, Tracy Wilson, et al. re: Slides for Opana R&D Project Review w/Attach: Opana Project Review June 08.ppt	6/4/2008	EPI000091510	EPI000091511		JX-002			
CX2572	Email from Linda Kitlinski to ClinEd re: QBR DRAFT Slides - Opana Brad w/Attach: OPANA Brand QBR-01-30-09.v6.ppt	2/10/2009	EPI000210720	EPI000210721		JX-002		Ordered 10/20/2017	
CX2573	Presentation: EN3288 Commercial Update, Demir Bingol	2/24/2010	EPI000290472	EPI000290472		JX-002			Tr. 1297:13; 1297:14; 1297:24; 1298:01; 1298:08; 1298:15
CX2574	Intentionally Not Used					N/A			
CX2575	Email from Demir Bingol to Tara Chapman, Bob Barto, Diana Frank, and William Fiske re: EN3288 Review-05-5-10 TC.pptx w/Attach: EN3288 Review-05-05-10.v2.pptx	5/6/2010	EPI000631980	EPI000631981		JX-002			
CX2576	Email from Demir Bingol to Kayla Keinhofer re: No Subject	2/11/2010	EPI000914419	EPI000914421		JX-002			
CX2577	Email from Doug Azzalina to Javier Avalos, Robert Candea, Steven Cooper, and Demir Bingol re: oxymorphone ER AG data request	5/24/2010	EPI000950429	EPI000950430		JX-002		Ordered 10/20/2017	
CX2578	Presentation: OPANA Brand LCM Update	12/11/2007	EPI001296881	EPI001296881		JX-002			
CX2579	Email from David Macera to Chuck Williams and Derek Elphick re: 10 Yr Plan - Revenue Forecast w/Attach: 10 Yr Revenue for Forecast Team v01 121611.xlsx	12/16/2011	EPI001434343	EPI001434344		JX-002			
CX2580	Presentation: EN3288 Launch Scenarios	2/2/2010	EPI001540148	EPI001540148		JX-002			
CX2581	Document: OPANA Lifecycle Management Team Meeting Highlights	2/2/2010	EPI001540841	EPI001540844		JX-002			
CX2582	Email from Demir Bingol to Laurel McDermott re: Slides for EOC w/Attach: EN3288 Strategic Options-06-24-10 v.4.pptx	6/25/2010	EPI001553464	EPI001553465		JX-002			
CX2583	Email from Mark Bradley to Alan Levin, Julie McHugh, and Karen Adler re: RAP w/Attach: Microsoft_Office_Excel_Worksheet4.xlsx, Microsoft_Office_Excel_97-2003_Worksheet2.xls, Microsoft_Office_Word_Document3.docx, Microsoft_Office_Word_Document6.docx...	10/27/2010	EPI001694497	EPI001694520		JX-002			
CX2584 CX2585- CX2593	Email from Alison Freeman-Gleason to Meg Snowden, Michael Nestor, Shawn Fathlahi, et al. re: co-promotion agreement w/Attach: ST-#2537506-v2-Endo_co-promotion_agreement.DOC, ST-#2537507-v1-WS_comparison_Endo_co-promotion_agreement_6_June_10.DOC Intentionally Not Used	6/6/2010	IMPAX-OPANA-CID00001619	IMPAX-OPANA-CID00001682	RX-274	JX-002			
CX2594 CX2595- CX2600	Email from Shawn Fathlahi to Todd Engle and Carole Ben-Maimon re: Actavis' Generic Opana ER Receives FDA Approval Intentionally Not Used	7/15/2013	IMPAX-OPANA-CID00007188	IMPAX-OPANA-CID00007190	RX-339	JX-002			
CX2601 CX2602- CX2606	Email from Shawn Fathlahi to Michael Nestor re: FROVA Rough S&M Analysis w/Attach: Frova Prelim. Opp. Analysis January 2009 Intentionally Not Used	1/20/2009	IMPAX-OPANA-CID00020102	IMPAX-OPANA-CID00020107		JX-002		Ordered 10/23/2017	
CX2607	Declaration of Brian Lortie in Support of Plaintiff's Motion for Preliminary Injunction, Endo Pharmaceuticals Inc v. Actavis Inc. and Actavis South Atlantic LLC, Endo Pharmaceuticals Inc v. Roxane Laboratories, Inc.	8/5/2013	EPI001456200	EPI001456223		JX-002		Ordered 10/20/2017	

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX2608	Plaintiff-Appellant's Reply In Support of Motion for an Injunction Pending Trial, Endo Pharmaceuticals Inc. v. Actavis, Inc. and Actavis South Atlantic, LLC	9/27/2013	EPI001486613	EPI001487275		JX-002			
CX2609	Decalaration of Henry G. Grabowski, Ph. D. In Support of Plaintiff's Motion for Preliminary Injunction, Endo Pharmaceuticals Inc v. Actavis Inc. and Actavis South Atlantic LLC, Endo Pharmaceuticals Inc v. Roxane Laboratories, Inc.	8/5/2013	EPI001488515	EPI001488566		JX-002		Ordered 10/20/2017	
CX2610	Email from Christine Crooks to Demir Bingol re: Revopan Playbook--PLEASE REVIEW MONDAY w/Attach: 2352_abbnhl_revopan_plybvk_lo5.pptx	12/11/2010	EPI000319915	EPI000319916		JX-002			Tr. 1269:18; 1269:20; 1269:22; 1311:20
CX2611	Email from David Macera to Alan Levin and Karen Adler re: 10 Yr Plan w/Attach: 10 yr Outlook v7 Q3 2012 Case.pdf, 10 Yr Outlook v7 Q3 2013 Case.pdf, 10 yr Outlook v7 Base Case.pdf, 10 yr Outlook with Kansas v7.xlsx	3/21/2011	EPI001901990	EPI001902036		JX-002			
CX2612	Intentionally Not Used					N/A			
CX2613	Email from Todd Engle to Shawn Fatholahi re: Actavis' Generic Opana ER Receives FDA Approval w/Attach: Graphs 07_17_13.xls	8/21/2013	IMPAX-OPANA-CID00007908	IMPAX-OPANA-CID00007914	RX-343	JX-002			
CX2614- CX2615	Intentionally Not Used					N/A			
CX2616	Email from Guy Donatiello to Chris Mengler, Meg Snowden, Alan Levin, et al. re: Highly Confidential - Rule 408 Settlement Communication	5/26/2010	IMPAX-OPANA-CID00005625	IMPAX-OPANA-CID00005626	RX-311	JX-002			
CX2617- CX2624	Intentionally Not Used					N/A			
CX2625	Email from Michael Nestor to David Paterson re: IPX066	5/22/2010	IMPAX-OPANA-CID00006708	IMPAX-OPANA-CID00006711		JX-002			Tr. 3012:06; 3012:07; 3012:09; 3013:16; 3014:25
CX2626	Impax Document: Settlement and License Agreement	7/6/2010	Impax_Opana_PartIII_0000147	Impax_Opana_PartIII_0000172	RX-364	JX-002			Tr. 1926:13
CX2627	Impax Presentation: Board of Directors Meeting February 2010	2/00/2010	Impax_Opana_PartIII_0002024	Impax_Opana_PartIII_0002054	RX-150	JX-002		Ordered 10/23/2017	
CX2628	Impax Presentation: Board of Directors Meeting November 2009	11/11/2009	Impax_Opana_PartIII_0002055	Impax_Opana_PartIII_0002090	RX-151	JX-002		Ordered 10/23/2017	
CX2629	Impax Presentation: Board of Directors Meeting August 2010	8/00/2010	Impax_Opana_PartIII_0002152	Impax_Opana_PartIII_0002193		JX-002			
CX2630	Email from David Paterson to Robert Cobuzzi, Michael Nestor, Chris Mengler, et al. re: IPX066	5/21/2010	IMPAX-OPANA-CID00001683	IMPAX-OPANA-CID00001685		JX-002			
CX2631- CX2634	Intentionally Not Used					N/A			
CX2635	Email from Kevin Sica to Ted Smolenski re: Zorn Model Oxymorphone 03 12 10.xls w/Attach: Zorn Model Oxymorphone 03 12 10.xls	3/12/2010	IMPAX-OPANA-CID00007071	IMPAX-OPANA-CID00007072		JX-002			
CX2636	Email from Todd Engler to Chris Mengler re: Zorn Model Oxymorphone 03 11 10.xls w/Attach Zorn Model Oxymorphone 03 11 10.xls	3/11/2010	IMPAX-OPANA-CID00007123	IMPAX-OPANA-CID00007124		JX-002			
CX2637	Intentionally Not Used					N/A			
CX2638	Email from Kimberly Kam to Steve Mollichella, Laura Bisbing, Meg Snowden re: Co-Promote Revisions w/Attach: Endo Pharmaceuticals Inc., Penwest Pharmaceuticals Settlement and License Agt 6-08-2010.pdf; Endo Pharmaceuticals Inc. Development and Co. Promotion	7/6/2010	IMPAX-OPANA-CID00012071	IMPAX-OPANA-CID00012132	RX-363	JX-002			
CX2639- CX2644	Intentionally Not Used					N/A			
CX2645	Email from Todd Engle to Carole Ben-Maimon re: Teledetailing Campaign for Oxymorphone ER	11/27/2013	IMPAX-OPANA-CID00005411	IMPAX-OPANA-CID00005411	RX-308	JX-002			
CX2646	Email from Shawn Fatholahi to Carole Ben-Maimon, Todd Engle re: Actavis' Generic Opana ER Receives FDA Approval	7/15/2013	IMPAX-OPANA-CID00007217	IMPAX-OPANA-CID00007219	RX-341	JX-002			
CX2647	Intentionally Not Used					N/A			
CX2648	Email from Todd Engle to Bill Riker re: Carole's Board Slides February 2013 V6 2.pptx	4/17/2013	IMPAX-OPANA-CID00012705	IMPAX-OPANA-CID00012746		JX-002			
CX2649- CX2651	Intentionally Not Used					N/A			
CX2652	Email from Kevin Sica to Todd Engle, Carole Ben-Maimon re: Plan Update w/Attach: 2014 5 Year Plan Presentation 10151.pptx; Plan with Sept 13 Forecast Update for Kloss V3.xlsx	10/15/2013	IMPAX-OPANA-CID00015150	IMPAX-OPANA-CID00015162		JX-002		Ordered 10/23/2017	
CX2653	Intentionally Not Used					N/A			
CX2654	Email from Carole Ben-Maimon to Joanne Tempone, Bryan Reasons re: Endo Deal	11/13/2012	IMPAX-OPANA-CID00019027	IMPAX-OPANA-CID00019029	RX-382	JX-002			
CX2655	Intentionally Not Used					N/A			

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX2656	Document: Q1 2013 Impax Laboratories Earnings Conference Call - Final	5/1/2013	CX2656-001	CX2656-014		JX-002			Tr. 1216:03, 05, 10, 15
CX2657	Document: Q2 2013 Impax Laboratories Earnings Conference Call - Final	8/8/2013	CX2657-001	CX2657-010		JX-002			
CX2658	Document: Q3 2012 Impax Laboratories Earnings Conference Call - Final	10/30/2012	CX2658-001	CX2658-014		JX-002			
CX2659	Document: Q3 2013 Impax Laboratories Earnings Conference Call - Final	11/4/2013	CX2659-001	CX2659-012		JX-002			
CX2660	Document: Q4 2012 Impax Laboratories Earnings Conference Call - Final	2/25/2013	CX2660-001	CX2660-017		JX-002			
CX2661	Intentionally Not Used					N/A			
CX2662	Email from Chris Mengler to Laura Bisbing, Larry Hsu, Art Koch, et al. re: Mengler Board Materials w/Attach: Tamsulosin Board May 2010 051310.ppt; BD for May BOD 051610.ppt; Mengler Board Presentation 051610.ppt	5/17/2010	IMPAX-OPANA-CID00018082	IMPAX-OPANA-CID00018105	RX-374	JX-002		Ordered 10/23/2017	Tr. 290:06; 335:02; 335:09; 335:12; 336:10; 336:14; 549:01; 549:03; 549:23; 550:04; 553:04
CX2663	Impax Document: Minutes of the Meeting of the Board of Directors of Impax Laboratories, Inc.	5/25/2010	Impax_Opana_PartIII_0002498	Impax_Opana_PartIII_0002498		JX-002		Ordered 10/23/2017	Tr. 256:14; 257:06; 257:09; 257:11; 280:09; 334:17; 334:19
CX2664	Email from Lisa Walker to Alicia Logan and Missy Combs re: EPC Document w/Attach: Oxymorphone Price Proposal-11-11-10.docx	11/14/2010	EPI000186499	EPI000186508		JX-002			
CX2665	Email from Demir Bingol to Brian Lortie re: Revopan Price Recommendation Document w/Attach: Oxymorphone Price Proposal-09-23-10.docx	9/29/2010	EPI000189249	EPI000189253		JX-002			
CX2666	Intentionally Not Used					N/A			
CX2667	Document: Oxymorphone Franchise Pricing Proposal for Revopan, OPANA ER and OPANA	1/5/2011	EPI000290639	EPI000290647		JX-002			
CX2668	Document: Price Change Proposal Summary Form 9.9% Price Increase for OPANA SKUs	2/2/2009	EPI000293419	EPI000293421		JX-002			
CX2669	Document: Price Change Proposal Summary Form 9.9% Price Increase for OPANA SKUs	9/1/2009	EPI000293431	EPI000293432		JX-002			
CX2670	Document: Executive Pricing Committee Approval Form Price Increase Proposal for OPANA ER	2/1/2010	EPI000293433	EPI000293444		JX-002			
CX2671	Document: Price Change Proposal Summary Form - Opana IR Price Increase	7/1/2009	EPI000293484	EPI000293496		JX-002			
CX2672	Intentionally Not Used					N/A			
CX2673	Email from Demir Bingol to Darnell Turner, Jon Ziss, Theresa Frey, et al. re: Current Strengths Price Increase w/Attach: OPANA Brand (Current Strengths) Price EPC Document-03-01-08-v3.doc	3/1/2008	EPI000299876	EPI000299888		JX-002			
CX2674	Email from Demir Bingol to Theresa Frey re: all cross functional members have approved the 9.9% w/Attach: OPANA (IR) Price EPC Document-09-11-08-v3.doc	9/11/2008	EPI000302043	EPI000302051		JX-002			
CX2675	Email from Lisa Walker to Demir Bingol re: Opana PI - 2/1 w/Attach: EPC Oxy Pain Franchise Pricing 12.1.10.pdf, Frova Lido Opana Voltaren PI.pdf	3/15/2011	EPI000573222	EPI000573240		JX-002			
CX2676	Intentionally Not Used					N/A			
CX2677	Email from Demir Bingol to Deanne Melloy re: EPC Package for New Strengths w/Attach: OPANA ER New Strengths EPC Proposal-01-26-07.doc, Attachment A - Gross-to-Net Analysis 11-08-07.xlsx, Attachment B - Medicaid Impact v3.xls	1/26/2008	EPI000769089	EPI000769096		JX-002			
CX2678	Email from Theresa Fray to Lisa Walker, Demir Bingol, Doug Azzalina, et al. re: EPC approved Price Increases and TX Medicaid Supplemental Rebate w/Attach: EPC - Frova Price Increase Effective 1.1.09.pdf, EPC - Lidoderm Price Increase effective 1.1.09.pdf.	12/11/2008	EPI001035752	EPI001035798		JX-002			
CX2679	Email from Demir Bingol to Pamela Wright and Deanne Melloy re: EPC Package w/Attach: OPANA ER New Strengths EPC Proposal-02-13-08.doc, Attachment A - Gross-to-Net Analysis-11-08-07.xlsx, Attachment B - Medicaid Impact v4-02-08-08.xlsx, Attachment C...	2/13/2008	EPI001541536	EPI001541546		JX-002			
CX2680	Email from Doug Azzalina to Linda Kitlinks re: Oxymorphone Dear Healthcare w/Attach: Oxymorphone EPC Price and Launch Incentives Proposal_Final 05-07-09.pdf	6/18/2009	EPI001797536	EPI001797545		JX-002			

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX2681	Email from Dawn Yocorn to Roberto Cuca, Brian Lortie, Kevin O'Brien, et al. re: EPC Approved CVS Caremark Multi Product Part D Proposal w/Attach: EPC Caremark MedD multi-product Pricing Proposal.pdf	1/25/2013	EPI001866066	EPI001866080		JX-002		Ordered 10/20/2017	
CX2682	Impax Presentation: Backup Slides - Impax Generic Business Board of Directors Meeting	5/13/2014	Impax_Opana_PartIII_0002298	Impax_Opana_PartIII_0002318	RX-152	JX-002		Ordered 10/23/2017	
CX2683- CX2684	Intentionally Not Used					N/A			
CX2685	Impax Presentation: Impax New Product Launches - Presentation to Board of Directors	12/10/2013	Impax_Opana_PartIII_0002381	Impax_Opana_PartIII_0002398	RX-154	JX-002		Ordered 10/23/2017	
CX2686	Impax Presentation: Impax Generic Business Board of Directors Meeting	12/4/2012	Impax_Opana_PartIII_0002399	Impax_Opana_PartIII_0002430	RX-155	JX-002		Ordered 10/23/2017	
CX2687- CX2688	Intentionally Not Used					N/A			
CX2689	Impax Document: Minutes of a Special Meeting of the Board of Directors of Impax Laboratories, Inc.	3/28/2014	Impax_Opana_PartIII_0004163	Impax_Opana_PartIII_0004164	RX-166	JX-002			Tr. 463:04
CX2690	Intentionally Not Used					N/A			
CX2691	Impax Document: Minutes of the Meeting of the Board of Directors of Impax Laboratories, Inc.	12/4/2012	Impax_Opana_PartIII_0004179	Impax_Opana_PartIII_0004182		JX-002		Ordered 10/23/2017	
CX2692- CX2694	Intentionally Not Used					N/A			
CX2695	Impax Presentation: Dutasteride (Avodart) Launch Assessment	00/00/0000	Impax_Opana_PartIII_0004256	Impax_Opana_PartIII_0004265	RX-170	JX-002			
CX2696	Letter from Paula Blizzard to Jamie Towey and Maren Schmidt re: CID issued to Impax Laboratories concerning FTC File No. 1410004	7/18/2014	CX2696-001	CX2696-039		JX-002		Ordered 10/23/2017	
CX2697	Email from Art Koch to Larry Hsu re: R&D Collaboration	6/6/2010	IMPAX-OPANA-CID00021793	IMPAX-OPANA-CID00021794	RX-212	JX-002			
CX2698- CX2699	Intentionally Not Used					N/A			
CX2700	Email from Chuck Hildenbrand to Art Koch re: OXM Impax Presentation: 2010 Budget Update and 2011 Budget Preview	6/21/2010	IMPAX-OPANA-CID00007944	IMPAX-OPANA-CID00007944		JX-002			
CX2701	Intentionally Not Used					N/A			
CX2702	Document: Q3 2011 Impax Laboratories Earnings Conference Call - Final	11/1/2011	CX2703-001	CX2703-014		JX-002			Tr. 261:07; 261:10; 261:13; 261:15
CX2703- CX2704- CX2709	Intentionally Not Used					N/A			
CX2710	Case 2:16-cv-02526-JLL-JAD: Impax Laboratories, Inc.'s Answer, Affirmative Defenses, and Counterclaims to Plaintiff's Amended Complaint	11/22/2016	Impax_Opana_PartIII_0000545	Impax_Opana_PartIII_0000651		JX-002			
CX2711	Intentionally Not Used					N/A			
CX2712	Email from Ted Smolenski to Meg Snowden, Huong Nguyen, Kevin Sica, et al. re: Prescription Sales and Quarterly Peak Calculations w/Attach: 4Q10 Prescription Sales and Quarterly Peak Calculations 2011-03-17.xlsx	3/19/2011	IMPAX-OPANA-CID00012052	IMPAX-OPANA-CID00012053		JX-002			
CX2713	Email from Todd Engle to Meg Snowden, Huong Nguyen re: Steering Committee w/Attach: IMPAX Prescription Sales and Quarterly Peak Calculations July 2010 Dec 2011.xlsx	3/7/2012	IMPAX-OPANA-CID00012054	IMPAX-OPANA-CID00012057		JX-002			
CX2714	Letter from Impax Laboratories to Endo Pharmaceuticals, Penwest Pharmaceuticals re: Paragraph IV Patent Certification Notice	12/13/2007	IMPAX-OPANA-CID00024463	IMPAX-OPANA-CID00024490		JX-002			
CX2715	Intentionally Not Used					N/A			
CX2716	Endo Presentation: Mission: Deliver the Difference for the Opana Brand in POA II	5/00/2008	ENDO_OP_0069444	ENDO_OP_0069472		JX-002			
CX2717	Endo Presentation: Opana ER Moderate to Severe Chronic Pain Regional Advisory Boards: Executive Summary	00/00/0000	ENDO_OP_0078189	ENDO_OP_0078226		JX-002			
CX2718	Intentionally Not Used					N/A			
CX2719	Email from Jon Ziss to Demir Bingol, Kristin Vitanza re: Opana ER 2008 - 5 Year Plan Forecast 11 05 07 v2.ppt w/Attach: Opana ER 2008 - 5 Year Plan Forecast 11 05 07 v2.ppt	11/5/2007	ENDO_OP_0149584	ENDO_OP_0149601		JX-002			
CX2720	Intentionally Not Used					N/A			
CX2721	Endo Document: Executive Summary Opana ER Pain Management Regional Advisory Board	10/30/2007	ENDO_OP_0283787	ENDO_OP_0283808		JX-002			
CX2722	Letter from Demir Bingol to Healthcare Professional re Opana ER	2/00/2007	ENDO_OP_0299459	ENDO_OP_0299460		JX-002			
CX2723	Intentionally Not Used					N/A			

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX2724	Email from Demir Bingol to Dave Holveck, Brian Lortie, Debbie Travers re: EN3288 Potential Launch Scenarios w/Attach: TRF Project Review-01-27-10.pptx; image001.emf; [Unnamed Presentation]	1/27/2010	EPI000188850	EPI000188851		JX-002			Tr. 1300:18; 1300:19; 1300:21; 1301:05; 1302:15; 1302:16; 1303:03; 1304:17; 1304:18; 1304:23; 1305:10
CX2725	Email from Brian Lortie to Demir Bingol re: EN3288 Potential Launch Scenarios	1/27/2010	EPI000192397	EPI000192398		JX-002			
CX2726	Email from Demir Bingol to Stephen McMorn, Debbie Travers, William Fiske, et al. re: EN3288-104 Topline Results	10/30/2009	EPI000209061	EPI000209062	RX-024	JX-002			
CX2727	Intentionally Not Used					N/A			
CX2728	Email from Demir Bingol to Traci Jackson, Debbie Travers, Art Vrecenak, et al. re: REVISED DATE: EN3288 CCLT Mtg	6/12/2010	EPI000792676	EPI000792677		JX-002			
CX2729	Email from Robert Candea to Steven Cooper, Demir Bingol, Bruce Wallace, et al. re: Approval Requested - Oxymorphone ER Pricing	6/5/2010	EPI000956401	EPI000956404		JX-002			
CX2730	Email from Brian Lortie to Demir Bingol re: Opana ER.pptx w/Attach: Opana ER.pptx	10/26/2010	EPI001297663	EPI001297664		JX-002			
CX2731	Email from Demir Bingol to Pharma.--RDs, Speciality--RDs, Pharmal--DMs, et al. re: 6/6/09 - KV Pharamceutical Company, Purdue Pharma L.P. Settle OxyContin(R)	6/10/2009	EPI001751547	EPI001751547		JX-002			Tr. 1276:10; 1276:11
CX2732	Email from Demir Bingol to Troy Rippley, Steven Cowan re: DEA Justification Document w/Attach: Opana ER Justification-05-15-11.docx	5/16/2011	EPI001773315	EPI001773318		JX-002		Ordered 10/20/2017	
CX2733	Email from Larry Romaine to SalesEndo--RDs, Maria Lane re: Voice Mail to the Field	6/8/2010	EPI001778327	EPI001778327		JX-002			
CX2734	Endo Spreadsheet: Net \$1B Opana ER 2015 5 4 11 (Sept Launch higher strengths)	5/4/2011	EPI000290117	EPI000290117		JX-002			
CX2735- CX2737	Intentionally Not Used					N/A			
CX2738	Endo Presentation: ELC 2012 Budget Review, Branded Pharmaceuticals	10/12/2011	EPI000003773	EPI000003841		JX-002			Tr. 2454:06; 2454:16; 2499:08
CX2739	Intentionally Not Used					N/A			
CX2740	Email from Brian Lortie to Mark Bradley re: Data request	6/7/2010	EPI000192537	EPI000192550		JX-002			
CX2741 CX2742- CX2743	Endo Document: Settlement and License Agreement between Endo and Penwest Pharmaceuticals	6/18/2010	EPI000828739	EPI000828801		JX-002			
CX2744	Intentionally Not Used					N/A			
CX2744	Email from Mark Bradley to Julie McHugh re: Data request	6/7/2010	EPI002161173	EPI002161181		JX-002			
CX2745	Email from Donna Papa to Brian Lortie, Sue Hall, Doug Macpherson, et al. re: Evaluation of IPX-203 w/Attach: Evaluation of IPX-203 (carbidopa_levodopa).pptx	10/28/2015	EPI002190360	EPI002190361		JX-002		Ordered 10/20/2017 & 10/23/2017	
CX2746	Email from Dough Macpherson to Jennifer Dubas re: Evaluation of IPX-203 w/Attach: Evaluation of IPX-203 (carbidopa_levodopa).pptx	10/29/2015	EPI002190362	EPI002190363		JX-002		Ordered 10/20/2017 & 10/23/2017	
CX2747	Email from Doug Macpherson to David Ailinger, Meg Snowden, Nancy Fetrow re: EXTERNAL: ENDO/IMPAX: Amendment to Development and Co-promotional Agreement	10/29/2015	EPI002190364	EPI002190364	RX-136	JX-002			
CX2748	Email from Alan Levin to Mark Bradley re: Final Imperial OEW	6/8/2010	EPI002159909	EPI001379352	RX-131	JX-002			Tr. 2544:21; 2545:04
CX2749	Impax Spreadsheet: Oxymorphone 5 10 20 30 40 06_06_12 full COGS upside	4/16/2013	Impax_Opana_PartIII_0001015	Impax_Opana_PartIII_0001015		JX-002			
CX2750 CX2751- CX2752	Email from Mark Bradley to Alan Levin re: Imperial OEW	6/1/2017	EPI002160935	EPI002160936		JX-002			
CX2753	Intentionally Not Used					N/A			
CX2753	Email from Meg Snowden to Huong Nguyen re: Mengler Board Slides w/Attach: Zorn Model Oxymorphone 05 14 10.xls	5/14/2010	Impax_Opana_PartIII_0063830	Impax_Opana_PartIII_0063832		JX-002			
CX2754	Email from Meg Snowden to Huong Nguyen re: Zorn Model Oxymorphone 03 22 10.xls w/Attach: Zorn Model Oxymorphone 03 22 10.xls	3/23/2010	Impax_Opana_PartIII_0063840	Impax_Opana_PartIII_0063841		JX-002			
CX2755 CX2756- CX2758	Email from Kevin Sica to Todd Engle re: Endo Opana Disclosures - FW: Charge Message Points w/Attach: Opana ER Peak Calculation for 1Q12.xls	5/2/2012	Impax_Opana_PartIII_0063864	Impax_Opana_PartIII_0063866	RX-213	JX-002			
CX2758	Intentionally Not Used					N/A			

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX2759	Case 2:09-cv-00831-KSH-PS US District Court Civil Docket	6/16/2010	CX2759-001	CX2759-022		JX-002			
CX2760- CX2766	Intentionally Not Used					N/A			
CX2767	Email from Jennifer Saionz to Thomas Rayski, Meg Snowden, Chris Mengler, et al. re: Impax - Endo w/Attach: 334990_Result.rtf; Impax - Endo - Settlement Agreement (PALIB1_3992129_5).DOC	6/7/2010	IMPAX-OPANA-CID00001478	IMPAX-OPANA-CID00001524		JX-002			
CX2768- CX2770	Intentionally Not Used					N/A			
CX2771	Email from Thomas Rayski to Meg Snowden, Chris Mengler, Ted Smolenski, et al. re: Impax - Endo w/Attach: Draft Impax- Endo Settlement Agreement (Opana) [Endo Markup] (3).DOC; Redline - Impax-EndoSettlement and License Agreement.pdf	6/6/2010	IMPAX-OPANA-CID00006732	IMPAX-OPANA-CID00006781	RX-334	JX-002			
CX2772	Email from Alan Levin to Karen Adler, Mark Bradley, Robert Cobuzzi re: Endo/Impax R&D Collaboration	6/6/2010	EPI001586766	EPI001586767	RX-088	JX-002			Tr. 2540:07; 2540:12
CX2773	Intentionally Not Used					N/A			
CX2774	Email from Alan Levin to Mark Bradley re: Imperial OEW	6/1/2010	EPI002160939	EPI002160940		JX-002			
CX2775	Email from Mark Bradley to Julie McHugh re: <no subject> w/Attach: 052110 Imperial OEW v1.docx; IPX_FactSheet_Impax.pdf	5/27/2010	EPI002160941	EPI002160951		JX-002			
CX2776	Email from Mark Bradley to Karen Adler re: R&D Valuation w/Attach: Imperial Valuation v2.xlsx	5/28/2010	EPI002160966	EPI002160967		JX-002		Ordered 10/23/2017	
CX2777	Email from Mark and Cheryl Bradley to Mark Bradley re: Imperial Valuation v6.xlsx w/Attach: Imperial Valuation v6.xlsx	6/6/2010	EPI002161024	EPI002161025		JX-002		Ordered 10/23/2017	
CX2778	Email from Mark and Cheryl Bradley to Mark Bradley re: Imperial Valuation v6.xlsx w/Attach: Imperial Valuation v6.xlsx	6/6/2010	EPI002161067	EPI002161068		JX-002		Ordered 10/23/2017	
CX2779	Email from Mark Bradley to Karen Adler re: Imperial valuation model w/Attach: Imperial Valuation v5.xlsx	6/5/2010	EPI002161113	EPI002161114	RX-135	JX-002		Ordered 10/23/2017	
CX2780 CX2781- CX2782	Email from Robert Cobuzzi to Alan Levin, Karen Adler, Mark Bradley, et al. re: Information requested w/Attach: IPX066 Commerical Opportunity 6-4-10.ppt; Copy of IPX066 US Sales Forecast.xls; IPX-203.ppt	6/5/2010	EPI001897548	EPI001897556	RX-105; RX-106; RX-107	JX-002		Ordered 10/23/2017	
CX2783	Intentionally Not Used					N/A			
CX2783	Email from Mark Bradley to Mark Schauwecker, Roberto Cuca re: 10 yr Outlook 062410 v2.xls w/Attach: 10 yr Outlook 062410 v2.xls	7/7/2010	EPI000594025	EPI000594026		JX-002			
CX2784	Email from Daniel Carbery to Brian Lortie, Steve Carchedi, Steven Cooper, et al. re: handouts from the ELC meeting today - Some items may be covered at tomorrow's commercial staff meeting with Dave Holveck w/Attach: Lansing OEW v2.doc; et al.	8/31/2009	EPI001923545	EPI001923561		JX-002			Tr. 1065:20, 22; 1066:01, 15, 21, 22; 1067:07; 1078:25; 1079:02
CX2785	Letter from Endo to FTC re CID Response to Specs 1, 8, 33, and 39	6/27/2014	FTC-PROD-0017053	FTC-PROD-0017074		JX-002			
CX2786	Email from David Macera to Paula Schiavo, Roberto Cuca, and Jeffrey Vaupen re: BoD budget deck link w/Attach: BoD Budget Review 2010-10-28c.pptx, Microsoft_Office_Excel_Worksheet1.xlsx, Microsoft_Office_Excel_Worksheet4.xlsx...	10/18/2010	EPI000338517	EPI000338522		JX-002			
CX2787	Email from Roberto Cuca to David Macera re: For our discussion at 4:30 w/Attach: 2011 Product Scenarios.xlsx	10/17/2010	EPI000338544	EPI000338545		JX-002			
CX2788	Intentionally Not Used					N/A			
CX2789	Email from Brian Hogan to Roberto Cuca, David Macera, Darnell Turner, and Lee Lenkner re: Opana ER / Revopan assumptions in Budget w/Attach: Final Factory Units Template - 082510.xlsx, 2011 Net Sales Template.xlsx	9/27/2010	EPI000822934	EPI000822936		JX-002			
CX2790	Intentionally Not Used					N/A			
CX2791	Email from David Macera to Darnell Turner and Mark Schauwecker re: Three Year Plan 2010.xlsx w/Attach: Three Year Plan 2010.xlsx	2/8/2010	EPI001118924	EPI001118925		JX-002			
CX2792	Email from Darnell Turner to David Macera re: Opana ER Forecast	3/8/2010	EPI001119516	EPI001119516		JX-002			
CX2793	Email from Edward DiNapoli to David Macera re: Opana ER Assumptions	9/16/2011	EPI001123902	EPI001123902		JX-002			

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX2794	Email from David Macera to Alan Levin, Karen Adler, and Denise Craig re: BOD 022310 Comp Committee 022310 v2.pptx w/Attach: BOD 022310 Comp Committee 022310 v2.pptx	2/23/2010	EPI001172033	EPI001172034		JX-002			
CX2795- CX2796	Intentionally Not Used					N/A			
CX2797	Email from David Macera to Derek Elphick re: Files w/Attach: 10 yr Outlook with Kansas v14b.xlsx, 10yr Plan summary - DM.xlsx	5/3/2011	EPI001831514	EPI001831516		JX-002			
CX2798	Intentionally Not Used					N/A			
CX2799	Email from Roberto Cuca to David Macera re: Opana ER Scenarios w/Attach: 2013 Opana Scenarios_Summary_12.19.12.xlsx	12/19/2012	EPI000341935	EPI000341937		JX-002			
CX2800- CX2801	Intentionally Not Used					N/A			
CX2802	Email from David Macera to Robert Cooper re: Novartis manufacturing issues: Impact on Endo (RBC Report; Jan 6th)	1/6/2012	EPI001124292	EPI001124292	RX-059	JX-002			
CX2803- CX2804	Intentionally Not Used					N/A			
CX2805	Email from David Macera to Cliff Larsen re: Opana ER upside & downside	11/4/2012	EPI001126150	EPI001126150		JX-002			
CX2806	Email from Derek Elphick to David Macera and Mark Gottlieb re: Leverage Sensitivity Draft with Scenario Analysis Draft w/Attach: Leverage Sensitivity Draft.pptx	12/20/2012	EPI001126447	EPI001126448		JX-002			
CX2807	Intentionally Not Used					N/A			
CX2808	Email from Mark Gottlieb to Alan Levin, Roberto Cuca, David Macera, et al re: New Scenarios - Base Case and Downside	12/22/2012	EPI001737746	EPI001737747		JX-002			
CX2809- CX2810	Intentionally Not Used					N/A			
CX2811	Email from David Macera to Roberto Cuca, Cindy Fryer, and Mark Gottlieb re: Opana ER downside w/Attach: image001.png, image002.png	6/12/2013	EPI000827650	EPI000827654		JX-002			
CX2812	Email from David Macera to Mark Gottlieb re: Model follow up questions	1/17/2013	EPI001127214	EPI001127216		JX-002			
CX2813	Email from David Macera to Joseph Rosenthal re: Opana ER - 10 Year Plan AB scenario w/Attach: 2013 Macera Scenarios.xlsx, ATT00001.htm	5/22/2013	EPI001128674	EPI001128676		JX-002			
CX2814- CX2816	Intentionally Not Used					N/A			
CX2817	Email from Joyce De Los Reyes to Art Koch, Ted Smolenski re: Approval Date Expectations w/Attach: Generic new product launch projection 052808.xls	6/4/2008	IMPAX-OPANA-CID00012325	IMPAX-OPANA-CID00012326		JX-002			
CX2818	Email from Kevin Sica to Denis Paquette, Tony Bright, Joe Camargo, et al. re: January Forecast Submission w/Attach: Forecast Change From Previous Forecast0109.xls	1/9/2009	Impax_Opana_PartIII_0022372	Impax_Opana_PartIII_0022373	RX-180	JX-002			
CX2819	Email from Kevin Sica to Denis Paquette, Tony Bright, Joe Camargo, et al. re: June 09 Forecast Submission w/Attach: Forecast Change From Previous Forecast 0609.xls	6/5/2009	Impax_Opana_PartIII_0006077	Impax_Opana_PartIII_0006078	RX-184	JX-002			
CX2820	Email from Kevin Sica to Denis Paquette, Tony Bright, John Meno, et al. re: Aug 09 Forecast Submission w/Attach: Forecast Change From Previous Forecast 0809.xls	8/7/2009	Impax_Opana_PartIII_0009002	Impax_Opana_PartIII_0009003		JX-002			
CX2821	Email from Kevin Sica to Denis Paquette, Tony Bright, John Meno, et al. re: Sept 09 Forecast Submission w/Attach: Forecast Change From Previous Forecast 0909.xls	9/8/2009	Impax_Opana_PartIII_0004617	Impax_Opana_PartIII_0004618		JX-002			
CX2822	Email from Kevin Sica to Denis Paquette, Tony Bright, John Meno, et al. re: Oct 09 Forecast Submission w/Attach: Forecast Change From Previous Forecast 1009.xls	10/7/2009	Impax_Opana_PartIII_0006069	Impax_Opana_PartIII_0006070		JX-002			
CX2823	Intentionally Not Used					N/A			
CX2824	Email from Kevin Sica to Denis Paquette, Tony Bright, Joe Camargo, et al. re: Jan 10 Forecast Submission w/Attach: Forecast Change from Previous Forecast 0110.xls	1/8/2010	Impax_Opana_PartIII_0008982	Impax_Opana_PartIII_0008983		JX-002			
CX2825	Email from Ted Smolenski to Kevin Sica re: 5-year w/Attach: 5-year forecast 2010-02-10.xls UPSIDE	2/11/2010	IMPAX-OPANA-CID00007095	IMPAX-OPANA-CID00007096	CX2921	JX-002			



COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX2826	Email from Kevin Sica to Chris Mengler, Ted Smolenski, Todd Engle re: 5 Year Forecast w/Attach: 5-year forecast 2010-02-17.xls UPSIDE	2/17/2010	IMPAX-OPANA-CID00007117	IMPAX-OPANA-CID00007118		JX-002			
CX2827	Intentionally Not Used					N/A			
CX2828	Email from Joyce De Los Reyes to Joe Camargo, Kevin Sica, Chuck Hildenbrand, et al. re: Generic new product launch projection 2010-04-05.xls w/Attach: Generic new product launch projection 2010-04-05.xls	4/5/2010	IMPAX-OPANA-CID00014245	IMPAX-OPANA-CID00014246	RX-369	JX-002			
CX2829	Email from Kevin Sica to Denis Paquette, Tony Bright, Joe Camargo, et al. re: May Forecast Submission w/Attach: Forecast Change From Previous Forecast 0510.xls	5/7/2010	Impax_Opana_PartIII_0022454	Impax_Opana_PartIII_0022455		JX-002			
CX2830	Email from Ted Smolenski to Chris Mengler, Kevin Sica, Todd Engle re: 5-year forecast 2010-May Update 2010--05-14v5.xls w/Attach: 5-year forecast 2010-May Update 2010--05-14v5.xls UPSIDE	5/15/2010	IMPAX-OPANA-CID00007077	IMPAX-OPANA-CID00007078		JX-002			
CX2831	Email from Ted Smolenski to Art Koch re: 5-year forecast 2010-May Update 2010--05-21--UPSIDE.xls w/Attach: 5-year forecast 2010-May Update 2010--05-21--UPSIDE.xls	5/21/2010	IMPAX-OPANA-CID00006578	IMPAX-OPANA-CID00006579		JX-002			
CX2832- CX2837	Intentionally Not Used					N/A			
CX2838	Email from Kevin Sica to Denis Paquette, Tony Bright, Joe Camargo, et al. re: June Forecast Submission w/Attach: Forecast Change From Previous Forecast 0610.xls	6/7/2010	Impax_Opana_PartIII_0013045	Impax_Opana_PartIII_0013046		JX-002			
CX2839- CX2841	Intentionally Not Used					N/A			
CX2842	Email from Kevin Sica to Denis Paquette, Tony Bright, Joe Camargo, et al. re: July Forecast Submission w/Attach: Forecast Change From Previous Forecast 0710.xls	7/12/2010	Impax_Opana_PartIII_0030783	Impax_Opana_PartIII_0030785		JX-002			
CX2843- CX2844	Intentionally Not Used					N/A			
CX2845	Email from Meg Snowden to Guy Donatiello, Andy Gesek, Roberto Cuca, Carrie Cooper, et al. re: steering committee	12/20/2010	IMPAX-OPANA-CID00006165	IMPAX-OPANA-CID00006166		JX-002			
CX2846- CX2850	Intentionally Not Used					N/A			
CX2851	Impax Document: Consulting Agreement between Impax Laboratories, Inc. and TCS Consulting Group, LLC	4/28/2017	Impax_Opana_PartIII_0081331	Impax_Opana_PartIII_0081336		JX-002			
CX2852	Email from Todd Engle to Chris Mengler, Larry Hsu, Chuck Hildenbrand, et al. re: Meeting Minutes from the Feb 2, 2010 Quarterly Launch Planning Meeting	2/6/2010	Impax_Opana_PartIII_0046715	Impax_Opana_PartIII_0046739		JX-002			
CX2853	Email from Ted Smolenski to Kevin Sica re: 5-year w/Attach: 5-year forecast 2010-02-10.xls_BASE	2/11/2010	IMPAX-OPANA-CID00007095	IMPAX-OPANA-CID00007096		JX-002			
CX2854	Email from Kevin Sica to Chris Mengler, Ted Smolenski, Todd Engle, et al. re: 5 Year Forecast w/Attach: 5-year forecast 2010-02-17.xls	2/17/2010	IMPAX-OPANA-CID00007117	IMPAX-OPANA-CID00007118		JX-002			
CX2855- CX2859	Intentionally Not Used					N/A			
CX2860	Email from Ted Smolenski to Todd Engle, Kevin Sica, Art Koch, et al. re: Oxymorphone	1/7/2011	IMPAX-OPANA-CID00021096	IMPAX-OPANA-CID00021097		JX-002			
CX2861- CX2862	Intentionally Not Used					N/A			
CX2863	Email from John Anthony to Chuck Hildenbrand, Mark Shaw re: Quota	5/28/2010	Impax_Opana_PartIII_0004275	Impax_Opana_PartIII_0004277		JX-002			
CX2864	Email from Todd Engle to Chuck Hildenbrand, John Anthony, Joe Camargo, et al. re: Oxymorphone Quota w/Attach: 3398_001.pdf; API Quota 032310.xls	4/9/2010	Impax_Opana_PartIII_0004872	Impax_Opana_PartIII_0004877		JX-002			
CX2865	Email from John Anthony to Michael J. Morley, Mark Shaw, Joe Camargo re: Withdrawal Impax request for a 2010 revised Oxymorphone Procurement Quota	6/14/2010	Impax_Opana_PartIII_0014615	Impax_Opana_PartIII_0014615		JX-002			
CX2866	Email from Chris Mengler to John Anthony, Todd Engle, Mark Shaw, et al. re: Oxymorphone	1/12/2010	Impax_Opana_PartIII_0014683	Impax_Opana_PartIII_0014687		JX-002			
CX2867	Email from Joe Camargo to John Anthony re: Attached Image	1/7/2010	Impax_Opana_PartIII_0015290	Impax_Opana_PartIII_0015292		JX-002			
CX2868	Email from John Anthony to Chuck Hildenbrand, Mark Shaw re: March 10 Forecast Submission w/Attach: B-2Quota2010.htm	3/9/2010	Impax_Opana_PartIII_0016249	Impax_Opana_PartIII_0016252	RX-175	JX-002			

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX2869	Email from Joe Camargo to Tamara Alegria re: Oxymorphone	1/11/2010	Impax_Opana_PartIII_0017165	Impax_Opana_PartIII_0017168		JX-002			
CX2870	Email from John Anthony to Larry Glenn, Pat Fiorentino re: Attached Image w/Attach: 0112_001.pdf	3/8/2010	Impax_Opana_PartIII_0017289	Impax_Opana_PartIII_0017291		JX-002			
CX2871- CX2873	Intentionally Not Used					N/A			
CX2874	Email from John Anthony to Mark Shaw, Larry Hsu, Chris Mengler, et al. re: Attached Image w/Attach: 4798_001.pdf	1/6/2010	Impax_Opana_PartIII_0018510	Impax_Opana_PartIII_0018515		JX-002			
CX2875	Intentionally Not Used					N/A			
CX2876	Email from Chris Mengler to John Anthony, Chuck Hildenbrand, Mark Shaw re: Oxymorphone	1/22/2010	Impax_Opana_PartIII_0019737	Impax_Opana_PartIII_0019741		JX-002			
CX2877	Email from John Anthony to Mark Shaw re: Attached Image w/Attach: 0348_001.pdf	4/16/2010	Impax_Opana_PartIII_0022354	Impax_Opana_PartIII_0022355		JX-002			
CX2878	Email from Joe Camargo to Chuck Hildenbrand re: 2010 CII Controlled Substances & Pseudoephedrine Quota request for Impax B-1 & B-2	2/17/2009	Impax_Opana_PartIII_0023017	Impax_Opana_PartIII_0023018		JX-002			
CX2879	Intentionally Not Used					N/A			
CX2880	Email from John Anthony to Michael Morley, Christine Sannerud, Mark Shaw re: Oxymorphone 2010 Quota for Impax	3/2/2010	Impax_Opana_PartIII_0028440	Impax_Opana_PartIII_0028441		JX-002			
CX2881	Email from John Anthony to Mark Shaw, Joe Camargo, Chuck Hildenbrand re: Attached Image w/Attach: 0728_001.pdf	6/17/2010	Impax_Opana_PartIII_0028949	Impax_Opana_PartIII_0028951		JX-002			
CX2882	Email from Todd Engle to Chuck Hildenbrand, John Anthony, Joe Camargo, et al. re: Oxymorphone Quota w/Attach: 3419_001.pdf	4/12/2010	Impax_Opana_PartIII_0029763	Impax_Opana_PartIII_0029765		JX-002			
CX2883- CX2887	Intentionally Not Used					N/A			
CX2888	Email from Chuck Hildenbrand to Art Koch, Jim Devlin, Joe Camargo re: Impax: Inventory Carrying Value - June 30, 2010 - OXM w/Attach: Oxymorphone Expiration Dates	6/24/2010	Impax_Opana_PartIII_0004656	Impax_Opana_PartIII_0004671		JX-002			
CX2889	Email from Chuck Hildenbrand to Larry Hsu, May Chu, Mark Shaw, et al. re: Monthly Highlights w/Attach: Monthly Highlights, Opns, Quality and Compliance - Apr 2010.doc	5/13/2010	Impax_Opana_PartIII_0004815	Impax_Opana_PartIII_0004819		JX-002			
CX2890	Email from Kangwen Lin to Chuck Hildenbrand, Joe Camargo, Andrew Fox, et al. re: Final meeting minutes for oxymorphone tech transfer meeting w/Attach: Oxymorphone 5, 10, 20, 40 mg 30, 15, 7.5mg ER tablets Dec Final.doc	12/14/2009	Impax_Opana_PartIII_0005535	Impax_Opana_PartIII_0005544		JX-002			
CX2891	Email from Kevin Sica to Denis Paquette, Tony Bright, Joe Camargo, et al. re: June 09 Forecast Submission w/Attach: Forecast Change From Previous Forecast 0609.xls	6/5/2009	Impax_Opana_PartIII_0009006	Impax_Opana_PartIII_0009007		JX-002			Tr. 970:16; 971:06, 22
CX2892	Email from Chuck Hildenbrand to Larry Hsu, May Chu, Joe Camargo re: 5 year Plan w/Attach: Production Plan - Capacity, 2010-14.xls; Production Plan - Capacity 2010-14.xls Glatt analysis.xls	12/16/2009	Impax_Opana_PartIII_0011183	Impax_Opana_PartIII_0011185		JX-002			
CX2893	Email from John Anthony to Joe Camargo, Chuck Hildenbrand, Mark Shaw, et al. re: Monthly Quota Chart w/Attach: 2010 Procurement Chart of DEA Pseudoephedrine Sulfate Quota-05-02-10.xls; et al.	5/6/2010	Impax_Opana_PartIII_0013559	Impax_Opana_PartIII_0013563		JX-002			
CX2894	Email from Chuck Hildenbrand to John Anthony, Joe Camargo, Mark Shaw re: Quota	3/6/2010	Impax_Opana_PartIII_0013591	Impax_Opana_PartIII_0013592		JX-002			
CX2895	Intentionally Not Used					N/A			
CX2896	Email from Joe Camargo to Chuck Hildenbrand, Denis Paquette, Sam Adams, et al. re: Monthly Report w/Attach: Monthly Report, 7-10.doc	8/10/2010	Impax_Opana_PartIII_0017542	Impax_Opana_PartIII_0017544		JX-002			Tr. 996:07, 15; 997:01; 1023:21; 1024:06
CX2897	Intentionally Not Used					N/A			
CX2898	Email from Joe Camargo to Todd Engle and Chuck Hildenbrand re: Launch Planning Input	5/12/2010	Impax_Opana_PartIII_0021986	Impax_Opana_PartIII_0021987	RX-179	JX-002			Tr. 977:05, 24; 1016:11
CX2899	Email from Chuck Hildenbrand to Joe Camargo, Jeff Blumenfeld, Kangwen Lin, et al. re: MBO Accomplishments w/Attach: C. Hildenbrand 2010 MBOs 030910.doc, WO targets w accomplishments.doc	2/6/2011	Impax_Opana_PartIII_0024286	Impax_Opana_PartIII_0024288		JX-002			
CX2900	Intentionally Not Used					N/A			
CX2901	Email from Chuck Hildenbrand to Joe Camargo re: <no subject>	5/26/2010	Impax_Opana_PartIII_0025384	Impax_Opana_PartIII_0025384	RX-182	JX-002			

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX2902	Email from Willi Huang to Joe Camargo, Chuck Hildenbrand, Kangwen Lin, et al. re: Oxymorphone	5/5/2011	Impax_Opana_PartIII_0026107	Impax_Opana_PartIII_0026108		JX-002			
CX2903	Intentionally Not Used					N/A			
CX2904	Email from Joe Camargo to Chuck Hildenbrand, Tony Bright, Jim Larrowe, et al. re: June Plan	5/25/2010	Impax_Opana_PartIII_0030026	Impax_Opana_PartIII_0030026	RX-187	JX-002			Tr. 1017:08
CX2905	Email from Joe Camargo to Chuck Hildenbrand re: Monthly Report w/Attach: Monthly Report, 5-10.doc	6/11/2010	Impax_Opana_PartIII_0030763	Impax_Opana_PartIII_0030765		JX-002			Tr. 989:14; 990:05, 10; 1022:25; 1023:07
CX2906	Email from Todd Engle to Chris Mengler, Larry Hsu, Richard Ting, et al. re: Agenda and hand out for the Quarterly Launch Planning Meeting today	11/24/2009	Impax_Opana_PartIII_0044720	Impax_Opana_PartIII_0044723		JX-002			
CX2907	Intentionally Not Used					N/A			
CX2908	Email from Kangwen Lin to Andrew Fox, Art Koch, Chris Mengler, et al. re: Generic meeting update - operation activities for 6/15 meeting w/Attach: OA for Generic meeting June 15.doc	6/15/2010	Impax_Opana_PartIII_0046747	Impax_Opana_PartIII_0046749		JX-002			
CX2909	Intentionally Not Used					N/A			
CX2910	Email from Joe Camargo to Chris Mengler re: Alternate Sourcing Projects	4/9/2009	Impax_Opana_PartIII_0049209	Impax_Opana_PartIII_0049210		JX-002			
CX2911- CX2913	Intentionally Not Used					N/A			
CX2914	Email from Joe Camargo to Andrew Fox, Art Koch, Bob Friedel, et al. re: Updated Checklist w/Attach: Product Launch Checklist.xls	6/8/2010	Impax_Opana_PartIII_0077849	Impax_Opana_PartIII_0077850	RX-226	JX-002			
CX2915	Email from Joe Camargo to Andrew Fox, Art Koch, Chuck Hildenbrand, et al. re: Updated Checklist w/Attach: Product Launch Checklist.xls	10/27/2009	Impax_Opana_PartIII_0079132	Impax_Opana_PartIII_0079133		JX-002			
CX2915A	Email from Joe Camargo to Andrew Fox, Art Koch, Chuck Hildenbrand, et al. re: Updated Checklist w/Attach: Product Launch Checklist.xls	10/27/2009	Impax_Opana_PartIII_0079132	Impax_Opana_PartIII_0079133		JX-002			
CX2916	Email from John Anthony to Todd Engle, Chris Mengler, Mark Shaw re: Oxymorphone w/Attach: 1936_001.pdf; Oxymorphone Forecast Detail 01 11 10 R2.xls	1/12/2010	Impax_Opana_PartIII_0019522	Impax_Opana_PartIII_0019537		JX-002			
CX2917	Letter from John Anthony to Christine Sannerud, DEA re: Oxymorphone Procurement Quota Year 2010	1/18/2010	Impax_Opana_PartIII_0081690	Impax_Opana_PartIII_0081692		JX-002			
CX2918	Letter from John Anthony to Christine Sannerud, DEA re: Oxymorphone Procurement Quota Year 2010	4/15/2010	Impax_Opana_PartIII_0081693	Impax_Opana_PartIII_0081695		JX-002			
CX2919	Impax Document: Minutes of the Meeting of the Board of Directors of Impax Laboratories, Inc.	8/17/2010	Impax_Opana_PartIII_0004185	Impax_Opana_PartIII_0004188		JX-002		Ordered 10/23/2017	
CX2920	Email from Chris Mengler to Larry Hsu, Todd Engle, Meg Snowden re: Mengler Board Slides	5/14/2010	Impax_Opana_PartIII_0063833	Impax_Opana_PartIII_0063834		JX-002			
CX2921	Intentionally Not Used					N/A			
CX2922	Email from Willi Huang to Ray Smith, Shan Gao, Joe Camargo, et al. re: At Risk Inventory report for March 2011 w/Attach: At Risk Inventory March 11 R0.xls	4/1/2011	Impax_Opana_PartIII_0005732	Impax_Opana_PartIII_0005733		JX-002			Tr. 1024:17; 1025:23; 1031:05
CX2923	Document: Complaint Counsel's Notice of Deposition of Impax Laboratories, Inc.	5/12/2017	CX2923-001	CX2923-007		JX-002			
CX2924	Email from Anna Fabish to the FTC re: Docket 9373 - Objections to Notice of Deposition of Impax Laboratories w/Attach: June 14 2017 Ltr to N Leefer re 33c1 deposition objections and designations.pdf	6/27/2017	CX2924-001	CX2924-007		JX-002			
CX2925- CX2926	Intentionally Not Used					N/A			
CX2927	Document: Respondent Impax Laboratories, Inc.'s Objections and Responses to Complaint Counsel's Second Set of Interrogatories	6/2/2017	CX2927-001	CX2927-029		JX-002			Tr. 279:25
CX2928	Document: Respondent Impax Laboratories, Inc.'s Objections and Responses to Complaint Counsel's Third Set of Interrogatories	6/29/2017	CX2928-001	CX2928-018		JX-002		Ordered 10/23/2017	
CX2929	Email from Larry Hsu to Chuck Hildenbrand, Chris Mengler, Art Koch, et al. re: Oxymorphone ER Tablets Tentatively Approved Today!!	5/14/2010	Impax_Opana_PartIII_0044621	Impax_Opana_PartIII_0044622	RX-195	JX-002			Tr. 308:20; 355:25; 356:15; 356:19; 584:05
CX2930	Email from Meg Snowden to Art Koch, Larry Hsu, Michael Nestor, et al. re: Highly Confidential - Rule 408 Settlement Communication w/Attach: Endo - Impax - Development Term Sheet (5-26-2010).DOC; Endo - Impax - Settlement Term Sheet (5-26-2010).docx	5/26/2010	IMPAX-OPANA-CID00006719	IMPAX-OPANA-CID00006729	RX-331	JX-002			Tr. 3016:05; 3016:07
CX2931- CX2932	Intentionally Not Used					N/A			

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX2933	Meeting Scheduler re: Co-Promote Teleconference with Attendees: Brian Lortie, Alan Levin, Robert Cobuzzi, Meg Snowden, et al.	6/7/2010	IMPAX-OPANA-CID00006143	IMPAX-OPANA-CID00006143	RX-326	JX-002			
CX2934	Intentionally Not Used					N/A			
CX2935	Email from Justin Watkins to Alison Freeman Gleason, Meg Snowden, Alan Levin, et al. re: Co-Promote Revisions w/Attach: #710157v9_BE01_ - Impax - Co-Promotion Agreement.DOC; et al.	6/7/2010	IMPAX-OPANA-CID00006853	IMPAX-OPANA-CID00006918		JX-002			
CX2936	Email from Meg Snowden to Joyce De Los Reyes re: Generic new product launch projection 2010-06-08 MS.xls	6/14/2010	IMPAX-OPANA-CID00020529	IMPAX-OPANA-CID00020530		JX-002			
CX2937	Intentionally Not Used					N/A			
CX2938	Email from Meg Snowden to Tim Scott and Mark Schlossberg re: EXTERNAL:RE: Impax License Agreement	4/21/2016	IMPAX-ENDO-DNJ0001564	IMPAX-ENDO-DNJ0001568		JX-002			
CX2939	Email from Meg Snowden to Fred Wilkinson, Douglas Boothe, and Mark Schlossberg re: Endo v. Impax	11/3/2016	IMPAX-ENDO-DNJ0005272	IMPAX-ENDO-DNJ0005275		JX-002			
CX2940- CX2941	Intentionally Not Used					N/A			
CX2942	Email from Guy Donatiello to Meg Snowden re: Impax License Agreement	10/1/2015	EPI002195693	EPI002195695		JX-002			
CX2943	Email from Guy Donatiello to Meg Snowden, George Gordon, Jennifer Dubas, et al. re: EXTERNAL: Impax License Agreement	4/19/2016	EPI002195706	EPI002195709		JX-002			
CX2944	Email from Guy Donatiello to Bob Rhoad, Martin Black, Matthew Maletta, et al. re: Letter to Mr. Chris Mengler and Ms. Margaret Snowden, Impax Laboratories, Inc.	10/31/2016	EPI002195723	EPI002195725		JX-002			Tr. 2905:01; 2905:05
CX2945- CX2946	Intentionally Not Used					N/A			
CX2947	Impax Presentation: Company Goal and Strategy November 17, 2009	11/17/2009	Impax_Opana_PartIII_0003904	Impax_Opana_PartIII_0003916		JX-002			
CX2948	Email from Suneel Gupta to Michael Nestor re: Endo contact person	6/3/2010	IMPAX-OPANA-CID00001599	IMPAX-OPANA-CID00001599	RX-269	JX-002			
CX2949	Email from Robert Cobuzzi to Michael Nestor, Chris Mengler, Alan Levin re: R&D Contact?	6/4/2010	IMPAX-OPANA-CID00001611	IMPAX-OPANA-CID00001612	RX-273	JX-002			
CX2950- CX2951	Intentionally Not Used					N/A			
CX2952	Email from Laura Zhu to Michael Nestor re: IPX066	5/21/2010	IMPAX-OPANA-CID00006714	IMPAX-OPANA-CID00006716		JX-002			
CX2953	Email from Bryan Reasons to Michael Nestor, Suneel Gupta re: Impax/Endo Development and Co-Promotion Agreement Milestones w/Attach: image001.png; image002.png	4/16/2013	IMPAX-OPANA-CID00007983	IMPAX-OPANA-CID00007987	RX-344	JX-002			
CX2954	Email from Suneel Gupta to Steve Mollicella, Meg Snowden, Michael Nestor re: Co-Promote Revisions	7/1/2010	IMPAX-OPANA-CID00011919	IMPAX-OPANA-CID00011923	RX-358	JX-002			
CX2955	Email from Michael Nestor to Suneel Gupta re: BoD slides w/Attach: BOD draft ver3.ppt	8/1/2010	IMPAX-OPANA-CID00012655	IMPAX-OPANA-CID00012699	RX-368	JX-002		Ordered 10/23/2017	
CX2956	Email from Michael Nestor to Brandon Smith re: Slide format w/Attach: BOD 07092013.ppt	7/5/2013	IMPAX-OPANA-CID00016072	IMPAX-OPANA-CID00016091	RX-370	JX-002		Ordered 10/23/2017	
CX2957	Email from Mark Donohue to Michael Nestor re: Call w/Attach: Impax Key Topic Messaging Points - Sept 28 2012.docx	9/27/2012	IMPAX-OPANA-CID00018692	IMPAX-OPANA-CID00018703		JX-002			
CX2958	Email from Larry Hsu to Bryan Reasons, Carole Ben-Maimon, Michael Nestor, et al. re: What has been disclosed	7/5/2012	IMPAX-OPANA-CID00019206	IMPAX-OPANA-CID00019208		JX-002			
CX2959	Intentionally Not Used					N/A			
CX2960	Email from Chris Mengler to Meg Snowden, Art Koch, Larry Hsu, et al. re: <no subject>	6/3/2010	IMPAX-OPANA-CID00019454	IMPAX-OPANA-CID00019454		JX-002			
CX2961	Email from Larry Hsu to Art Koch, Meg Snowden, Michael Nestor, et al. re: Status	6/5/2010	IMPAX-OPANA-CID00019476	IMPAX-OPANA-CID00019476		JX-002			
CX2962	Email from Meg Snowden to Michael Nestor, Shawn Fatholahi, Suneel Gupta, et al. re: R&D Collaboration	6/6/2010	IMPAX-OPANA-CID00021838	IMPAX-OPANA-CID00021839	RX-569	JX-002			
CX2963	Email from Michael Nestor to Meg Snowden, Art Koch, Larry Hsu, et al. re: Info requested by Endo on successor to IPX-066	6/4/2010	IMPAX-OPANA-CID00022261	IMPAX-OPANA-CID00022261		JX-002			
CX2964	Email from Jennifer Saionz to Alan Levin, Guy Donatiello, Martin Black, et al. re: Impax - Endo w/Attach: Impax inserts_(PAU 81_3993075_1) .DOC	6/6/2010	IMPAX-OPANA-CID00001416	IMPAX-OPANA-CID00001438	RX-267	JX-002			

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX2965	Email from Justin Watkins to Alison Freeman Gleason, Meg Snowden, Michael Nestor, et al. re: Co-Promotion Agreement - Revised Draft w/Attach: #710157v7_BE01_- Impax - Co-Promotion Agreement DOC; et al.	6/7/2010	IMPAX-OPANA-CID00001525	IMPAX-OPANA-CID00001591		JX-002			
CX2966	Email from David Paterson to Robert Cobuzzi, Michael Nestor, Chris Mengler, and Meg Snowden re: IPX066 w/Attach: 066 Apr2010AAN poster final poster.ppt, IPX066_IMPAX_Partner_Confidential_032010_FINAL.pdf	5/19/2010	IMPAX-OPANA-CID00001974	IMPAX-OPANA-CID00002103	RX-284	JX-002			
CX2967	Email from Sibel Ucpinar to Todd Engle re: Opana ER volume 1 of 5 w/Attach: 2007-06-25 79-087 Original ANDA vol 1 of 7.pdf	10/17/2012	IMPAX-OPANA-CID00009918	IMPAX-OPANA-CID00010400	RX-349	JX-002			
CX2968	Intentionally Not Used					N/A			
CX2969	Email from Martin Black to Stephen Hash, Guy Donatiello re: Opana w/Attach: Document.pdf	2/20/2009	Actavis_FTC_Opana_000156	Actavis_FTC_Opana_000177		JX-002		Ordered 10/20/2017	
CX2970	Intentionally Not Used					N/A			
CX2971	Actavis Spreadsheet: FM8-1-Oxymorphone ER V2	2/13/2008	Actavis_FTC_Opana_000334	Actavis_FTC_Opana_000334		JX-002		Ordered 10/20/2017	
CX2972	Actavis Spreadsheet: FM-Oxymorphone ER #2	8/27/2010	Actavis_FTC_Opana_000347	Actavis_FTC_Opana_000347		JX-002		Ordered 10/20/2017	
CX2973	Actavis Document: Product Introduction Notification, Oxymorphone HCL ER Tab	9/17/2013	Actavis_FTC_Opana_000376	Actavis_FTC_Opana_000376		JX-002			
CX2974	Actavis Document: Temporarily Unavailable Notification, Oxymorphone HCL ER	5/2/2016	Actavis_FTC_Opana_000378	Actavis_FTC_Opana_000378		JX-002			
CX2975	Actavis Spreadsheet: Oxymorphone ER August 2013	12/17/2013	Actavis_FTC_Opana_000379	Actavis_FTC_Opana_000379	RX-001	JX-002		Ordered 10/20/2017	
CX2976	Case 2:16-cv-02526-JLL-JAD: Document 1: Complaint	5/4/2016	CX2976-001	CX2976-156		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		
CX2977- CX2983	Intentionally Not Used					N/A			
CX2984	Impax Document: Minutes of the Regular Meeting of the Board of Directors of Impax Laboratories, Inc.	12/9/2015	Impax_Opana_PartIII_0004195	Impax_Opana_PartIII_0004208		JX-002		Ordered 10/23/2017	
CX2985	Intentionally Not Used					N/A			
CX2986	Email from Suneel Gupta to Adrienne Ford, Bryan Reasons, Michael Nestor, et al. re: Impax/Endo Development and Co-Promotion Agreement Milestones	10/29/2013	IMPAX-OPANA-CID00005538	IMPAX-OPANA-CID00005539	RX-309	JX-002			
CX2987- CX2989	Intentionally Not Used					N/A			
CX2990	SAT: Actavis 30(b)(6)	5/24/2017	CX2990-001	CX2990-006		JX-002			
CX2991- CX2994	Intentionally Not Used					N/A			
CX2995	Email from Carolyn Kong to Bob Barto re: QuRE: Summary of June 26 LCM Followup Meeting	6/30/2008	EPI000091528	EPI000091530		JX-002			
CX2996	Email from Erika George to Bob Barto re: Voice Mail Message ('4262') ( 35 seconds )	6/30/2008	EPI000091531	EPI000091531		JX-002			
CX2997	Email from Munira Rampersaud to Tara Chapman re: Generic Oxymorphone ER	1/23/2010	EPI000098031	EPI000098033		JX-002			
CX2998	Email from Ira Lentz to Tara Chapman re: Generic Oxymorphone ER w/Attach: P-25963-A P-25964-A; Endo P25963A P25964A 10-13-09.pdf; P22848A, P22845A, P22847A; et al.	10/19/2009	EPI000120230	EPI000120238		JX-002			
CX2999	Email from Ira Lentz to Tara Chapman re: Generic Oxymorphone ER w/Attach: Endo P-26099-A P-26100-A P-26101-A 11-20-09.pdf	11/20/2009	EPI000122808	EPI000122813		JX-002			
CX3000	Email from Ira Lentz to Tara Chapman re: Destruction of Generic Oxymorphone ER Tabs	6/11/2010	EPI000132119	EPI000132119		JX-002			
CX3001	Email from Missy Combs to Jeanne Brackins, Alicia Logan re: Oxymorphone ER potential 8-2010 launch scenario.xlsx w/Attach: Oxymorphone ER potential 8-2010 launch scenario.xlsx	10/3/2009	EPI000186383	EPI000186384		JX-002			
CX3002	Email from Alicia Logan to Brian Lihou re: (NEEDED FOR LAUNCH) Oxymorphone ER BOM correction and Change control w/Attach: Scan001.PDF	5/25/2010	EPI000383935	EPI000383941		JX-002			
CX3003	Email from Alicia Logan to Doug Azzalina re: Oxymorphone ER Launch Volumes	5/26/2010	EPI000383942	EPI000383942		JX-002			
CX3004	Email from Alicia Logan to Lisa Walker, Jason Bender re: Generic Launches	4/27/2010	EPI000938484	EPI000938486		JX-002			

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX3005	Email from Rene Curtis to Alicia Logan re: Oxymorphone ER labels	5/4/2010	EPI000948491	EPI000948491		JX-002			
CX3006	Email from Cassie Mapp to Demir Bingol re: CI Question w/Attach: Opana ER Generic Market Defense Final Presentation 12-16-2008.ppt	4/14/2010	EPI001552909	EPI001552910		JX-002			
CX3007	Email from Nancy Olson to Alan Levin, Caroline Manogue, Julie McHugh, et al. re: Executive Pricing Committee Meeting w/Attach: Oxymorphone ER Price Proposal Summary 06-02-10.pdf; Mycophenolate Mofetil Price A Pricing 6.3.10.pdf	6/4/2010	EPI001688857	EPI001688861		JX-002			
CX3008	Endo Document: Generics Summary September 9 2009	9/9/2009	EPI002011791	EPI002011793		JX-002			
CX3009	Email from Brian Hogan to Roberto Cuca re: Opana ER Combined P&L scenarios - Jul-10 generics.xlsx w/Attach: Opana ER Combined P&L scenarios - Jul-10 generics.xlsx	6/1/2010	EPI001588866	EPI001588867		JX-002			
CX3010	Email from Guy Donatiello to Alan Levin, Robert Cobuzzi, Roberto Cuca re: Imperial Alternatives	5/30/2010	EPI002201683	EPI002201685		JX-002			
CX3011	Email from Clark Baker to Brian Hogan, Demir Bingol, Lee Lenkner, et al. re: Opana ER / IR P&L Scenario Model w/Attach: OPANA Generic Scenarios.xlsx	5/25/2010	EPI000314222	EPI000314224		JX-002			
CX3012	Intentionally Not Used					N/A			
CX3013	Email from Roberto Cuca to Jack Boyle re: Impax contract w/Attach: Endo Credit.xlsx	3/13/2012	EPI000594257	EPI000594258		JX-002			
CX3014- CX3016	Intentionally Not Used					N/A			
CX3017	Email from Brian Hogan to Roberto Cuca, Lee Lenkner re: Opana ER / IR P&L Scenario Model w/Attach: OPANA Brand P&L Model Scenarios - Generic launch v3.xlsx	5/28/2010	EPI001588856	EPI001588859		JX-002			Tr. 645:17, 20; 652:07; 653:20; 656:06, 12, 17; 658:05
CX3018	Intentionally Not Used					N/A			
CX3019	Email from Roberto Cuca to Jack Boyle, Daniel Rudio re: BoD slides w/Attach: NCH Impact Slide.ppt	4/6/2012	EPI001595189	EPI001595190		JX-002			
CX3020- CX3024	Intentionally Not Used					N/A			
CX3025	Email from Alan Levin to Roberto Cuca re: Impax - Endo	6/7/2010	EPI001688925	EPI001688926	RX-098	JX-002			
CX3026- CX3033	Intentionally Not Used					N/A			
CX3034	Email from Carrie Cooper to Roberto Cuca, Andy Gesek, Suzanne Bair re: steering committee	1/20/2011	EPI002159928	EPI002159930		JX-002			
CX3035- CX3037	Intentionally Not Used					N/A			
CX3038	Email from Brian Hogan to Roberto Cuca re: EN3288 Core Commercial Launch Team (CCTL) Update	4/2/2010	EPI002196175	EPI002196188		JX-002			Tr. 2448:08; 2454:01; 2498:05
CX3039	Email from Roberto Cuca to Alan Levin, Darnell Turner, David Macera re: Per share price impact of generic Opana ER launch	3/15/2010	EPI002196198	EPI002196219		JX-002			
CX3040- CX3041	Intentionally Not Used					N/A			
CX3042	Email from Roberto Cuca to Erin Rybaltowski re: Finance materials for posting w/Attach: ELC mtg Mar 19-21 -- Finance Overview -- 2013-03-15.pptx; Microsoft_Excel_Worksheet1 .xlsx; Microsoft_Excel_Worksheet2.xlsx; et al.	3/18/2013	EPI002197252	EPI002197256		JX-002			
CX3043	Email from Roberto Cuca to Julie McHugh re: Penwest	6/9/2010	EPI002198102	EPI002198102		JX-002			
CX3044	Intentionally Not Used					N/A			
CX3045	Email from Roberto Cuca to Alan Levin, Edward Sweeney, Guy Donatiello re: Opana ER	6/4/2010	EPI002199918	EPI002199919		JX-002			
CX3046	Email from Jack Boyle to Alan Levin, Roberto Cuca re: OPANA ER PRESS RELEASE DRAFTS	4/16/2013	EPI002200864	EPI002200866		JX-002			
CX3047	Email from Cindy Fryer to Jim Wolfe, Moti Rubin, Kevin Gibbs, et al. re: Introduction - Last RAP Attached w/Attach: ENdo_RAP_vFinal_06.05.13.pptx	7/16/2013	EPI002217646	EPI002217647		JX-002			
CX3048	Email from Roberto Cuca to Todd Engle, Carrie Cooper re: Steering Committee w/Attach: IMPAX Prescription Sales and Quarterly Peak Calculations July 2010 - Dec 2011.xlsx	3/7/2012	IMPAX-OPANA-CID00005714	IMPAX-OPANA-CID00005717	RX-313	JX-002			

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX3049	Endo Press Release: Endo Health Solutions Responds to FDA 's Denial of OPANA® ER Citizen Petition and the Potential Approval of Additional Non-Abuse Deterrent Formulations of Generic Oxymorphone	5/10/2013	CX3049-001	CX3049-003		JX-002			
CX3050	Intentionally Not Used					N/A			
CX3051	Endo Presentation: Ratings Agency Presentation	7/19/2013	EPI002160028	EPI002160028		JX-002			
CX3052	Intentionally Not Used					N/A			
CX3053	Email from Ray Smith to Joe Camargo, Chuck Hildenbrand, and Meg Snowden re: OXM	6/4/2010	Impax_Opana_PartIII_0002588	Impax_Opana_PartIII_0002589		JX-002			Tr. 993:15, 25; 994:04; 995:05
CX3054	Intentionally Not Used					N/A			
CX3055	Email from Kevin Sica to Denis Paquette re: January Forecast Submission w/Attach: Forecast Change From Previous Forecast0109.xls	1/9/2009	Impax_Opana_PartIII_0006087	Impax_Opana_PartIII_0006088		JX-002			
CX3056- CX3057	Intentionally Not Used					N/A			
CX3058	Email from Joe Camargo to Sammy Bhardway, Alexander Garza, Tamara Alegria, et al. re: Attached Image w/Attach: 0728_001.pdf	6/17/2010	Impax_Opana_PartIII_0013410	Impax_Opana_PartIII_0013412		JX-002			
CX3059	Intentionally Not Used					N/A			
CX3060	Email from Joe Camargo to John Anthony, Todd Engle, Chris Mengler, et al. re: Oxymorphone	1/11/2010	Impax_Opana_PartIII_0030639	Impax_Opana_PartIII_0030641		JX-002			
CX3061	Email from Joe Camargo to Leatha Revels, Kangwen Lin, Denis Paquette, et al. re: Oxymorphone PV Start	1/8/2010	Impax_Opana_PartIII_0015365	Impax_Opana_PartIII_0015365		JX-002			
CX3062	Email from Huyen Vo to Joe Camargo, Denis Paquette, Gerard D. Cravello re: <no subject>	5/26/2010	Impax_Opana_PartIII_0018294	Impax_Opana_PartIII_0018294		JX-002			
CX3063	Email from Joe Camargo to Chuck Hildenbrand, Chris Mengler, and Todd Engle re: March 10 Forecast Submission	3/9/2010	Impax_Opana_PartIII_0018507	Impax_Opana_PartIII_0018509	RX-177	JX-002			
CX3064	Intentionally Not Used					N/A			
CX3065	Email from Joe Camargo to Denis Paquette, Chuck Hildenbrand, Kevin Sica, et al. re: Final March Plan w/Attach: March Plan in Lots and Hours.xls	2/18/2010	Impax_Opana_PartIII_0026043	Impax_Opana_PartIII_0026044		JX-002			
CX3066- CX3068	Intentionally Not Used					N/A			
CX3069	Email from Joe Camargo to Chuck Hildenbrand re: Updated Version w/Attach: 2010 Performance to Objectives.doc	1/17/2011	Impax_Opana_PartIII_0033451	Impax_Opana_PartIII_0033453		JX-002			Tr. 999:09, 15, 23; 1000:13; 1001:19; 1033:09; 1034:22
CX3070- CX3072	Intentionally Not Used					N/A			
CX3073	Email from Ted Smolenski to Joe Camargo, Kevin Sica, Chuck Hildenbrand, et al. re: Generic new product launch projection 2009-02-02.xls w/Attach: Generic new product launch projection 2009-02-02.xls	2/2/2009	Impax_Opana_PartIII_0069451	Impax_Opana_PartIII_0069452		JX-002			
CX3074- CX3075	Intentionally Not Used					N/A			
CX3076	Email from Joe Camargo to Andrew Fox, Art Koch, Chuck Hildenbrand et al. re: Checklist w/Attach: Product Launch Checklist.xls	5/26/2010	Impax_Opana_PartIII_0077872	Impax_Opana_PartIII_0077873		JX-002			
CX3077	Intentionally Not Used					N/A			
CX3078	Email from Joe Camargo to Andrew Fox re: Updated Checklist w/Attach: Product Launch Checklist.xls	5/11/2010	Impax_Opana_PartIII_0079088	Impax_Opana_PartIII_0079089		JX-002			Tr. 980:25, 981:12, 17; 1013:24; 1014:15
CX3079	Intentionally Not Used					N/A			
CX3080	Impax Document: Consulting Agreement	6/1/2017	Impax_Opana_PartIII_0081324	Impax_Opana_PartIII_0081329		JX-002			
CX3081	Email from Joe Camargo to John Anthony, Mark Shaw, and Chuck Hildenbrand re: Impax requested a revised 2010 Oxymorphone Quota	6/9/2010	IMPAX-OPANA-CID00021069	IMPAX-OPANA-CID00021069		JX-002			Tr. 992:13
CX3082	Email from Todd Engle to Kevin Sica, Meg Snowden re: QLPM Sales Forecasts w/Attach: QLPM 051410 Draft.doc	5/18/2010	IMPAX-OPANA-CID00002107	IMPAX-OPANA-CID00002112		JX-002			
CX3083	Email from Todd Engle to Kevin Sica re: Oxymorphone ER peak sales	1/22/2013	IMPAX-OPANA-CID00004062	IMPAX-OPANA-CID00004062		JX-002			
CX3084	Intentionally Not Used					N/A			
CX3085	Email from Chris Mengler to Larry Hsu, Art Koch re: 5-year forecast 2010-May Update 2010--05-14v4.xls w/Attach: 5-year forecast 2010-May Update 2010--05-14v4.xls	5/14/2010	IMPAX-OPANA-CID00006958	IMPAX-OPANA-CID00006959		JX-002			
CX3086- CX3088	Intentionally Not Used					N/A			

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX3089	Email from Joyce De Los Reyes to Joe Camargo, Charles Hildenbrand, Pete Valko, et al. re: Generic new product launch projection 081208.xls	8/12/2008	IMPAX-OPANA-CID00012345	IMPAX-OPANA-CID00012346		JX-002			
CX3090- CX3091	Intentionally Not Used					N/A			
CX3092	Email from Steve Mollichella to Kevin Sica, Todd Engle re: ENDO Payment Calculation w/Attach: Opana ER Peak Calculation for 4Q12 R1 with IMS data.xls	1/29/2013	Impax_Opana_PartIII_0063870	Impax_Opana_PartIII_0063871	RX-215	JX-002			
CX3093- CX3095	Intentionally Not Used					N/A			
CX3096	Impax Presentation: Board Presentation (Non-GAAP)	00/00/2014	Impax_Opana_PartIII_0002842	Impax_Opana_PartIII_0002868		JX-002		Ordered 10/23/2017	Tr. 1223:18; 1224:02
CX3097- CX3101	Intentionally Not Used					N/A			
CX3102	Email from Sean Palmer to Mark Donohue re: Furyk Rating Agency Presentation w/Attach: Impax RAP_v10.20.14.pptx	10/19/2014	Impax_Opana_PartIII_0041757	Impax_Opana_PartIII_0041807		JX-002		Ordered 10/23/2017	
CX3103- CX3104	Intentionally Not Used					N/A			
CX3105	Email from Larry Kloss to Bryan Reasons and George Hill re: 7 Year Plan Summary - 9-9-14 - Update (ALTERNATE w/o IPX 203) w/Attach: 7 Year Plan Summary - 9-9-14 - Update.xlsx	9/8/2014	Impax_Opana_PartIII_0058604	Impax_Opana_PartIII_0058605	RX-203	JX-002		Ordered 10/23/2017	
CX3106	Email from Larry Kloss to Michael Nestor re: IPX203 Financial (Base) Forecast w/Attach: IPX203 Project Timeline_costing (Base_Optimistic)_14Aug2015.potx, IPX203 Operational (Optimistic) Forecast 2015-08-14.xlsx, IPX203 Operational (Optimistic) Forecast...	8/15/2015	Impax_Opana_PartIII_0063716	Impax_Opana_PartIII_0063725	RX-210	JX-002		Ordered 10/23/2017	
CX3107	Email from Larry Kloss to Bryan Reasons, Michael Nestor, Fred Wilkinson, et al. re: 2015 Plan - Executive Review 11-20-14 R1 (Update) w/Attach: Dec 14 BOD 2015 Plan 11-20-14 R1.pdf	11/19/2014	Impax_Opana_PartIII_0063751	Impax_Opana_PartIII_0063765		JX-002		Ordered 10/23/2017	
CX3108- CX3110	Intentionally Not Used					N/A			
CX3111	Email from Joyce de los Reyes to Richard Ting and April Isaacson re: PEC meeting (9AM PT/ 12PM ET) w/Attach: PEC 2015-07-02.pptx	7/2/2015	Impax_Opana_PartIII_0081075	Impax_Opana_PartIII_0081123	RX-239	JX-002		Ordered 10/23/2017	
CX3112	Impax Memorandum from Meg Snowden to Endo Pharmaceuticals Inc. and Penwest Pharmaceuticals Co. re: Settlement and License Agreement by and among Endo Pharmaceuticals Inc., Penwest Pharmaceuticals Co., and Impax Laboratories, Inc. dated June 8, 2010	1/18/2013	IMPAX-OPANA-CID00000323	IMPAX-OPANA-CID00000347		JX-002			
CX3113- CX3114	Intentionally Not Used					N/A			
CX3115	Email from Todd Engle to Larry Hsu, Carole Ben-Maimon, Bryan Reasons, and George Hill re: Updated Materials for Today's Generic Sales and Marketing Meeting w/Attach: Generic Sales and Marketing Meeting Sept 16 2013.pptx	10/2/2013	IMPAX-OPANA-CID00005436	IMPAX-OPANA-CID00005450		JX-002			
CX3116	Intentionally Not Used					N/A			
CX3117	Email from Jeff Miller to Timothy Niedrist re: Update Requested => Impax-Endo Agreement w/Attach: Update Requested => Impax-Endo Agreement	7/2/2012	IMPAX-OPANA-CID00011740	IMPAX-OPANA-CID00011754	RX-355	JX-002			
CX3118	Intentionally Not Used					N/A			
CX3119	Email from Leann Nassar to Bryan Reasons re: Carole's BOD Presentation w/Attach: BOD Slides 12412 Final Generic.pptx	11/21/2012	IMPAX-OPANA-CID00013639	IMPAX-OPANA-CID00013671		JX-002			
CX3120	Intentionally Not Used					N/A			
CX3121	Email from Steve Mollichella to Suneel Gupta, Bryan Reasons, Wenchi Liu, et al. re: Impax-Form 10K-Question w/Attach: 10K Alliance Agreements-R2.xlsx	2/13/2012	IMPAX-OPANA-CID00018543	IMPAX-OPANA-CID00018544		JX-002			
CX3122	Email from Steve Mollichella to Suneel Gupta re: Impax-Form 10K-Question	2/14/2012	IMPAX-OPANA-CID00018550	IMPAX-OPANA-CID00018550		JX-002			
CX3123- CX3124	Intentionally Not Used					N/A			
CX3125	Email from Joanne Tempono to Carole Ben-Maimon and Bryan Reasons re: Endo Deal	11/13/2012	IMPAX-OPANA-CID00019021	IMPAX-OPANA-CID00019022		JX-002			
CX3126	Email from Larry Hsu to Carole Ben-Maimon, Bryan Reasons, Todd Engle, et al. re: Documents I think You'll Find of Interest	2/7/2013	IMPAX-OPANA-CID00019320	IMPAX-OPANA-CID00019323		JX-002			



COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX3127- CX3128	Intentionally Not Used					N/A			
CX3129	Endo Spreadsheet: Endo Contribution Margin Report - Period	6/11/2014	EPI000731506	EPI000731506		JX-002			
CX3130	Email from Roberto Cuca to Alan Levin, Darnell Turner, and David Macera re: Per share price impact of generic Opana ER launch	3/15/2010	EPI002159607	EPI001588193	RX-130	JX-002			
CX3131	Email from Alan Levin to Roberto Cuca, Karen Adler, Mark Bradley, and Denise Craig re: Impax and Sandoz Litigations Settled w/Attach: Sandoz June 2010 FINAL Joint-1.doc	6/8/2010	EPI002200039	EPI002200047		JX-002			
CX3132	Email from Alan Levin to Robert Cobuzzi re: IPX066	5/22/2010	EPI002201680	EPI002201682		JX-002			
CX3133	Email from Alan Levin to Blaine Davis re: Penwest Royalties	6/7/2010	EPI002201727	EPI002201728		JX-002			
CX3134	Endo Document: Key Messages	6/4/2010	EPI002209609	EPI002209611		JX-002			
CX3135	Endo Document: Minutes of a Special Meeting of the Board of Directors of Endo Pharmaceuticals Holdings Inc.	5/27/2010	EPI002219841	EPI002219842		JX-002			
CX3136	Email from Caroline Manogue to Jonathan Neely, Alan Levin, Sean Lannon, et al. re: Jefferies Investor Slides v3.pptx w/Attach: Jefferies Investor Slidesv3.pptx, ENDP Jefferies Global Life Sciences Script v3.docx	6/9/2010	EPI002221135	EPI002221149		JX-002			
CX3137- CX3139	Intentionally Not Used					N/A			
CX3140	Impax Presentation: Impax Generic Business Board of Directors Meeting December 11, 2014	12/11/2014	Impax_Opana_PartIII_0003069	Impax_Opana_PartIII_0003109		JX-002		Ordered 10/23/2017	
CX3141	Intentionally Not Used					N/A			
CX3142	Email from Sammy Bhardwaj to Tamara Alegria, Joe Camargo and John Anthony re: Attached Image	3/8/2010	Impax_Opana_PartIII_0015359	Impax_Opana_PartIII_0015360		JX-002			
CX3143- CX3145	Intentionally Not Used					N/A			
CX3146	Email from Todd Engle to Joe Camargo re: Nov Manufacturing Plan w/Attach: Nov 09 Plan in Lots 091012.xls	10/22/2009	Impax_Opana_PartIII_0034840	Impax_Opana_PartIII_0034841		JX-002			
CX3147	Intentionally Not Used					N/A			
CX3148	Email from Todd Engle to Kevin Sica and Thomas Sammier re: Copy of Oxymorphone ER price increase model Aug 2015 TMS 8-8-15.xls w/Attach: Copy of Oxymorphone ER price increase model Aug 2015 TMS 8-8-15.xls	8/19/2015	Impax_Opana_PartIII_0052672	Impax_Opana_PartIII_0052673		JX-002		Ordered 10/23/2017	
CX3149	Email from Mike Grisby to Todd Engle re: M&D Price Adjustment Request: Oxymorphone HCI ER CII Inventory w/Attach: Gen Prod Rev Oxymorph ER 030716 - 1.pdf, Gen Prod Rev Oxymorph ER 030716 - 2.pdf	3/16/2016	Impax_Opana_PartIII_0052702	Impax_Opana_PartIII_0052706		JX-002		Ordered 10/23/2017	
CX3150	Email from William Ball to Tracy Plouffe, Jim MacDonald and Todd Engle re: Oxymorphone price increases w/Attach: OptiSource Price Increase - Oct. 2015.doc	1/21/2016	Impax_Opana_PartIII_0052804	Impax_Opana_PartIII_0052807		JX-002		Ordered 10/23/2017	
CX3151- CX3153	Intentionally Not Used					N/A			
CX3154	Email from Larry Hsu to Todd Engle, Chris Mengler, and Meg Snowden re: Mengler Board Slides	5/14/2010	Impax_Opana_PartIII_0063822	Impax_Opana_PartIII_0063823		JX-002			
CX3155	Email from Todd Engle to Chris Menger and Meg Snowden re: Zorn Model Oxymorphone 03 22 10.xls	3/23/2010	Impax_Opana_PartIII_0063847	Impax_Opana_PartIII_0063848		JX-002			
CX3156	Email from Ted Smolenski to Joyce De Los Reyes, Kevin Sica, Todd Engle, Chris Mengler, et al. re: Endo: One Deal Away from Being Interesting w/Attach: ENDP--UBS--2010-02-22.pdf	2/23/2010	Impax_Opana_PartIII_0080324	Impax_Opana_PartIII_0080341		JX-002			
CX3157	Email from Jason Laeser to Anna Fabish, Ted Hassi, Stephen McIntyre, et al. re: In the Matter of Impax Laboratories, Inc., Docket 9373 w/Attach: Letter to Impax 081117.pdf; Impax DEA quota request documents - oxymorphone quota.pdf	8/11/2017	Impax_Opana_PartIII_0081769	Impax_Opana_PartIII_0081823		JX-002			
CX3158	Email from Kent Summers to Heather Thomson, Ann Harty, Todd Berner, et al. re: EN3288 Value Strategy: Slides for Monday w/Attach: EN3288 HOST 030110v7.pptx	2/28/2010	EPI000325812	EPI000325818		JX-002			Tr. 721:07, 08, 24;
CX3159	Email from Nicholas Albert to Joshua Drew, Kevin O'Connell, William Best, et al. re: sales training referenced in Opana ER RiskMap Update Report w/Attach: Exalgo Background.pdf; EXALGO Annotated PI.pdf	9/17/2010	EPI000281799	EPI000281852		JX-002			

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX3160	Document: Endo Pharmaceuticals Holdings Inc. SEC Form 10-K 2009	2/26/2010	CX3160-001	CX3160-228		JX-002			
CX3161	Intentionally Not Used					N/A			
CX3162	Document: Impax White Paper to FTC	2/16/2015	CX3162-001	CX3162-045		JX-002			
CX3163	Document: Answer of Respondent Impax Laboratories Inc. to the Federal Trade Commission's Administrative Complaint	2/7/2017	CX3163-001	CX3163-024		JX-002			
CX3164	Document: Respondent Impax Laboratories, Inc.'s Objections and Responses to Complaint Counsel's Requests for Admission	8/3/2017	CX3164-001	CX3164-022		JX-002			
CX3165	Email from David Paterson to Suneel Gupta re: IPX203	11/17/2014	Impax_Opana_PartIII_0059855	Impax_Opana_PartIII_0059855		JX-002			
CX3166	Impax Presentation: Impax Pharmaceutical R&D	1/24/2013	IMPAX-OPANA-CID00019616	IMPAX-OPANA-CID00019694		JX-002		Ordered 10/23/2017	
CX3167	Impax Presentation: Brand R&D Presentation	8/11/2010	IMPAX-OPANA-CID00019989	IMPAX-OPANA-CID00020051		JX-002		Ordered 10/23/2017	
CX3168	Email from Richard Reeve to Kevin Pong, Mark Bradley, Debbie Travers, et al. re: Project Biloxi: Revisions to the OEW w/Attach: 041211 Biloxi OEW v13 RR.docx, Microsoft Powerpoint_Slide1.sldx	4/13/2011	EPI000161793	EPI000161829		JX-002			
CX3169	Email from Demir Bingol to Brian Lortie and Steven Cowan re: EOC action item re: Opane ER / 3288 supply chain	2/8/2011	EPI000189554	EPI000189556		JX-002			
CX3170	Email from Sam Rasty to Demir Bingol re: Opana A&P cost question w/Attach: OEW for Project Nevada - Nekfar-118 license 16May08 + market opp.doc, Unnamed Presentation, Unnamed Document	5/28/2008	EPI000300513	EPI000300526		JX-002			
CX3171	Email from Jocelyn Gilmour to Mahen Gundecha, Demir Bingol, Carolyn Kong, et al. re: Old Project Newcastle Information w/Attach: OROS Hydromorphone.doc, Neuromed OEW v3.doc, Unnamed Presentation, Newcastle TPP.doc, Key Questions on Newcastle (dp comments)	6/22/2009	EPI000771172	EPI000771191		JX-002		Ordered 10/20/2017	
CX3172	Email from Meg Snowden to Robert Cobuzzi, Chris Mengler, Michael Nestor, et al. re: IPX066	5/19/2010	EPI000873937	EPI000873937		JX-002			
CX3173	Email from Pranay Patel to Andy Gesek re: Revised Cuba OEW Commercial 4-27-12 w/Attach: Revised Cuba OEW Commercial 4-27-12.docx	4/27/2012	EPI001124711	EPI001124727		JX-002			
CX3174	Email from David Paterson to Robert Cobuzzi, Michael Nestor, Chris Mengler, and Meg Snowden re: IPX066 w/Attach: IPX066_IMPAX_Partner_Confidential_032010_FINAL.pdf, 066 Apr2010AAN poster final poster.ppt	5/20/2010	EPI001433193	EPI001433293		JX-002			
CX3175	Email from Robert Cobuzzi to Donna Petak re: Licensing Update for BoD Book w/Attach: Corp Dev Update for Oct BOD (7).pptx, Freeport OEW v6 091509.docx, Lansing OEW 092509 v3.doc, Unnamed Presentation, Unnamed Presentation, Astoria OEW 100809 v12.docx..	10/16/2009	EPI001828150	EPI001828209		JX-002			
CX3176	Endo Document: IPX-203 Opportunity Evaluation Worksheet (OEW)	6/00/2009	EPI001849033	EPI001849050		JX-002		Ordered 10/23/2017	
CX3177	Endo Cover Email Withheld as Privileged, Attachments: April 2010 Government Affairs Activity Report, Agenda for the Board of Directors Meeting (April 28, 2010), Financial Forecast Board of Directors Meeting Presentation, Commercial Operating Model...	4/00/2010	EPI001896379	EPI001896435		JX-002			
CX3178	Email from Michael Nestor to Robert Cobuzzi and Suneel Gupta re: Information requested	6/4/2010	EPI002156025	EPI002156026		JX-002			
CX3179	Email from Kevin Pong to Guy Donatiello, Charles Gombar and Robert Cobuzzi re: Project Imperial: JDC	9/17/2010	EPI002156098	EPI002156098		JX-002			
CX3180	Email from Robert Cobuzzi to Kevin Pong re: Bob, Kevin Pong need to speak w/ you for 1 minute before the Qatar call. Did not mention subject. Thanks, Donna	9/14/2010	EPI002156228	EPI002156229		JX-002			
CX3181	Email from Donna Papa to Andy Gesek, Nancy Fefrow, Craig Paterson, et al. re: Evaluation of IPX-203 (carbidopa_levodopa).pptx w/Attach: Duopa PI.pdf, Evaluation of IPX-203 (Carbidopa_levodopa).pptx, Rytary PI.pdf	10/28/2015	EPI002190281	EPI002190359		JX-002		Ordered 10/20/2017 & 10/23/2017	Tr. 1108:06, 08, 19; 1109:04; 1110:24; 1112:05; 1113:11; 1114:09; 1119:17; 1120:14; 1121:16; 1192:07, 11; 1194:15

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX3182	Email from Guy Donatiello to Ginola Johnson re: Agreements w/Attach: Sandoz - Endo Settlement Agreement EXECUTION VERSION.pdf; Impax - Endo Settlement Agreement_Opana_[Execution Version].pdf; Impax-Endo Co-Promotion Agreement.pdf	6/21/2010	EPI000828479	EPI000828555		JX-002			
CX3183	Email from Art Koch to Alan Levin, Meg Snowden, Guy Donatiello, et al. re: Gross Margin	6/7/2010	EPI000874092	EPI000874092		JX-002			
CX3184	Email from Brian Lortie to Julie McHugh re: Update	6/7/2010	EPI001170646	EPI001170647		JX-002			
CX3185	Email from Todd Engle to Joe Camargo, Meg Snowden re: Launch Planning Input w/Attach: QLPM 051810 Draft.doc	5/18/2010	Impax_Opana_PartIII_0077527	Impax_Opana_PartIII_0077571		JX-002			
CX3186	Email from Meg Snowden to Guy Donatiello re: Signature pages	6/8/2010	IMPAX-OPANA-CID00002220	IMPAX-OPANA-CID00002220		JX-002			
CX3187	Email from Larry Hsu to Ted Smolenski, Art Koch re: opana ER	1/8/2011	IMPAX-OPANA-CID00003557	IMPAX-OPANA-CID00003558	RX-293	JX-002			
CX3188	Endo Press Release: Endo Pharmaceuticals Reports Strong Third Quarter 2010 Financial Results; Reaffirms 2010 Financial Guidance and Provides Financial Guidance for 2011	11/1/2010	CX3188-001	CX3188-018		JX-002			
CX3189	Endo Press Release: Endo Pharmaceuticals Agrees to Acquire Penwest Pharmaceuticals and Submits NDA for New Formulation of Long-Acting Oxymorphone Designed to be Crush-Resistant	8/9/2010	CX3189-001	CX3189-007		JX-002			
CX3190	Document: Respondent Impax Laboratories, Inc.'s Objections and Responses to Complaint Counsel's Second Set of Interrogatories (Revised)	8/10/2017	CX3190-001	CX3190-029		JX-002		Ordered 10/23/2017	
CX3191	Actavis Spreadsheet: Oxymorphone Sales Accruals	3/29/2017	Actavis_FTC_Opana_000375	Actavis_FTC_Opana_000375		JX-002		Ordered 10/20/2017	
CX3192	Actavis Document: 2009 Opana Settlement Agreement	2/20/2009	ACTLID00000001	ACTLID00000002		JX-002		Ordered 10/20/2017	
CX3193	Endo Presentation: EN3288 Strategic Recommendation	2/16/2010	EPI000004174	EPI000004190		JX-002			
CX3194	Endo Document: US FDA Advisory Committee Briefing Document EN3288	12/2/2010	EPI000006894	EPI000007031		JX-002			
CX3195	Email from Tara Chapman to Frank Yuen, Jill Connell, Linda Kitlinski, et al. re: Opana ER RiskMAP Update Report - Due April 30 w/Attach: Opana ER RiskMap Update Report (01Oct2008-31Dec2008).doc	4/3/2009	EPI000116711	EPI000116735		JX-002			
CX3196	Endo Document: BOA Merrill Lynch Analysis: Raising PO to \$35	9/14/2010	EPI000183325	EPI000183347		JX-002			
CX3197	Email from Marv Kelly to Edward DiNapoli, Brian Lortie, Larry Romaine, et al. re: Branded Pharma Day 1_edited backup final.pptx w/Attach: Branded Pharma Day 1_edited backup final.pptx	3/18/2013	EPI000191570	EPI000191580		JX-002			
CX3198	Email from Andy Gesek to Brian Lortie re: Branded Pharmaceuticals deep dive 82913.pptx w/Attach: Branded Pharmaceuticals deep dive 82913.pptx	8/29/2013	EPI000191948	EPI000191949		JX-002			
CX3199	Endo Presentation: 2009-2013 Opana Brand Single Strategy Plan	7/21/2008	EPI000206065	EPI000206067		JX-002		Ordered 10/20/2017	
CX3200	Email from Anthony Analla to Ronald Jackson re: Message from John Kranyak, Sr. Director Market Research and Insights	1/5/2011	EPI000901059	EPI000901060		JX-002			
CX3201	Email from Kristin Vitanza to Kelley Ferris, Anita Brandon re: Delatestry w/Attach: 2-14-11 Discontinuation Opana ER.PDF	8/1/2011	EPI000980097	EPI000980099		JX-002			
CX3202	Email from Cliff Larsen to Andy Gesek re: Opana ER Scenario Request by KV	5/16/2013	EPI001128605	EPI001128605		JX-002			
CX3203	Email from Brian Risk to Brian Munroe re: Letter to FDA and Opana Citizens Petitions w/Attach: Date-Stamped Opana ER CP 31 Aug 2012.pdf; Endo CP Submission (8-13-12) date-stamped.pdf; Coalition letter to FDA re ADF conditions 101812.pdf	10/18/2012	EPI001180038	EPI001180099	GX1221; RX-065	JX-002			Tr. 477:03
CX3204	Endo Document: Plaintiffs Opposition to Defendants' and Intervenor's Motions to Dismiss and Plaintiffs Reply in Support of Motion for Preliminary Injunction	12/14/2012	EPI001624475	EPI001624514		JX-002			
CX3205	Endo Document: Project Greenland: Grunenthal ADF formulation of Oxymorphone	12/13/2007	EPI002155994	EPI002155999		JX-002			
CX3206	Endo Document: Pricing Proposal Submission Form: GPO Hospital Contract Strategy for Opana ER	4/19/2012	EPI002173430	EPI002173434		JX-002		Ordered 10/20/2017	

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX3207	Endo Document: Pricing Proposal Submission Form: OPANA ER (CRF) Unit Dose (UD) Line Extension WAC Pricing & Discount Strategies	11/7/2012	EPI002173492	EPI002173494		JX-002			
CX3208	Email from Ted Smolenski to Joe Camargo, Chuck Hildenbrand re: Oxymorphone HCl Tablets 5 mg & 10 mg (Acceptance for Filing Letter Received) and Oxymorphone ER (Final Approval Received) - It's a Double Celebration! w/Attach: Oxymorphone IR Acceptance for F	6/16/2010	Impax_Opana_PartIII_0045547	Impax_Opana_PartIII_0045557		JX-002			
CX3209	Email from Jeff McCown to George Hill, Connie Chiang, David Howard re: Dara w/Attach: Project Dara Financials (8 11 14).xlsx	8/11/2014	Impax_Opana_PartIII_0060481	Impax_Opana_PartIII_0060482		JX-002		Ordered 10/23/2017	
CX3210	Email from Michelle Mikolai to Todd Engle re: COA and BE Summary Data w/Attach: FDA Approval Letter_Oxymorphone HCl ER Tablets.pdf; MSDS_Oxymorphone Hydrochloride.pdf; Package Insert_Oxymorphone HCl ER Tablets.pdf	1/16/2013	IMPAX-OPANA-CID00002349	IMPAX-OPANA-CID00002363		JX-002			
CX3211	Email from Chris Mengler to Larry Hsu re: Mengler Board Slides w/Attach: Mengler Board Presentation 051310.ppt	5/14/2010	IMPAX-OPANA-CID00018106	IMPAX-OPANA-CID00018127		JX-002			
CX3212	Letter from Joshua Davis to Maren Schmidt re: Endo CID Response to Specs 1, 8, 33, 39	6/27/2014	CX3212-001	CX3212-021		JX-002			
CX3213	Document: Endo Pharmaceuticals Holdings Inc. SEC Form 10-K 2007	2/26/2008	CX3213-001	CX3213-279		JX-002			
CX3214	Document: Endo Pharmaceuticals Holdings Inc. SEC Form 10-K 2010	2/28/2011	CX3214-001	CX3214-594		JX-002			
CX3215	Document: Endo Pharmaceuticals Holdings Inc. SEC Form 10-K 2012	3/1/2013	CX3215-001	CX3215-355	RX-496	JX-002			
CX3216	Document: Endo Pharmaceuticals Holdings Inc. SEC Form 10-Q March 31, 2010	5/3/2010	CX3216-001	CX3216-103		JX-002			
CX3217	Impax Press Release: Impax Comments on Status of ANDA for Generic Opana(R) ER	10/4/2007	CX3217-001	CX3217-002		JX-002			
CX3218	Impax Press Release: Impax Comments on Lawsuit Related to Generic Version of Opana(R) ER	11/19/2007	CX3218-001	CX3218-002		JX-002			
CX3219	Document: Q2 2011 Endo Pharmaceuticals Holdings Earnings Call Transcript	8/9/2011	CX3219-001	CX3219-029		JX-002			
CX3220	Document: Q2 2012 Endo Pharmaceuticals Holdings Earnings Call Transcript	8/7/2012	CX3220-001	CX3220-027		JX-002			
CX3221	Document: Q4 2011 Endo Pharmaceuticals Holdings Earnings Call Transcript	2/24/2012	CX3221-001	CX3221-028		JX-002			
CX3222	Impax Presentation: Board of Directors Meeting May 2010	5/00/2010	Impax_Opana_PartIII_0003917	Impax_Opana_PartIII_0003939	RX-163	JX-002			
CX3223	Impax Document: Minutes of a Special Meeting of the Board of Directors of Impax Laboratories, Inc.	7/5/2013	Impax_Opana_PartIII_0004183	Impax_Opana_PartIII_0004184	RX-168	JX-002			Tr. 467:19
CX3224	Intentionally Not Used					N/A			
CX3225	Email from Kevin Sica to Denis Paquette, Tony Bright, Joe Camargo, et al. re: Dec 09 Forecast Submission w/Attach: Forecast Change From Previous Forecast 1209.xls	12/7/2009	Impax_Opana_PartIII_0006052	Impax_Opana_PartIII_0006053		JX-002			
CX3226	Email from Kevin Sica to Denis Paquette, Tony Bright, Joe Camargo, et al. re: Feb 10 Forecast Submission w/Attach: Forecast Change From Previous Forecast 0210.xls	2/5/2010	Impax_Opana_PartIII_0006056	Impax_Opana_PartIII_0006057		JX-002			
CX3227	Email from Kevin Sica to Denis Paquette, Tony Bright, Joe Camargo, et al. re: April Forecast Submission w/Attach: Forecast Change From Previous Forecast 0410.xls	4/7/2010	Impax_Opana_PartIII_0006060	Impax_Opana_PartIII_0006062		JX-002			
CX3228	Email from Kevin Sica to Denis Paquette, Tony Bright, Joe Camargo, et al. re: July 09 Forecast Submission w/Attach: Forecast Change From Previous Forecast 0709.xls	7/8/2009	Impax_Opana_PartIII_0006075	Impax_Opana_PartIII_0006076		JX-002			
CX3229	Email from Kevin Sica to Denis Paquette, Tony Bright, John Meno, et al. re: Nov 09 Forecast Submission w/Attach: Forecast Change From Previous Forecast 1109.xls	11/6/2009	Impax_Opana_PartIII_0008996	Impax_Opana_PartIII_0008997		JX-002			
CX3230	Email from Kevin Sica to Denis Paquette, Tony Bright, Joe Camargo, et al. re: March 10 Forecast Submission w/Attach: Forecast Change From Previous Forecast 0310.xls	3/5/2010	Impax_Opana_PartIII_0022449	Impax_Opana_PartIII_0022450		JX-002			
CX3231	Spreadsheet: Commercial Forecast - 5-Yr 2010 May Update.xlsx	00/00/0000	Impax_Opana_PartIII_0081650	Impax_Opana_PartIII_0081650		JX-002			

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX3232	Email from Larry Kloss to Art Koch re: 5-year forecast 2010-May Update 201--05-14v5.xls w/Attach: 5-year forecast 2010-May Update 201--05-14v5.xls	5/15/2010	IMPAX-OPANA-CID00007080	IMPAX-OPANA-CID00007081		JX-002			
CX3233	Intentionally Not Used					N/A			
CX3234	Compl., Endo Pharm. Inc. v. Par Pharm. Co., No. 1:12-cv-09261-UA (S.D.N.Y. Dec. 19, 2012)	12/19/2012	CX3234-001	CX3234-003		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		
CX3235	Dkt. No. 209, Endo Pharm. Inc. v. Actavis LLC, No. 14-cv-01381-RGA (D. Del. Apr. 7, 2017)	4/7/2017	CX3235-001	CX3235-001		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		
CX3236	Intentionally Not Used					N/A			
CX3237	Endo Pharm. Inc. v. Teva Pharm. USA, Inc., No. 15-2021 (Fed. Cir. appeal docketed Sept. 15, 2015)	9/15/2015	CX3237-001	CX3237-001		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		
CX3238- CX3239	Intentionally Not Used					N/A			
CX3240	Endo Press Release: Endo Announces Commercial Availability of Opana® ER (oxymorphone HCl) Extended-Release and Opana® (oxymorphone HCl) Immediate-Release Tablets CII	7/24/2006	CX3240-001	CX3240-005		JX-002			
CX3241	Endo Press Release: Endo Completes Transition of OPANA® ER Franchise to New Formulation Designed to be Crush Resistant	6/14/2012	CX3241-001	CX3241-002		JX-002			
CX3242	Letter from Caroline Manogue and Benjamin Palleiko to Gary Buehler, FDA re: NDA No. 21-610 -- Opana ER (oxymorphone HCl) extended release tablets ANDA No. 79-087 (Impax Laboratories)	10/25/2007	EPI001604413	EPI001604430		JX-002			
CX3243	Document: FDA Approval Letter, Opana ER, NDA No. 201655	12/9/2011	CX3243-001	CX3243-009		JX-002			
CX3244	Impax Press Release: IMPAX Announces FDA Acceptance of ANDA for Generic Version of Opana® ER	12/17/2007	CX3244-001	CX3244-002		JX-002			
CX3245	Impax Press Release: Impax Laboratories Receives Tentative FDA Approval for Generic Opana(R) ER 5, 7.5, 10, 20, 30 and 40 mg Tablets	5/14/2010	CX3245-001	CX3245-002		JX-002			
CX3246	Document: Opana ER (NDA No. 021610) Label	8/2/2006	CX3246-001	CX3246-002		JX-002			
CX3247	U.S. Food & Drug Administration, Drugs@FDA, "Numorphan," NDA No. 011738	8/1/2017	CX3247-001	CX3247-003		JX-002			
CX3248	U.S. Food & Drug Administration, Drugs@FDA, "Opana ER," NDA No. 021610	8/1/2017	CX3248-001	CX3248-006		JX-002			
CX3249	U.S. Patent No. 5,662,933	11/3/1995	CX3249-001	CX3249-001		JX-002			
CX3250	U.S. Patent No. 7,276,250	7/3/2002	CX3250-001	CX3250-001		JX-002			
CX3251	U.S. Patent No. 8,309,060	1/9/2012	CX3251-001	CX3251-001		JX-002			
CX3252	U.S. Patent No. 8,309,122	2/28/2007	CX3252-001	CX3252-001		JX-002			
CX3253	U.S. Patent No. 8,329,216	6/29/2006	CX3253-001	CX3253-001		JX-002			
CX3254	U.S. Patent No. 8,808,737	3/3/2010	CX3254-001	CX3254-001		JX-002			
CX3255	U.S. Patent No. 8,871,779	3/3/2007	CX3255-001	CX3255-001		JX-002			
CX3256	Document: Avinza Prescribing Information	4/00/2014	CX3256-001	CX3256-027		JX-002			
CX3257	Document: Butrans Prescribing Information	6/00/2014	CX3257-001	CX3257-041		JX-002			
CX3258	Document: Dolophine Prescribing Information	4/00/2015	CX3258-001	CX3258-024		JX-002			
CX3259	Document: Duragesic Prescribing Information	3/00/2017	CX3259-001	CX3259-056		JX-002			
CX3260	Document: Embeda Prescribing Information	12/00/2016	CX3260-001	CX3260-030		JX-002			
CX3261	Document: Exalgo Prescribing Information	3/00/2010	CX3261-001	CX3261-030		JX-002			
CX3262	Document: Hysingla Prescribing Information	12/00/2016	CX3262-001	CX3262-020		JX-002			
CX3263	Document: Kadian Prescribing Information	12/00/2016	CX3263-001	CX3263-035		JX-002			
CX3264	Document: MS Contin Prescribing Information	4/00/2014	CX3264-001	CX3264-022		JX-002			
CX3265	Document: Nucynta Prescribing Information	12/00/2016	CX3265-001	CX3265-033		JX-002			
CX3266	Document: Opana ER Prescribing Information	12/00/2016	CX3266-001	CX3266-026		JX-002			
CX3267	Document: Opana Prescribing Information	7/00/2012	CX3267-001	CX3267-015		JX-002			
CX3268	Document: OxyContin Prescribing Information	12/00/2016	CX3268-001	CX3268-029		JX-002			
CX3269	Document: Ultram ER Prescribing Information	7/00/2014	CX3269-001	CX3269-023		JX-002			
CX3270	Document: Zohydro Prescribing Information	12/00/2016	CX3270-001	CX3270-028		JX-002			
CX3271	Impax Annual Report 2015: We Care to Make a Difference (December 31, 2015 SEC Form 10-K)	2/22/2016	CX3271-001	CX3271-160		JX-002			
CX3272	Document: Declaration of Margaret Snowden Verifying all Impax Interrogatory Responses	8/10/2017	CX3272-001	CX3272-002		JX-002			

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX3273	Document: Declaration of Demir Bingol, Civil Action Nos. 09-cv-831 (KSH) (PS), 09-cv-832 (KSH) (PS), 09-cv-833 (KSH) (PS)	5/21/2010	CX3273-001	CX3273-010	RX-486	JX-002			Tr. 1280:22; 1280:24; 1281:01; 1281:02; 1281:14; 1281:21; 1282:02; 1282:05; 1282:15; 1283:08; 1286:18; 1287:23; 1287:25; 1288:13; 1292:23; 1315:23
CX3274	Email from Chris Mengler to Chuck Hildenbrand, Art Koch, Meg Snowden, et al. re: Oxymorphone ER Tablets Tentatively Approved Today!!	5/13/2010	Impax_Opana_PartIII_0068875	Impax_Opana_PartIII_0068876		JX-002			
CX3275	Document: Contract Settlement Agreement [Execution Version]	8/5/2017	Impax_Opana_PartIII_0081712	Impax_Opana_PartIII_0081742		JX-002		Ordered 10/23/2017	Tr. 2724:08; 2729:10
CX3276	Document: First Amendment to 2010 Settlement and License Agreement [Execution Version]	8/5/2017	Impax_Opana_PartIII_0081743	Impax_Opana_PartIII_0081763		JX-002			
CX3277	Case 2:16-cv-02526-JLL-JAD Amended Complaint and Exhibits A, B, C, D	8/1/2016	CX3277-001	CX3277-163		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		
CX3278	Impax Annual Report 2010 (December 31, 2010 SEC Form 10-K)	2/25/2011	CX3278-001	CX3278-144		JX-002			Tr. 267:15
CX3279	Impax Annual Report 2011 (December 31, 2011 SEC Form 10-K)	2/28/2012	CX3279-001	CX3279-092		JX-002			
CX3280	Impax Annual Report 2012 (December 31, 2012 SEC Form 10-K)	2/26/2013	CX3280-001	CX3280-140		JX-002			
CX3281	Actavis Spreadsheet: NPA Opioids 2014-10-07	10/9/2014	ACTLID00216620	ACTLID00220254	RX-005	JX-002			
CX3282	Actavis Spreadsheet: NPA Topical Treatments 2014-10-07	10/9/2014	ACTLID00220255	ACTLID00220255		JX-002			
CX3283	Actavis Spreadsheet: NSP Opioids 2014-10-07	10/7/2014	ACTLID00235955	ACTLID00242664		JX-002			
CX3284	Actavis Spreadsheet: NSP Topical Treatments 2014-10-07	10/9/2014	ACTLID00242665	ACTLID00248717		JX-002			
CX3285	Endo Presentation: Chronic and Breakthrough Pain Treatment Flow	3/00/2009	EPI000001067	EPI000001227		JX-002			
CX3286	Endo Spreadsheet: WAC Price	5/22/2014	EPI000066412	EPI000066412		JX-002			
CX3287	Endo Spreadsheet: Lidoderm-Opana ER 2009-2014	5/22/2014	EPI000066414	EPI000066414		JX-002			
CX3288	Endo Spreadsheet: Specification 60 - COGS 2008-Q12014	6/11/2014	EPI000731501	EPI000731501		JX-002			
CX3289	Endo Spreadsheet: Specification 60 - 2008-2013 ER 522-70	6/11/2014	EPI000731502	EPI000731502		JX-002		Ordered 10/20/2017	
CX3290	Endo Spreadsheet: Specification 60 - 2014 Lido and TRF	6/15/2014	EPI000731513	EPI000731513		JX-002		Ordered 10/20/2017	
CX3291	Endo Spreadsheet: Specification 58	7/22/2014	EPI001492559	EPI001492559		JX-002		Ordered 10/20/2017	
CX3292	Endo Spreadsheet: Final 2016 Opana ER	6/26/2017	EPI002200322	EPI002200322		JX-002		Ordered 10/20/2017	
CX3293	Impax Spreadsheet: COPA Q1 2015	3/15/2017	Impax_Opana_PartIII_0000001	Impax_Opana_PartIII_0000001		JX-002			
CX3294	Impax Spreadsheet: Oxymorphone ER Shipment Data Jan 15 to Feb 17	3/16/2017	Impax_Opana_PartIII_0000003	Impax_Opana_PartIII_0000003		JX-002		Ordered 10/23/2017	
CX3295	Impax Spreadsheet: IMS data All	3/16/2017	Impax_Opana_PartIII_0000004	Impax_Opana_PartIII_0000004		JX-002			
CX3296	Impax Spreadsheet: Monthly Module Views- Rx (NPA)_1_Apr-30-2017	5/8/2017	Impax_Opana_PartIII_0002021	Impax_Opana_PartIII_0002021	RX-149	JX-002		Ordered 10/23/2017	
CX3297	Impax Spreadsheet: copa data q1 2015	5/1/2017	Impax_Opana_PartIII_0002022	Impax_Opana_PartIII_0002022		JX-002		Ordered 10/23/2017	
CX3298	Impax Spreadsheet: Monthly Module Views- Sales (NSP)_1_May-17-2017	5/17/2017	Impax_Opana_PartIII_0002023	Impax_Opana_PartIII_0002023		JX-002		Ordered 10/23/2017	
CX3299	Impax Spreadsheet: Oxymorphone AMP WAC AWP	3/11/2014	IMPAX-OPANA-CID00000270	IMPAX-OPANA-CID00000274		JX-002			
CX3300	Impax Spreadsheet: COPA data	3/19/2014	IMPAX-OPANA-CID00000350	IMPAX-OPANA-CID00000483		JX-002			
CX3301	Impax Spreadsheet: CARS Indirect Historical Pricing for Oxymorphone HCl (3-21-14)	3/21/2014	IMPAX-OPANA-CID00001064	IMPAX-OPANA-CID00001079		JX-002		Ordered 10/23/2017	
CX3302	Impax Spreadsheet: NSP 0715	7/15/2014	IMPAX-OPANA-CID00020806	IMPAX-OPANA-CID00020806		JX-002			
CX3303	Impax Spreadsheet: NPA 0715 data pull	7/15/2014	IMPAX-OPANA-CID00020807	IMPAX-OPANA-CID00020807		JX-002			
CX3304	Impax Spreadsheet: 2014 oxymorphone Sales	1/9/2015	IMPAX-OPANA-CID00023835	IMPAX-OPANA-CID00023835		JX-002		Ordered 10/23/2017	
CX3305	IMS_NPA_2003-2008 - HIGHLY CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER	00/00/0000	IMS_NPA_2003-2008 - HIGHLY CONFIDEN	IMS_NPA_2003-2008 - HIGHLY CONFIDEN		JX-002		Ordered 10/23/2017	
CX3306	IMS_NSP_2003-2008 - HIGHLY CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER	00/00/0000	IMS_NSP_2003-2008 - HIGHLY CONFIDEN	IMS_NSP_2003-2008 - HIGHLY CONFIDEN		JX-002		Ordered 10/23/2017	
CX3307	OXYMORPHONE_IR_2009-2010 - HIGHLY CONFIDENTIAL	00/00/0000	OXYMORPHONE_IR_2009-2010 - HIGHLY C	OXYMORPHONE_IR_2009-2010 - HIGHLY C		JX-002		Ordered 10/23/2017	
CX3308	Email from Larry Hsu to Chris Mengler, Todd Engle, Meg Snowden, et al. re: Mengler Board Slides	5/14/2010	Impax_Opana_PartIII_0063824	Impax_Opana_PartIII_0063825		JX-002			
CX3309	Case 2:09-cv-00831-KSH-PS: Transcript of May 14, 2010 Teleconference	5/17/2010	CX3309-001	CX3309-020		JX-002			

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX3310	Email from Anna Fabish to Nick Leefer, Ted Hassi, Michael Antalics, et al. re: Docket 9373 - Forecast and Board of Director Documents in Impax's Productions w/Attach: 7202017_Letter_to_Complaint_Counsel_re_Board_Documents_and_Forecasts.pdf	7/21/2017	CX3310-001	CX3310-010		JX-002			
CX3311	Email from William Hicks to Jamie Towey, Paula Blizzard re: Civil Investigative Demand to Impax Laboratories, Inc. (FTC File No. 1410004) w/Attach: March 27, 2014 Ltr. to J. Towey.PDF	3/27/2014	CX3311-001	CX3311-006		JX-002			
CX3312	Letter from Anna Fabish to Nick Leefer re: In re Impax Laboratories, Inc., Dkt. No. 9373	5/11/2017	CX3312-001	CX3312-010		JX-002		Ordered 10/23/2017	
CX3313	Document: Q4 2009 Impax Laboratories Earnings Conference Call - Final	2/25/2010	CX3313-001	CX3313-015		JX-002			
CX3314	Letter from Joshua Davis to J. Maren Schmidt re: FTC File No. 1410004 / Endo Pharmaceuticals Inc.	6/16/2014	CX3314-001	CX3314-008		JX-002			
CX3315	Intentionally Not Used					N/A			
CX3316	Email from J. Maren Schmidt to Barbara Wootton, Jamie Towey, Eric Sprague, et al. re: Endo Pharmaceuticals Inc.	4/20/2015	CX3316-001	CX3316-005		JX-002			
CX3317	Actavis Document: ActionSTAT Additional Pack Size Availability for Oxymorphone Hydrochloride Extended-Release	1/2/2014	Actavis_FTC_Opana_000377	Actavis_FTC_Opana_000377		JX-002			
CX3318	Endo Spreadsheet: 2008-2013 ER 553-70	6/11/2014	EPI000731503	EPI000731503		JX-002		Ordered 10/20/2017	
CX3319	Endo Spreadsheet: 2008-2013 ER 571-70	6/11/2014	EPI000731504	EPI000731504		JX-002		Ordered 10/20/2017	
CX3320	Endo Spreadsheet: 2008-2013 ER 617-70	6/11/2014	EPI000731505	EPI000731505		JX-002		Ordered 10/20/2017	
CX3321	Endo Spreadsheet: 2008-2013 ER 674-70	6/11/2014	EPI000731507	EPI000731507		JX-002		Ordered 10/20/2017	
CX3322	Endo Spreadsheet: 2008-2013 ER 693-70	6/11/2014	EPI000731508	EPI000731508		JX-002		Ordered 10/20/2017	
CX3323	Endo Spreadsheet: 2008-2013 ER 907-70	6/11/2014	EPI000731509	EPI000731509		JX-002		Ordered 10/20/2017	
CX3324	Endo Spreadsheet: 2008-2013 ER 907-75	6/11/2014	EPI000731510	EPI000731510		JX-002			
CX3325	Endo Spreadsheet: 2012-2013 TRF ALL	6/11/2014	EPI000731512	EPI000731512		JX-002		Ordered 10/20/2017	
CX3326	Endo Spreadsheet: Final 2014 OPANA ER	7/5/2017	EPI002200323	EPI002200323		JX-002		Ordered 10/20/2017	
CX3327	Endo Spreadsheet: Final 2015 Opana ER	7/5/2017	EPI002200324	EPI002200324		JX-002		Ordered 10/20/2017	
CX3328	Impax Spreadsheet: Copy of Oxymorphone ER - GTN&COGS Apr'15 to Feb'17	3/16/2017	Impax_Opana_PartIII_0000002	Impax_Opana_PartIII_0000002		JX-002		Ordered 10/23/2017	
CX3329	Email from Danielle Morelli to Andrew Fox, Tim Jones re: Oxymorphone	6/1/2011	IMPAX-OPANA-CID00020787	IMPAX-OPANA-CID00020792	RX-395	JX-002			
CX3330	Email from Barbara Wootton to Maren Schmidt, Jamie Towey, Eric Sprague, et al. re: FTC File No. 1410004--HIGHLY CONFIDENTIAL w/Attach: Endo Responses to V. Chen Additional Data Questions.pdf; EPI - HIGHLY CONFIDENTIAL Indirect customers.xlsx; et al.	6/9/2015	FTC-PROD-0016597	FTC-PROD-0016607		JX-002			
CX3331	Email from Steven Reade to Maren Schmidt, Jamie Towey, Eric Sprague, et al. re: Endo Pharmaceuticals Inc. w/Attach: 2.13.15 Letter to FTC.PDF; 2.13.15 Responses to FTC Data Questions.pdf	2/13/2015	FTC-PROD-0017763	FTC-PROD-0017772		JX-002			
CX3332	Email from Justin Watkins to Eliot Choy, Doug Macpherson, Guy Donatiello re: Endo Signature Pages w/Attach: Co-Promote Agmt - Endo Sig Page.pdf; Settlement Agmt - End Sig Page.pdf	6/8/2010	EPI000183779	EPI000183781		JX-002			
CX3333	Email from Art Koch to Alan Levin, Guy Donatiello, Meg Snowden, et al. re: <no subject>	6/4/2010	EPI000874044	EPI000874048		JX-002			
CX3334	Email from Alan Levin to Julie McHugh re: Good news....	6/3/2010	EPI001379279	EPI001379279		JX-002			
CX3335	Email from David Paterson to Robert Cobuzzi, Michael Nestor, Meg Snowden, et al. re: IPX066 w/Attach: DATA LIST.doc	5/22/2010	EPI001433181	EPI001433188		JX-002			
CX3336	Email from Alan Levin to Roberto Cuca re: Highly Confidential - Rule 408 Settlement Communication	5/31/2010	EPI001688706	EPI001688709		JX-002			
CX3337	Intentionally Not Used					N/A			

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX3338	Email from Kevin Pong to Stephen Bai, Paula Clark, Frank Diana, et al. re: Project Imperial DD Reports w/Attach: Project Imperial_Regulatory DD Report_Clark.docx; Project Imperial_CDMA DDReport_Kopeccky.docx; Project Imperial_Clin Pharm DD Report_Bai.doc	6/3/2010	EPI002156237	EPI002156256		JX-002			
CX3339	Email from Ivan Gergel to Stephen Bai, Frank Diana, Sandeep Gupta re: Information Requested	6/5/2010	EPI002159879	EPI002159881		JX-002			Tr. 2603:18; 2603:20; 2603:23
CX3340	Email from Karen Adler to Edward Sweeney re: You are not alone	6/5/2010	EPI002161112	EPI002161112		JX-002			
CX3341	Email from Mark Bradley to Julie McHugh, Lori Tierney re: Data request	6/7/2010	EPI002161155	EPI002161163		JX-002			
CX3342	Impax Document: Co-Promotion Agreement dated as of June xx, 2010 by and between Endo Pharmaceuticals Inc. and [Impax Laboratories, Inc.] DBR DRAFT	6/4/2010	Impax_Opana_PartIII_0002558	Impax_Opana_PartIII_0002585		JX-002			
CX3343	Email from Michael Nestor to Suneel Gupta re: IPX203	3/17/2015	Impax_Opana_PartIII_0056586	Impax_Opana_PartIII_0056586		JX-002			
CX3344	Intentionally Not Used					N/A			
CX3345	Email from David Ailinger to David Paterson, Suneel Gupta, Michael Nestor re: Endo IPX-203 w/Attach: Endo08072015.ppt	8/7/2015	Impax_Opana_PartIII_0063726	Impax_Opana_PartIII_0063735	RX-211	JX-002		Ordered 10/23/2017	
CX3346	Intentionally Not Used					N/A			
CX3347	Email from Todd Engle to Chris Mengler, Larry Hsu, Chuck Hildenbrand, et al. re: Quarterly Launch Planning Meeting Background Documentation w/AttachL launch planning 02 02 10 R2.doc	2/2/2010	Impax_Opana_PartIII_0044547	Impax_Opana_PartIII_0044571	RX-194	JX-002			Tr. 1751: 09; 1751:11; 1752:10; 1753:10; 1753:15; 1771:24; 1772:08; 1788:19; 1789:07
CX3348	Email from Todd Engle to Chris Mengler, Larry Hsu, Chuck Hildenbrand, et al. re: Quarterly Launch Planning Meeting May 20, 2010 Agenda Materials w/Attach: QLPM 052010.doc	5/20/2010	Impax_Opana_PartIII_0069160	Impax_Opana_PartIII_0069201	RX-216	JX-002			Tr. 556:08; 556:13; 557:06; 557:20; 558:03; 1755:08; 1756:03; 1756:10; 1756:14; 1757:05; 1775:10; 1789:15; 1789:17; 1790:11
CX3349	Email from Art Koch to Alan Levin, Meg Snowden, Michael Nestor, et al. re: <no subject>	6/6/2010	IMPAX-OPANA-CID00001411	IMPAX-OPANA-CID00001412	RX-042	JX-002			
CX3350	Intentionally Not Used					N/A			
CX3351	Email from Jonathan Neely to Dave Holveck, Alan Levin, Julie McHugh, et al. re: Documents for Tomorrow's Earnings Call Prep Session w/Attach: ENDP Q2 2010 financial results conference call script v8.docx; et al.	7/22/2010	EPI001175573	EPI001175620		JX-002			
CX3352	Letter from Christine Levin to Bradley Albert re: In the Matter of Impax Laboratories, Inc., Dkt. No. 9373	7/26/2017	CX3352-001	CX3352-002		JX-002			
CX3353	Letter from Christine Levin to Bradley Albert re: In the Matter of Impax Laboratories, Inc., Dkt. No. 9373	8/2/2017	CX3353-001	CX3353-011		JX-002			
CX3354	Letter from Christine Levin to Eric Sprague re: clarification to Brad Albert's June 22, 2017 letter concerning Endo's transaction data	8/9/2017	CX3354-001	CX3354-001		JX-002			
CX3355	FDA Document: Introduction for the FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics	5/00/2017	CX3355-001	CX3355-021		JX-002			Tr. 747:05, 06; 749:07; 750:01, 14; 754:01; 2172:14; 2172:17; 2173:11
CX3356	Case 2:16-cv-02526-JLL-JAD: Motion to Dismiss	7/11/2016	CX3356-001	CX3356-050		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		
CX3357	Case 2:16-cv-02526-JLL-JAD: Amended Motion to Dismiss	8/29/2016	CX3357-001	CX3357-049		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		
CX3358	Case 2:16-cv-02526-JLL-JAD: Declaration in Support of Motion to Dismiss	8/29/2016	CX3358-001	CX3358-010		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		
CX3359	Case 2:16-cv-02526-JLL-JAD: Brief in Opposition of Motion to Dismiss	10/3/2016	CX3359-001	CX3359-047		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		
CX3360	Case 2:16-cv-02526-JLL-JAD: Reply Brief in Support of Motion to Dismiss	10/11/2016	CX3360-001	CX3360-020		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		



COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX3361	Case 2:16-cv-02526-JLL-JAD: Opinion	10/25/2016	CX3361-001	CX3361-014		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		
CX3362	Case 2:16-cv-02526-JLL-JAD: Order	10/25/2016	CX3362-001	CX3362-001		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		
CX3363	Case 2:16-cv-02526-JLL-JAD: Joint Discovery Plan	1/30/2017	CX3363-001	CX3363-011		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		
CX3364	Case 2:16-cv-02526-JLL-JAD: Pretrial Scheduling Order	2/6/2017	CX3364-001	CX3364-004		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		
CX3365	Case 2:16-cv-02526-JLL-JAD: Letter from Brian Goldberg to Judge Dickson re: Joint Proposed Revised Scheduling Order	5/4/2017	CX3365-001	CX3365-039		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		
CX3366	Case 2:16-cv-02526-JLL-JAD: Discovery Confidentiality Order	5/5/2017	CX3366-001	CX3366-029		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		
CX3367	Case 2:16-cv-02526-JLL-JAD: Revised Scheduling Order	5/5/2017	CX3367-001	CX3367-001		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		
CX3368	Case 2:16-cv-02526-JLL-JAD: Joint Letter to Judge Dickson re: Discovery Disputes	5/10/2017	CX3368-001	CX3368-009		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		
CX3369	Case 2:16-cv-02526-JLL-JAD: Notice of Withdrawal of Pro Hac Vice Counsel	6/16/2017	CX3369-001	CX3369-003		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		
CX3370	Case 2:16-cv-02526-JLL-JAD: Notice of Unopposed Motion to Seal	7/13/2017	CX3370-001	CX3370-027		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		
CX3371	Case 2:16-cv-02526-JLL-JAD: Order to Seal	7/20/2017	CX3371-001	CX3371-007		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		
CX3372	Case 2:16-cv-02526-JLL-JAD: Letter from Brian Goldberg to Judge Linares re: Stipulation and Order	8/8/2017	CX3372-001	CX3372-004		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		
CX3373	Case 2:16-cv-02526-JLL-JAD: Order of Dismissal	8/21/2017	CX3373-001	CX3373-004		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		
CX3374	Email from Kevin Sica to Kevin Sica re: May 09 Forecast Submission w/Attach: Forecast Change From Previous Forecast 0509.xls	5/7/2009	Impax_Opana_PartIII_0006079	Impax_Opana_PartIII_0006080		JX-002			
CX3375	Email from Kevin Sica to Denis Paquette re: April 09 Forecast Submission UPDATED w/Attach: Forecast Change From Previous Forecast 0409 UPDATED.xls	4/7/2009	Impax_Opana_PartIII_0006081	Impax_Opana_PartIII_0006082		JX-002			
CX3376	Email from Kevin Sica to Denis Paquette re: March Forecast Submission w/Attach: Forecast Change From Previous Forecast 0309.xls	3/6/2009	Impax_Opana_PartIII_0006083	Impax_Opana_PartIII_0006084		JX-002			
CX3377	Email from Kevin Sica to Denis Paquette re: February Forecast Submission w/Attach: Forecast Change From Previous Forecast0209.xls	2/6/2009	Impax_Opana_PartIII_0006085	Impax_Opana_PartIII_0006086		JX-002			
CX3378	Email from Pamela Politis to Lamar Caison, Yelena Bond re: PAragraph iv agreements w/Attach: Impax Laboratories, Inc.- Settlement&LicenseAgmt(PenwestPhamn)Jun10.pdf: et al.	11/12/2010	EPI001985443	EPI001985456		JX-002			
CX3379- CX3382	Intentionally Not Used					N/A			

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX3383	Actavis Document: Settlement and License Agreement	2/20/2009	ACTLID00049661	ACTLID00049661		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted	Ordered 10/20/2017	
CX3384-CX3433	Intentionally Not Used					N/A			
CX3434	Case 2:16-cv-02526-JLL-JAD: Docket	9/11/2017	CX3434-001	CX3434-005		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		
CX3435	Case 2:16-cv-02526-JLL-JAD: Complaint	5/4/2016	CX3435-001	CX3435-156		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		
CX3436	Case 2:16-cv-02526-JLL-JAD: Impax Laboratories, Inc.'s Answer, Affirmative Defenses, and Counterclaims to Plaintiff's Amended Complaint	11/22/2016	CX3436-001	CX3436-107		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		
CX3437	Case 2:16-cv-02526-JLL-JAD: Amended Complaint	8/1/2016	CX3437-001	CX3437-163		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		Tr. 2083:08; 2088:13; 2089:09; 2892:10
CX3438	Email from Susan Ostrander to Carole Ben-Maimon re: Board Presentation from 8/22 meeting w/Attach: 4a- Generic Aug2012 FINAL.pptx	11/5/2012	Impax_Opana_PartIII_0080393	Impax_Opana_PartIII_0080427		JX-002		Ordered 10/23/2017	Tr. 1741:25; 1742:02; 1742:13; 1742:24; 1746:20; 1746:21; 1748:1; 1765:21; 1790:22; 1790:23; 1791:12
CX3439	Document: Respondent Impax's Responses and Objections to CC's First Set of Interrogatories	5/5/2017	CX3439-001	CX3439-010		JX-002			
CX3440	Document: Respondent Impax's Supplemental Responses and Objections to First Set of Interrogatories	5/22/2017	CX3440-001	CX3440-004		JX-002			
CX3441	Document: Respondent Impax's Responses and Objections to CC's Interrogatory No. 19 (Revised)	8/11/2017	CX3441-001	CX3441-017		JX-002		Ordered 10/23/2017	
CX3442	Document: Respondent Impax's Responses and Objections to CC's Third Set of Interrogatories (Revised)	8/11/2017	CX3442-001	CX3442-019		JX-002		Ordered 10/23/2017	
CX3443	Email from Brian Hogan to Roberto Cuca re: Opana ER / IR P & L Scenario Model w/Attach: Opana ER Net ASP analysis - generic v4.xlsx	5/26/2010	EPI000180183	EPI000180188		JX-002			
CX3444	Email from James Bradley to Brian Lortie, Andy Geseck re: Three year forecast- revised w/Attach: Three Year Company Total--OPANA-TRF scenarios.xlsx; Three Year Plan 2010.xlsx	2/5/2010	EPI000710067	EPI000710069		JX-002			
CX3445	Email from Demir Bingol to Brian Lortie re: Opana ER Combined P&L scenarios - Jul-10 generics.xlsx w/Attach: Opana ER Combined P&L scenarios - Jul-10 generics.xlsx	6/1/2010	EPI001553350	EPI001553351		JX-002			
CX3446	Email from Karen Adler to Robert Cobuzzi, Alan Butcher, Robert Barrett, et al. re: Three Year Forecast for Compensation Discussion at 3 pm w/Attach: Three Year Plan 2010 (3) .xlsx; Three Year Company Total--OPANA-TRF scenarios (2).xlsx	2/11/2010	EPI001828479	EPI001828481		JX-002			
CX3447	Email from Alan Levin to Erik Groot, Nancy Santilli, Karen Adler, et al. re: Endo: Ratings Agency Presentation w/Attach: 090724-ENDP-Ratings Agency Presentation-V58.ppt; et al.	8/9/2009	EPI001892413	EPI001892427		JX-002			
CX3448	Endo Spreadsheet: Lidoderm, Opana TRF, Opana ER Orig. FY08 Jan- FY14 Dec	12/00/2014	EPI-000003392	EPI-000003392		JX-002			
CX3449	Impax Document: Paragraph IV Patent Certification: 5,662,933	00/00/0000	IMPAX-OPANA-CID00000017	IMPAX-OPANA-CID00000018	RX-466	JX-002			
CX3450	Impax Document: Paragraph IV Patent Certification: 5,958,456	00/00/0000	IMPAX-OPANA-CID00000019	IMPAX-OPANA-CID00000020	RX-265	JX-002			
CX3451	Impax Document: Paragraph IV Patent Certification: 7,276,250	00/00/0000	IMPAX-OPANA-CID00000021	IMPAX-OPANA-CID00000022		JX-002			
CX3452	Endo Document: Delcaration of Guy Donatiello in Support of Plaintiff's Motion for Preliminary Injunction	9/10/2013	EPI001489431	EPI001489708		JX-002			
CX3453	Email from Brian Lortie to Julie McHugh re: Opana ER impact	6/1/2010	EPI002442186	EPI002442187		JX-002			
CX3454	Email from Marjorie O'Brien to Guy Donatiello, Pamela Politis, Ginola Johnson re: LEGAL EXPENSES - FORECAST w/Attach: Litigation Details for May LBE Forecast.xlsx	5/10/2010	EPI002395438	EPI002395439		JX-002			
CX3455	Case 1:12-cv-08985-TPG-GWG: Transcript	9/19/2013	CX3455-001	CX3455-057		JX-002			

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX3456- CX3999	Case 09-cv-831, 832, 833: Declaration of John S. Russell, M.S.	5/21/2010	EPI002496955	EPI002496985		JX-002			
CX4000	Intentionally Not Used					N/A			
CX4001	Excerpt of IH Transcript: Paul Bisaro (Actavis)	11/20/2014	CX4000-001	CX4000-051		JX-002			
CX4002	IH Transcript: Arthur A. Koch, Jr (Impax)	10/27/2014	CX4001-001	CX4001-072		JX-002			
CX4003	IH Transcript: Theodore Smolenski (Impax)	9/30/2014	CX4002-001	CX4002-088		JX-002			Tr. 1658:09
CX4004	IH Transcript: Margaret Snowden (Impax)	10/15/2014	CX4003-001	CX4003-080		JX-002			
CX4005	IH Transcript: Todd Engle (Impax)	8/20/2014	CX4004-001	CX4004-113		JX-002			Tr. 1745:15; 1745:16; 1745:22
CX4006	IH Transcript: Alan Levin (Endo) Day 1	11/13/2014	EPI002160614	EPI002160688	RX-516	JX-002			
CX4007	IH Transcript: Alan Levin (Endo) Day 2	11/14/2014	ENDO-OPANA-000001782	ENDO-OPANA-000001839	RX-517	JX-002			
CX4008	IH Transcript: Brian Lortie (Endo)	9/18/2014	EPI002160510	EPI002160613	RX-505	JX-002			
CX4009	IH Transcript: Caroline Manogue (Endo) Day 1	9/25/2014	ENDO-OPANA-000002562	ENDO-OPANA-000002649	RX-506	JX-002			
CX4010	IH Transcript: Caroline Manogue (Endo) Day 2	12/2/2014	ENDO-OPANA-000002650	ENDO-OPANA-000002719	RX-520	JX-002			
CX4011	IH Transcript: Christopher Mengler (Impax)	9/10/2014	CX4010-001	CX4010-087		JX-002			
CX4012	IH Transcript: David Holveck (Endo)	11/18/2014	EPI002160689	EPI002160778	RX-518	JX-002			
CX4013	Excerpt of IH Transcript: Guy Donatiello (Endo)	12/9/2014	ENDO-OPANA-000001104	ENDO-OPANA-000001210		JX-002			
CX4014	IH Transcript: Kevin Pong, Ph.D. (Endo)	12/4/2014	ENDO-OPANA-000003125	ENDO-OPANA-000003203	RX-521	JX-002			
CX4015	IH Transcript: Larry Hsu (Impax)	10/30/2014	CX4014-001	CX4014-075		JX-002			
CX4016	IH Transcript: Robert Barto (Endo)	11/25/2014	ENDO-OPANA-000000001	ENDO-OPANA-000000077	RX-519	JX-002			
CX4017	Excerpt of IH Transcript: Robert Cobuzzi (Endo)	9/11/2014	ENDO-OPANA-000000438	ENDO-OPANA-000000560		JX-002			
CX4018	Deposition Transcript: Alan Levin (Endo)	8/10/2017	CX4017-001	CX4017-074	RX-543	JX-002			
CX4019	Deposition Transcript: Arthur A. Koch, Jr. (Impax)	6/6/2017	CX4018-001	CX4018-061		JX-002			
CX4020	Deposition Transcript: Brian Lortie (Endo)	6/27/2017	CX4019-001	CX4019-070		JX-002			
CX4021	Deposition Transcript: Bryan Reasons (Impax)	8/11/2017	CX4020-001	CX4020-060		JX-002		Ordered 10/23/2017	
CX4022	Deposition Transcript: Carole Ben-Maimon (Impax)	5/31/2017	CX4021-001	CX4021-078		JX-002			
CX4023	Deposition Transcript: Christopher Mengler (Impax)	5/25/2017	CX4022-001	CX4022-093		JX-002			
CX4024	Deposition Transcript: Chuck Hildenbrand (Impax)	7/25/2017	CX4023-001	CX4023-086		JX-002			
CX4025	Deposition Transcript: David Macera (Endo)	7/12/2017	CX4024-001	CX4024-067	RX-537	JX-002			
CX4026	Deposition Transcript: Demir Bingol (Endo)	6/15/2017	CX4025-001	CX4025-079		JX-002			
CX4027	Deposition Transcript: Huong Nguyen (Impax)	6/29/2017	CX4026-001	CX4026-079	RX-535	JX-002			
CX4028	Deposition Transcript: John Anthony (Impax)	7/25/2017	CX4027-001	CX4027-074		JX-002			
CX4029	Deposition Transcript: Joseph Carmarqo (Impax)	8/9/2017	CX4028-001	CX4028-092		JX-002			
CX4030	Deposition Transcript: Kevin Sica (Impax)	8/8/2017	CX4029-001	CX4029-044	RX-542	JX-002			
CX4031	Deposition Transcript: Larry Hsu (Impax)	7/28/2017	CX4030-001	CX4030-054		JX-002			
CX4032	Deposition Transcript: Mark Bradley (Endo)	7/6/2017	CX4031-001	CX4031-076	RX-536	JX-002			
CX4033	Deposition Transcript: Margaret Snowden (Impax)	8/2/2017	CX4032-001	CX4032-093		JX-002			
CX4034	Deposition Transcript: Michael Nestor (Impax)	8/4/2017	CX4033-001	CX4033-075		JX-002		Ordered 10/23/2017	Tr. 3019:24
CX4035	Deposition Transcript: Richard Rogerson (Actavis)	8/4/2017	CX4034-001	CX4034-043	RX-541	JX-002			
CX4036	Deposition Transcript: Roberto Cuca (Endo)	8/4/2017	CX4035-001	CX4035-067		JX-002			
CX4037	Deposition Transcript: Shawn Fatholahi (Impax)	5/23/2017	CX4036-001	CX4036-066	RX-533	JX-002			
CX4038	Deposition Transcript: Theodore Smolenski (Impax)	7/18/2017	CX4037-001	CX4037-105		JX-002			
CX4039	Deposition Transcript: Todd Engle (Impax)	8/17/2017	CX4038-001	CX4038-076		JX-002			
CX4040	Deposition Transcript: Roger G. Noll	10/2/2017	CX4039-001	CX4039-108		JX-002			
CX4041	Deposition Transcript: Max H. Bazerman	9/28/2017	CX4040-001	CX4040-088		JX-002			
CX4042	Deposition Transcript: Seddon R. Savage	9/29/2017	CX4041-001	CX4041-058		JX-002			
CX4043	Deposition Transcript: John Geltosky	9/27/2017	CX4042-001	CX4042-086		JX-002			
CX4044	Deposition Transcript: Thomas Hoxie	10/6/2017	CX4043-001	CX4043-118		JX-002			
CX4045	Deposition Transcript: Sumanth Addanki	10/5/2017	CX4044-001	CX4044-106		JX-002			
CX4046	Deposition Transcript: E. Anthony Figg	9/29/2017	CX4045-001	CX4045-121		JX-002			
CX4047- CX4999	Deposition Transcript: Edward Michna	10/3/2017	CX4046-001	CX4046-079		JX-002			
CX5000	Intentionally Not Used					N/A			
CX5001	Expert Report: Roger G. Noll	8/25/2017	CX5000-001	CX5000-292		JX-002	Admitted on condition that expert testifies at the hearing of this matter	Ordered 11/28/2017	Tr. 1650:13; 1677:15; 1677:16; 1680:07; 1680:08
CX5002	Expert Report: Max H. Bazerman	8/18/2017	CX5001-001	CX5001-069		JX-002	Admitted on condition that expert testifies at the hearing of this matter		
CX5003	Expert Report: Seddon R. Savage	8/25/2017	CX5002-001	CX5002-106		JX-002	Admitted on condition that expert testifies at the hearing of this matter		Tr. 706:03, 04; 727:20; 735:20; 738:06; 740:19; 2189:02; 2189:04; 2193:02
CX5004	Expert Report: John Geltosky	8/25/2017	CX5003-001	CX5003-070		JX-002	Admitted on condition that expert testifies at the hearing of this matter		Tr. 706:03, 04; 727:20; 735:20; 738:06; 740:19; 1130:23

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX5004	Rebuttal Expert Report: Roger G. Noll	9/20/2017	CX5004-001	CX5004-117		JX-002	Admitted on condition that expert testifies at the hearing of this matter		Tr. 1606:25
CX5005	Rebuttal Expert Report: Max H. Bazerman	9/20/2017	CX5005-001	CX5005-015		JX-002	Admitted on condition that expert testifies at the hearing of this matter		
CX5006	Rebuttal Expert Report: Seddon R. Savage	9/20/2017	CX5006-001	CX5006-021		JX-002	Admitted on condition that expert testifies at the hearing of this matter		
CX5007	Rebuttal Expert Report: Thomas Hoxie	9/20/2017	CX5007-001	CX5007-053		JX-002	Admitted on condition that expert testifies at the hearing of this matter		
CX5008- CX6019	Intentionally Not Used					N/A			
CX6020	Congressional Budget Office, Prices for Brand-Name Drugs under Selected Federal Programs, June 2005	07/00/2005	CX6020-001	CX6020-024		JX-002			
CX6021	Centers for Disease Control and Prevention, Opioid Morphine Equivalent Factors (March 2015)	03/00/2015	CX6021-001	CX6021-001		JX-002			
CX6022 - CX6032	Intentionally Not Used					N/A			
CX6033	Endo Press Release: Endo Receives FDA Approval for Opana(R) ER (oxymorphone HCl) Extended-Release and Opana(R) (oxymorphone HCl) Immediate Release Tablets CII	6/23/2006	CX6033-001	CX6033-001		JX-002			
CX6034	Endo Press Release: Endo Pharmaceuticals to Launch Three New Dosage Strengths of OPANA® ER	3/3/2008	CX6034-001	CX6034-003		JX-002			
CX6035	Endo Press Release: Endo Provides Update On OPANA® ER	7/6/2017	CX6035-001	CX6035-010		JX-002			
CX6036 - CX6037	Intentionally Not Used					N/A			
CX6038	FDA Letter from Bob Rappaport to Susan Rinnea, Alza Corporation re: NDA 19-813/S-039	2/4/2005	CX6038-001	CX6038-004		JX-002			
CX6039	FDA Letter from Keith Webber to Monique Weitz, Actavis South Atlantic LLC re: ANDA 079046	12/13/2010	CX6039-001	CX6039-007		JX-002			
CX6040	FDA Document: Chemical Review Application: BuTrans™ (Buprenorphine) Transdermal System	12/19/2000	CX6040-001	CX6040-037		JX-002			
CX6041	FDA Document: FENTANYL TRANSDERMAL SYSTEM - fentanyl patch, extended release	2/9/2011	CX6041-001	CX6041-028		JX-002			
CX6042	FDA Document: Generic Drugs: Questions & Answers	8/15/2017	CX6042-001	CX6042-008		JX-002			
CX6043	FDA Document: Guidance for Industry: Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs — General Considerations	3/00/2014	CX6043-001	CX6043-029		JX-002			
CX6044	FDA Document: FDA Listing of Authorized Generics as of June 30, 2017	6/30/2017	CX6044-001	CX6044-092		JX-002			
CX6045	FDA Document: Drugs@FDA: FDA Approved Drug Products - Oxymorphone Hydrochloride	8/15/2017	CX6045-001	CX6045-002		JX-002			
CX6046	FDA Document: Drugs@FDA: FDA Approved Drug Products - Oxymorphone Hydrochloride Therapeutic Equivalents	8/15/2017	CX6046-001	CX6046-002		JX-002			
CX6047	FDA Document: FDA recommends against the continued use of propoxyphene	11/19/2010	CX6047-001	CX6047-005		JX-002			
CX6048	FDA Press Release: FDA requests removal of Opana ER for risks related to abuse	6/8/2017	CX6048-001	CX6048-003		JX-002			
CX6049	Document: Fentanyl 019813_ORIGINAL APPROVAL_PACKAGE	8/7/1990	CX6049-001	CX6049-344		JX-002			
CX6050	FDA Presentation: Regulatory History of Opana ER	3/13/2017	CX6050-001	CX6050-165		JX-002			
CX6051	Intentionally Not Used					N/A			
CX6052	Federal Trade Commission, Authorized Generic Drugs: Short-Term Effects and Long-Term Impacts, (August 2011)	8/00/2011	CX6052-001	CX6052-270		JX-002			
CX6053	Federal Trade Commission, Generic Drug Entry Prior to Patent Expiration: An FTC Study (July 2002)	7/00/2002	CX6053-001	CX6053-129		JX-002			
CX6054	U.S. Department of Justice and the Federal Trade Commission, Horizontal Merger Guidelines (2010)	8/19/2010	CX6054-001	CX6054-037		JX-002			

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX6055	Federal Trade Commission, Pay-For-Delay: How Drug Company Pay-Offs Cost Consumers Billions (2010)	1/00/2010	CX6055-001	CX6055-016		JX-002			
CX6056 - CX6059	Intentionally Not Used					N/A			
CX6060	Impax Press Release: Impax Laboratories Receives Final FDA Approval for Generic OPANA® ER Tablets	7/22/2010	CX6060-001	CX6060-002		JX-002			
CX6061 - CX6085	Intentionally Not Used					N/A			
CX6086	Federal Trade Commission, "The Past and Future of Direct Effects Evidence", Remarks of J. Thomas Rosch, March 30, 2011	3/30/2011	CX6086-001	CX6086-017		JX-002			
CX6087 - CX6098	Intentionally Not Used					N/A			
CX6099	Centers for Disease Control and Prevention Guideline for Prescribing Opioids for Chronic Pain – United States, 2016	3/18/2016	CX6099-001	CX6099-052		JX-002			
CX6100	Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report (MMWR) (November 4, 2011)	11/4/2011	CX6100-001	CX6100-036		JX-002			
CX6101 - CX6106	Intentionally Not Used					N/A			
CX6107	FDA Document: Joint Meeting of the Drug Safety and Risk Management and Anesthetic and Analgesic Drug Products Advisory Committees (March 13, 2017)	3/13/2017	CX6107-001	CX6107-354		JX-002			
CX6108 - CX6131	Intentionally Not Used					N/A			
CX6132	Agreements Filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Summary of Agreements Filed in FY 2007, Federal Trade Commission Bureau of Competition. May 2008	05/00/2008	CX6132-001	CX6132-008		JX-002			
CX6133	Agreements Filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Summary of Agreements Filed in FY 2006, Federal Trade Commission Bureau of Competition. January 2007	1/00/2007	CX6133-001	CX6133-010		JX-002			
CX6134	Agreements Filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Summary of Agreements Filed in FY 2009, Federal Trade Commission Bureau of Competition. April 2011.	4/00/2011	CX6134-001	CX6134-009		JX-002			
CX6135 - CX6136	Intentionally Not Used					N/A			
CX6137	Agreements Filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Summary of Agreements Filed in FY 2004, Federal Trade Commission Bureau of Competition. December 2004.	12/00/2004	CX6137-001	CX6137-008		JX-002			
CX6138	Agreements Filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Summary of Agreements Filed in FY 2008, Federal Trade Commission Bureau of Competition. January 2010.	1/00/2010	CX6138-001	CX6138-008		JX-002			
CX6139	Agreements Filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Summary of Agreements Filed in FY 2013, Federal Trade Commission Bureau of Competition. December 2014.	12/00/2014	CX6139-001	CX6139-004		JX-002			
CX6140	Agreements Filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Summary of Agreements Filed in FY 2014, Federal Trade Commission Bureau of Competition. January 2016.	1/00/2016	CX6140-001	CX6140-004		JX-002			

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	In Camera	Trial Transcript Citation
CX6141	Letter from the FDA to Endo Pharmaceuticals re NDA 201655 Approval	12/9/2011	CX6141-001	CX6141-006		JX-002			
CX6142 - CX6143	Intentionally Not Used					N/A			
CX6144	Authorized Generic Drugs: Short-Term Effects and Long-Term Impact (Federal Trade Commission, August 2011)	8/00/2011	CX6144-001	CX6144-270		JX-002			
CX6145 - CX6146	Intentionally Not Used					N/A			
CX6147	Agreements Filed with the Federal Trade Commission under the Medicare Prescription Drug,Improvement, and Modernization Act of 2003, Summary of Agreements Filed in FY 2005, Federal Trade Commission Bureau of Competition. April 2006.	4/00/2006	CX6147-001	CX6147-007		JX-002			
CX6148	Generic Drug Entry Prior to Patent Expiration: An FTC Study (Federal Trade Commission, July 2002)	7/00/2002	CX6148-001	CX6148-129		JX-002			

Notice of Electronic Service

**I hereby certify that on January 04, 2018, I filed an electronic copy of the foregoing Complaint Counsel's Exhibit List, with:**

D. Michael Chappell  
Chief Administrative Law Judge  
600 Pennsylvania Ave., NW  
Suite 110  
Washington, DC, 20580

Donald Clark  
600 Pennsylvania Ave., NW  
Suite 172  
Washington, DC, 20580

**I hereby certify that on January 04, 2018, I served via E-Service an electronic copy of the foregoing Complaint Counsel's Exhibit List, upon:**

Bradley Albert  
Attorney  
Federal Trade Commission  
balbert@ftc.gov  
Complaint

Daniel Butrymowicz  
Attorney  
Federal Trade Commission  
dbutrymowicz@ftc.gov  
Complaint

Nicholas Leefer  
Attorney  
Federal Trade Commission  
nleefer@ftc.gov  
Complaint

Synda Mark  
Attorney  
Federal Trade Commission  
smark@ftc.gov  
Complaint

Maren Schmidt  
Attorney  
Federal Trade Commission

mschmidt@ftc.gov  
Complaint

Eric Sprague  
Attorney  
Federal Trade Commission  
esprague@ftc.gov  
Complaint

Jamie Towey  
Attorney  
Federal Trade Commission  
jtowey@ftc.gov  
Complaint

Chuck Loughlin  
Attorney  
Federal Trade Commission  
cloughlin@ftc.gov  
Complaint

Alpa D. Davis  
Attorney  
Federal Trade Commission  
adavis6@ftc.gov  
Complaint

Lauren Peay  
Attorney  
Federal Trade Commission  
lpeay@ftc.gov  
Complaint

James H. Weingarten  
Attorney  
Federal Trade Commission  
jweingarten@ftc.gov  
Complaint

Edward D. Hassi  
O'Melveny & Myers, LLP  
ehassi@omm.com  
Respondent



Michael E. Antalics  
O'Melveny & Myers, LLP  
mantalics@omm.com  
Respondent

Benjamin J. Hendricks  
O'Melveny & Myers, LLP  
bhendricks@omm.com  
Respondent

Eileen M. Brogan  
O'Melveny & Myers, LLP  
ebrogan@omm.com  
Respondent

Anna Fabish  
O'Melveny & Myers, LLP  
afabish@omm.com  
Respondent

Stephen McIntyre  
O'Melveny & Myers, LLP  
smcintyre@omm.com  
Respondent

Rebecca Weinstein  
Attorney  
Federal Trade Commission  
rweinstein@ftc.gov  
Complaint

Garth Huston  
Attorney  
Federal Trade Commission  
ghuston@ftc.gov  
Complaint

**I hereby certify that on January 04, 2018, I served via other means, as provided in 4.4(b) of the foregoing Complaint Counsel's Exhibit List, upon:**

Markus Meier  
Attorney  
Federal Trade Commission  
mmeier@ftc.gov  
Complaint

Rebecca Weinstein  
Attorney